Field of the Invention The present invention relates to compounds, compositions and methods for preventing and treating thrombotic conditions such as coronary artery and cerebrovascular disease. More particularly, the invention relates to compounds, and prodrugs thereof, that selectively inhibit serine proteases of the coagulation cascade.

Background of the Invention Hemorrhage, intravascular thrombosis, and embolism are common clinical manifestations of many diseases (see R. I. Handin in Harrison's Principles of Internal Medicine (J. D. Wilson, et al. eds., 12th ed. 1991) New York, McGraw-Hill Book Co. , pp. 348-351). The normal hemostatic system limits blood loss by precisely regulated interactions between components of the vessel wall, circulating blood platelets, and plasma proteins.

However, unregulated activation of the hemostatic system may cause thrombosis, which can reduce blood flow to critical organs like the brain and myocardium.

Physiological systems control the fluidity of blood in mammals (see P. W. Majerus, et al. in Goodman & Gilman's The Pharmacological Basis of Therapeutics (J. G. Hardman & L. E. Limbird, eds. , 9th ed. 1996) New York, McGraw-Hill

Book Co. , pp. 1341-1343). Blood must remain fluid within the vascular systems and yet quickly be able to undergo hemostasis. Hemostasis, or clotting, begins when platelets first adhere to macromolecules in subendothelian regions of injured and/or damaged blood vessels. These platelets aggregate to form the primary hemostatic plug and stimulate local activation of plasma coagulation factors leading to generation of a fibrin clot that reinforces the aggregated platelets. Plasma coagulation factors, also referred to as protease zymogens, include factors II, V, VII, VIII, IX, X, XI, and XII. These coagulation factors or protease zymogens are activated by serine proteases leading to coagulation in a so called "coagulation cascade"or chain reaction.

Coagulation or clotting occurs in two ways through different pathways. An intrinsic or contact pathway leads from XII to XIIa to XIa to IXa and to the conversion of X to Xa. Factor Xa in combination with factor Va converts prothrombin (II) to thrombin (IIa) leading to conversion of fibrinogen to fibrin. Polymerization of fibrin leads to a fibrin clot. An extrinsic pathway is initiated by the conversion of coagulation factor VII to VIIa by factor Xa. Factor VIla, a plasma protease, is exposed to, and combines with its essential cofactor tissue factor (TF) which resides constitutively beneath the endothelium.

The resulting factor VIIa/TF complex proteolytically activates its substrates, factors IX and X, triggering a cascade of reactions that leads to the generation of thrombin and a fibrin clot as described above.

While clotting as a result of an injury to a blood vessel is a critical physiological process for mammals, clotting can also lead to disease states. A pathological process called thrombosis results when platelet aggregation and/or a fibrin clot blocks (i. e. , occludes) a blood vessel. Arterial thrombosis may result in ischemic necrosis of the tissue supplied by the artery. When the

thrombosis occurs in a coronary artery, a myocardial infarction or heart attack can result. A thrombosis occurring in a vein may cause tissues drained by the vein to become edematous and inflamed. Thrombosis of a deep vein may be complicated by a pulmonary embolism.

Preventing or treating clots in a blood vessel may be therapeutically useful by inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, inhibiting embolus formation, and for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels.

In order to treat such conditions, researchers have sought to discover chemical compounds that efficaciously and selectively control the clotting process. In addition, such compounds may provide a better understanding of the pathways involved in the coagulation process.

Thus far, many of the compounds that have been discovered possess a polar or basic functional group which is integrally responsible for the desired biological activity. Frequently, this polar functional group is a nitrogen atom of, for example, a guanidine, alkyl-amidine or aryl-amidine group. Because these functionalities are highly basic, they remain protonated at physiologically relevant pH's. The ionic nature of such protonated species hinders their permeability across lipophilic membranes, which can reduce bioavailability when the pharmaceutical agent is administered orally.

In order to circumvent such a problem, it is often advantageous to perform a derivatization or chemical modification of the polar functionality such that the pharmaceutical agent becomes neutrally charged and more

lipophilic, thereby facilitating absorption of the drug.

However, for the derivatization to be useful, the derivatization must be bioconvertable at the target site or sites of desired pharmacological activity and cleaved under normal physiological conditions to yield the biologically active drug. The term"prodrug"has been used to denote such a chemically modified intermediate.

Summary of the Invention Among the various aspects of the present invention, therefore, is the provision of compounds useful for selective inhibition of certain enzymes that act upon the coagulation cascade thereby preventing and treating thrombotic conditions in mammals.

Another aspect of the present invention is the provision of prodrug compounds useful for selective inhibition of certain enzymes that act upon the coagulation cascade thereby preventing and treating thrombotic conditions in mammals. In general, these prodrug compounds undergo hydrolysis, oxidation, reduction or elimination at a derivatized amidine group to yield the active compound.

Briefly, therefore, the present invention is directed to a compound, per se, to a prodrug of the compound, to pharmaceutical compositions comprising the compound or prodrug and a pharmaceutically acceptable carrier, and to methods of use. The compound corresponds to formula (1) :

wherein: X, and X6 are members of an unsaturated heterocyclic ring, and are independently nitrogen, CH, C (F), C (C1), or C (Br) ; L1 is a linker, linking Z1 to the heterocyclic ring and optionally additionally containing a bond to X6 to. form a fused ring with the heterocyclic ring; Z1 is C1-C8 alkyl, C2-C, alkenyl, or C2-C8 alkynyl, the alkyl, alkenyl, or alkynyl being optionally substituted with fluorine, hydroxy, carboxy, or alkoxycarbonyl; Z3 comprises a substituted phenyl, thienyl, or furanyl ring, the phenyl, thienyl, or furanyl ring being substituted with an amidine or a derivatized amidine group, and optionally substituted with fluorine, hydroxy, carboxy, alkoxycarbonyl, or hydrocarbyloxy; Z4 comprises a 5-or 6-membered heteroaryl or aryl ring, the ring atoms of Z4 being Z401 Z411 Z42t Z44 and Z*5 when Z4 is a 5-membered ring and Z401 Z41t Z42t Z43, Z44 and Z45 when Z4 is a 6-membered ring, Z40, Z41, Z42, Z43, Z44 and Z45, being carbon, nitrogen, oxygen or sulfur, Z40 being the ring atom through which Z4 is attached to the heterocyclic core ring, Z41 and Z45 each being in an alpha position relative to Z40, Z42 and Z44 each being in a beta position relative to Z40, Z43 being in the gamma position relative to Z40 when Z4 is a 6-membered ring, Z4 having a substituent R42 covalently attached to Z42, and a second substituent bonded to one of Z41, Z43, Z44, or Z45, the substituent being R41 when bonded to Z4. the substituent being R43 when bonded to Z43, the substituent being R44 when bonded to Z44, and the substituent being R45 when bonded to Z45 ; R42 is amino; and R41, R43, R44 and R45 are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, heterocyclo, halogen, or a substituted or unsubstituted heteroatom selected from nitrogen, oxygen, sulfur and phosphorus,

provided at least one of R41, R43, R44 or R45 is other than hydrogen.

Other aspects and features of this invention will be in part apparent and in part pointed out hereafter.

Abbreviations and Definitions The term"elimination"as used herein is generally meant to encompass any one or more of the following reactions: (1) a reaction that results in a compound fragmenting into two or more compounds; and (2) a reaction that results in one or more groups being removed from a compounds without being replaced by other groups.

The term"oxidation"as used herein is generally meant to encompass any one or more of the following reactions: (1) a reaction that results in an increase in the oxidation number of an atom in a compound, whether the atom is uncharged or charged and whether free or covalently bound; (2) a reaction that results in the loss of hydrogen from a compound; (3) a reaction that results in the loss or removal of one or more electrons from a compound, with or without concomitant loss or removal of a proton or protons; (4) the action or process of reacting a compound with oxygen; and (5) a reaction that results in the addition of one or more oxygen atoms to a compound.

The term"reduction"as used herein is generally meant to encompass any one or more of the following reactions: (1) any reaction which results in a decrease in the oxidation number of an atom in a compound; and (2) any reaction that results in oxygen being withdrawn from, hydrogen being added to, or an electron being added to (with or without the addition of a proton) a compound.

The term"hydrolysis"as used herein is generally meant to encompass any one or more of the following reactions: (1) any reaction which results in the addition of a nucleophile to a compound to form a new bond with concurrent loss of a group from the compound; (2) any

reaction which results in the addition of water to a compound; and (3) any reaction that results in the rupture of one or more chemical bonds by reaction with, and involving the addition of, the elements of water.

The term"physiological conditions"are those conditions characteristic to an organism's (to a human. beings) healthy or normal functioning.

The terms"hydrocarbon"and"hydrocarbyl"as used herein describe organic compounds or radicals consisting exclusively of the elements carbon and hydrogen. These moieties include alkyl, alkenyl, alkynyl, and aryl moieties. These moieties also include alkyl, alkenyl, alkynyl, and aryl moieties substituted with other aliphatic or cyclic hydrocarbon groups, such as alkaryl, alkenaryl and alkynaryl. Unless otherwise indicated, these moieties preferably comprise 1 to 20 carbon atoms.

The"substituted hydrocarbyl"moieties described herein are hydrocarbyl moieties which are substituted with at least one atom other than carbon, including moieties in which a carbon chain atom is substituted with a heteroatom such as nitrogen, oxygen, silicon, phosphorus, boron, sulfur, or a halogen atom. Exemplary substituted hydrocarbyl moieties include, heterocyclo, alkoxyalkyl, alkenyloxyalkyl, alkynyloxyalkyl, aryloxyalkyl, hydroxyalkyl, protected hydroxyalkyl, keto, acyl, nitroalkyl, aminoalkyl, cyano, alkylthioalkyl, arylthioalkyl, ketals, acetals, amides, acids, esters and the like.

The term"heteroatom"shall mean atoms other than carbon and hydrogen.

Unless otherwise indicated, the alkyl groups described herein are preferably lower alkyl containing from one to eight carbon atoms in the principal chain and up to 20 carbon atoms. They may be straight or branched chain or cyclic and include methyl, ethyl, propyl, isopropyl, cycylopropyl, butyl, hexyl and the like.

Unless otherwise indicated, the alkenyl groups described herein are preferably lower alkenyl containing from two to eight carbon atoms in the principal chain and up to 20 carbon atoms. They may be straight or branched chain or cyclic and include ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, hexenyl, and the like.

Unless otherwise indicated, the alkynyl groups described herein are preferably lower alkynyl containing from two to eight carbon atoms in the principal chain and up to 20 carbon atoms. They may be straight or branched chain and include ethynyl, propynyl, butynyl, isobutynyl, hexynyl, and the like.

The terms"aryl"or."ar"as used herein alone or as part of another group denote optionally substituted homocyclic aromatic groups, preferably monocyclic or bicyclic groups containing from 6 to 12 carbons in the ring portion, such as phenyl, biphenyl, naphthyl, substituted phenyl, substituted biphenyl or substituted naphthyl. Phenyl and substituted phenyl are the more preferred aryl.

The terms"halogen"or"halo"as used herein alone or as part of another group refer to chlorine, bromine, fluorine, and iodine.

The terms"heterocyclo"or"heterocyclic"as used herein alone or as part of another group denote optionally substituted, fully saturated or unsaturated, monocyclic or bicyclic, aromatic or nonaromatic groups having at least one heteroatom in at least one ring, and preferably 5 or 6 atoms in each ring. The heterocyclo group preferably has 1 or 2 oxygen atoms, 1 or 2 sulfur atoms, and/or 1 to 4 nitrogen atoms in the ring, and may be bonded to the remainder of the molecule through a carbon or heteroatom.

Exemplary heterocyclo include heteroaromatics such as furanyl, thienyl, pyridyl, oxazolyl, pyrrolyl, indolyl, quinolinyl, or isoquinolinyl and the like. Exemplary substituents include one or more of the following groups:

hydrocarbyl, substituted hydrocarbyl, keto, hydroxy, protected hydroxy, acyl, acyloxy, alkoxy, alkenoxy, alkynoxy, aryloxy, halogen, amido, amino, nitro, cyano, thiol, ketals, acetals, esters and ethers.

The term"heteroaromatic"as used herein alone or as part of another group denote optionally substituted aromatic groups having at least one heteroatom in at least one ring, and preferably 5 or 6 atoms in each ring. The heteroaromatic group preferably has 1 or 2 oxygen atoms, 1 or 2 sulfur atoms, and/or 1 to 4 nitrogen atoms in the ring, and may be bonded to the remainder of the molecule through a carbon or heteroatom. Exemplary heteroaromatics include furanyl, thienyl, pyridyl, oxazolyl, pyrrolyl, indolyl, quinolinyl, or isoquinolinyl and the like.

Exemplary substituents include one or more of the following groups: hydrocarbyl, substituted hydrocarbyl, keto, hydroxy, protected hydroxy, acyl, acyloxy, alkoxy, alkenoxy, alkynoxy, aryloxy, halogen, amido, amino, nitro, cyano, thiol, ketals, acetals, esters and ethers.

The term"acetamidyl"as used herein describes a chemical moiety represented by the formula NR1C (0) R2.

The term"carboxamido"as used herein, describes a chemical moiety represented by the formula C (O) NR1R2.

The term"alkoxycarbonyl"as used herein describes a chemical moiety represented by the formula C (O) OR.

The term"sulfonamido"as used herein describes a chemical moiety represented by the formula SO2NR1R2.

The term"alkylsulfonyl"as used herein describes a chemical moiety represented by the formula SO2R.

The term"sulfonamidyl"as used herein describes a chemical moiety represented by the formula NRSO2R.

As described herein for the terms"acetamidyl", "carboxamido","alkocycarbonyl","sulfonamido", "alkylsulfonyl", and"sulfonamidyl", R, Ri and R2 are independently hydrogen, alkyl, aryl, and arylakyl, optionally substituted with halogen, hydroxy or alkoxy.

Description of the Preferred Embodiment One aspect of the invention embraces compounds that correspond to formula (1) :

wherein: X5 and X6 are members of an unsaturated heterocyclic ring, and are independently nitrogen, CH, C (F), C (C1), or C (Br); Li is a linker, linking Z1 to the heterocyclic ring and optionally additionally containing a bond to X6 to form a fused ring with the heterocyclic ring; is Cl-C8 alkyl, C2-C8 alkenyl, or C2-C8 alkynyl, the alkyl, alkenyl, or alkynyl being optionally substituted with fluorine, hydroxy, carboxy, or alkoxycarbonyl; Z3 comprises a substituted phenyl, thienyl, or furanyl ring, the phenyl, thienyl, or furanyl ring being substituted with an amidine or a derivatized amidine group, and optionally substituted with fluorine, hydroxy, carboxy, alkoxycarbonyl, or hydrocarbyloxy; Z4 comprises a 5-or 6-membered heteroaryl or aryl ring, the ring atoms of Z4 being Z40, Z411 Z42, Z44 and Z4. when Z4 is a 5-membered ring and Z401 Z411 Z42, Z43, Z44 and Z45 when Z4 is a 6-membered ring, Z40, Z41, Z42, Z43, Z44 and Z45, being carbon, nitrogen, oxygen or sulfur, Z40 being the ring atom through which Z4 is attached to the heterocyclic core ring, Z41 and Z45 each being in an alpha position relative to Z40, Z42 and Z44 each being in a beta

position relative to Z40/Z43 being in the gamma position relative to Z40 when Z4 is a 6-membered ring, Z4 having a substituent R42 covalently attached to Z42, and a second substituent bonded to one of Z41, Z43, Z44, or Z45, the substituent being R41 when bonded to Z411 the substituent being R43 when bonded to Z43, the substituent being R44 when bonded to Z44, and the substituent being R4. when bonded to Zig ; R42 is amino ; and R41, R43, R44 and R4. are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, heterocyclo, halogen, or a substituted or unsubstituted heteroatom selected from nitrogen, oxygen, sulfur and phosphorus, provided at least one of R41, R43, R44 or R45 is other than hydrogen.

In another embodiment of compounds of formula (1), Z is Cl-C. alkyl, C2-C, alkenyl, or C2-C8 alkynyl, the alkyl, alkenyl, or alkynyl being optionally substituted with fluorine; Z3 comprises a substituted phenyl or substituted thienyl ring, the phenyl or thienyl ring being substituted with an amidine or a derivatized amidine group, and optionally further substituted with fluorine or hydroxy; R44 is hydrocarbyl, substituted hydrocarbyl, heterocyclo, halogen, or a substituted or unsubstituted heteroatom selected from nitrogen, oxygen, sulfur and phosphorus; and Xi, X6, Ll, L3, Z4 and R42 are as defined above.

In another embodiment of compounds corresponding to formula (1), Xs is CH, X6 is nitrogen and Ll, Z1, Z3 and Z4 are as defined above. In an alternative embodiment of compounds of formula (1), Xs and X6 are CH and Ll, Z1, Z3 and Z4 are as defined above. In another alternative embodiment of compounds of formula (1), Xs is nitrogen, X6 is CH and Ll, Z1, Z3 and Z4 are as defined above. In yet another alternative embodiment of compounds of formula

(1), Xs and X6 are nitrogen and Ll, Z1, Z3 and Z4 are as defined above.

In one embodiment of compounds corresponding to formula (1), the Li linkage is a bond or an alkylene chain, (CH2) m wherein m is 0 to 5. In another embodiment, m is 0 to 2. A preferred L1 linkage is a bond.

In one embodiment of compounds corresponding to formula (1), Z1 is Cl-ces alkyl optionally substituted at any substitutable position with fluorine, hydroxy, carboxy or alkoxycarbonyl. Preferred Ci-Cg alkyl groups include propyl, isopropyl, cyclopropyl, tert-butyl and cyclobutyl.

In another alternative of this embodiment (i. e. , when Z is optionally substituted Cl-ces alkyl), Z1 is other than isopropyl or cyclobutyl. In still another alternative of this embodiment, Z1 is other than unsubstituted isopropyl or cyclobutyl. In yet still another alternative of this embodiment, Z1 is isopropyl or cyclobutyl substituted with fluorine, hydroxy, carboxy, or alkocycarbonyl. In another alternative of this embodiment, Z, is trifluoroethyl or carboxymethyl.

In one embodiment of compounds corresponding to formula (1), Z3 comprises a substituted phenyl, thienyl or furanyl ring, the phenyl, thienyl or furanyl ring being substituted with an amidine or a derivatized amidine group and optionally substituted at any substitutable position with fluorine, hydroxy, carboxy, alkoxycarbonyl or hydrocarbyloxy. In another alternative of this embodiment, Z3 is subsituted with an amidine or a derivatized amidine group and at least one of hydroxy, carboxy, alkoxycarbonyl, or hydrocarbyloxy. In still another alternative of this embodiment, Z3 is hydroxy or carboxy substituted. In yet another alternative of this embodiment, Z3 corresponds to formula (a):

wherein R304 and R3o6 are independently selected from the group consisting of hydrogen, fluorine, hydroxy, carboxy, hydrocarbyloxy, and alkoxycarbonyl; and R305 and R30, are independently selected from the group consisting of hydrogen, fluorine, methoxy, hydroxy, and carboxy.

Preferred R304, R. 3os, R306, and R307 include hydrogen, fluorine, hydroxy, carboxy and methoxy.

In still another alternative of this embodiment, Z3 is other than 4-amidinobenzyl, 4-amidino-2-fluorobenzyl, and 4-amidino-3-fluorobenzyl.

In another embodiment, Z3 is a phenyl, thienyl, or furanyl ring substituted with a derivatized amidine which, upon hydrolysis, oxidation, reduction, or elimination, or any combination thereof, under physiological conditions yields an amidine group, as discussed more fully below.

In one embodiment, Z4 corresponds to formula (b):

wherein R42 is amino; R44 is hydrocarbyl, substituted hydrocarbyl, halogen or an optionally substituted heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur; and R41, R43 and R45 are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, halogen or an optionally substituted heteroatom selected from the group consisting of oxygen, nitrogen and sulfur.

In another embodiment of compounds wherein Z4 corresponds to formula (b) and R42 is amino, R44 is selected from the group consisting of hydrocarbyl, substituted hydrocarbyl, acetamidyl, alkoxy, hydroxy, amino, alkylsulfonyl, haloalkoxy, haloalkythio, alkoxycarbonyl, carboxy, sulfonamido, carboxamido and sulfonamidyl, optionally substituted with fluorine. In another alternative of this embodiment (i. e. , when Z4 corresponds to formula (b) and R42 is amino), R44 is selected from the group consisting of hydrocarbyl, substituted hydrocarbyl, acetamidyl, alkoxy, hydroxy, amino, alkylsulfonyl, haloalkoxy, haloalkythio, alkoxycarbonyl, sulfonamido, carboxamido and sulfonamidyl, optionally substituted with fluorine. In still another alternative of this embodiment, R44 is selected from the group consisting of hydroxy, carboxy, carboxamido, alkoxy, alkylsulfonyl, sulfonamido, and alkoxycarbonyl. In yet

another alternative of this embodiment, R44 is selected from the group consisting of sec-butylamide, carboxy, ethoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isopropylamide and hydroxy. In still another alternative of this embodiment R41, R43 and R45 are independently selected from the group consisting of hydrogen, halogen, alkoxy, or hydroxy and R44 is as defined in any of the alternative embodiments above. In yet another alternative of this embodiment, R41, R43 and R45 are independently selected from the group consisting of hydrogen and halogen and R44 is as defined in any of the alternative embodiments above. In still another alternative of this embodiment, Z41/Z43 or Z45 is substituted with fluorine or chlorine. A preferred halogen is chlorine. A more preferred halogen is fluorine. A preferred alkoxy is methoxy.

In another embodiment of compounds wherein Z4 corresponds to formula (b) and R42 is amino, R45 is selected from the group consisting of hydrocarbyl, substituted hydrocarbyl, acetamidyl, alkoxy, hydroxy, amino, alkylsulfonyl, haloalkoxy, haloalkythio, alkoxycarbonyl, carboxy, sulfonamido, carboxamido and sulfonamidyl, optionally substituted with fluorine. In another alternative of this embodiment (i. e. , when Z4 corresponds to formula (b) and R42 is amino), R45 is selected from the group consisting of hydrocarbyl, substituted hydrocarbyl, acetamidyl, alkoxy, hydroxy, amino, alkylsulfonyl, haloalkoxy, haloalkythio, alkoxycarbonyl, sulfonamido, carboxamido and sulfonamidyl, optionally substituted with fluorine. In still another alternative of this embodiment, R45 is selected from the group consisting of hydroxy, carboxy, carboxamido, alkoxy, alkylsulfonyl, sulfonamido, and alkoxycarbonyl. In yet another alternative of this embodiment, R45 is selected from the group consisting of sec-butylamide, carboxy, ethoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isopropylamide and hydroxy. In still another alternative

of this embodiment R4l, R43 and R44 are independently selected from the group consisting of hydrogen, halogen, alkoxy, or hydroxy and R45 is as defined in any of the alternative embodiments above. In yet another alternative of this embodiment, R41, R43 and R44 are independently selected from the group consisting of hydrogen and halogen and R45 is as defined in any of the alternative embodiments above. In still another alternative of this embodiment, Z411 Z43 or Z44 is substituted with fluorine or chlorine. A preferred halogen is chlorine. A more preferred halogen is fluorine. A preferred alkoxy is methoxy.

In yet another embodiment of compounds wherein Z4 corresponds to formula. (b) and R42 is amino, R43 is selected from the group consisting of hydrocarbyl, substituted hydrocarbyl, acetamidyl, alkoxy, hydroxy, amino, alkylsulfonyl, haloalkoxy, haloalkythio, alkoxycarbonyl, carboxy, sulfonamido, carboxamido and sulfonamidyl, optionally substituted with fluorine. In another alternative of this embodiment (i. e. , when Z4 corresponds to formula (b) and R42 is amino), Ra3 is selected from the group consisting of hydrocarbyl, substituted hydrocarbyl, acetamidyl, alkoxy, hydroxy, amino, alkylsulfonyl, haloalkoxy, haloalkythio, alkoxycarbonyl, sulfonamido, carboxamido and sulfonamidyl, optionally substituted with fluorine. In still another alternative of this embodiment, R43 is selected from the group consisting of hydroxy, carboxy, carboxamido, alkoxy, alkylsulfonyl, sulfonamido, and alkoxycarbonyl. In yet another alternative of this embodiment, R43 is selected from the group consisting of sec-butylamide, carboxy, ethoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isopropylamide and hydroxy. In still another alternative of this embodiment R4l, R44 and R45 are independently selected from the group consisting of hydrogen, halogen, alkoxy, or hydroxy and R43 is as defined in any of the alternative embodiments above. In yet another alternative

of this embodiment, R41, R44 and R,,, are independently selected from the group consisting of hydrogen and halogen and R43 is as defined in any of the alternative embodiments above. In still another alternative of this embodiment, Z41 Z44 or Z45 iS substituted with fluorine or chlorine. A preferred halogen is chlorine. A more preferred halogen is fluorine. A preferred alkoxy is methoxy.

In still another embodiment of compounds wherein Z4 corresponds to formula (b) and R42 is amino, R41 is selected from the group consisting of hydrocarbyl, substituted hydrocarbyl, acetamidyl, alkoxy, hydroxy, amino, alkylsulfonyl, haloalkoxy, haloalkythio, alkoxycarbonyl, carboxy, sulfonamido, carboxamido and. sulfonamidyl, optionally substituted with fluorine. In another alternative of this embodiment (i. e. , when Z4 corresponds to formula (b) and R42 is amino), R41 is selected from the group consisting of hydrocarbyl, substituted hydrocarbyl, acetamidyl, alkoxy, hydroxy, amino, alkylsulfonyl, haloalkoxy, haloalkythio, alkoxycarbonyl, sulfonamido, carboxamido and sulfonamidyl, optionally substituted with fluorine. In still another alternative of this embodiment, R41 is selected from the group consisting of hydroxy, carboxy, carboxamido, alkoxy, alkylsulfonyl, sulfonamido, and alkoxycarbonyl. In yet another alternative of this embodiment, R, : L is selected from the group consisting of sec-butylamide, carboxy, ethoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isopropylamide and hydroxy. In still another alternative of this embodiment R43, R44 and R45 are independently selected from the group consisting of hydrogen, halogen, alkoxy, or hydroxy and R41 is as defined in any of the alternative embodiments above. In yet another alternative of this embodiment, R43, R44 and R4. are independently selected from the group consisting of hydrogen and halogen and R41 is as defined in any of the alternative embodiments above. In still another alternative of this embodiment,

Z43, Z44 or Z45 is substituted with fluorine or chlorine. A preferred halogen is chlorine. A more preferred halogen is fluorine. A preferred alkoxy is methoxy.

In one embodiment of compounds corresponding to formula (1), Li is a bond. In one alternative of this embodiment (i. e. , when Li is a bond), Z1 is Ci-Cg alkyl substituted at any substitutable position with fluorine, hydroxy, carboxy or alkoxycaronyl. In another alternative of this embodiment, Zl is an unsubstituted Cl-C5 alkyl group. In another alternative of this embodiment, Z3 is phenyl substituted with an amidine group and optionally substituted at any substitutable position with fluorine, hydroxy, carboxy, of hydrocarbyloxy. In another alternative of this embodiment, Z3 is phenyl substituted with a derivatized amidine group which, upon hydrolysis, oxidation, reduction, or elimination, or any combination thereof, under physiological conditions yields an amidine group. In yet another alternative of this embodiment, Z4 is phenyl substituted with R42 and R44 wherein R42 is amino and R44 is selected from the group consisting of hydrocarbyl, substituted hydrocarbyl, acetamidyl, alkoxy, hydroxy, amino, alkylsulfonyl, haloalkoxy, haloalkythio, alkoxycarbonyl, carboxy, sulfonamido, carboxamido and sulfonamidyl, optionally substituted with fluorine. In still a further alternative of this embodiment, Z4 is phenyl substituted with R42 and R,, wherein R42 is amino and R45 is selected from the group consisting of hydrocarbyl, substituted hydrocarbyl, acetamidyl, alkoxy, hydroxy, amino, alkylsulfonyl, haloalkoxy, haloalkythio, alkoxycarbonyl, carboxy, sulfonamido, carboxamido and sulfonamidyl, optionally substituted with fluorine. In another alternative embodiment of this embodiment, Z4 is phenyl substituted with R42 and R43 wherein R42 is amino and R43 is selected from the group consisting of hydrocarbyl, substituted hydrocarbyl, acetamidyl, alkoxy, hydroxy, amino, alkylsulfonyl, haloalkoxy, haloalkythio,

alkoxycarbonyl, carboxy, sulfonamido, carboxamido and sulfonamidyl, optionally substituted with fluorine. In still another alternative of this embodiment, Z4 is phenyl substituted with R42 and R41 wherein R42 is amino and R41 is selected from the group consisting of hydrocarbyl, substituted hydrocarbyl, acetamidyl, alkoxy, hydroxy, amino, alkylsulfonyl, haloalkoxy, haloalkythio, alkoxycarbonyl, carboxy, sulfonamido, carboxamido and sulfonamidyl, optionally substituted with fluorine.

In another embodiment of compounds corresponding to formula (1), Z1 is Cl-C. alkyl optionally substituted at any substitutable position with fluorine, hydroxy, carboxy, or alkoxycarbonyl. In one alternative of this embodiment (i. e. , when Z1 is optionally substituted Cl-C, alkyl), L1 is a bond, methylene or ethylene. In another alternative of this embodiment, Z3 is phenyl substituted with an amidine group and optionally substituted at any substitutable position with fluorine, hydroxy, carboxy, alkoxycarbonyl, or hydrocarbyloxy. In another alternative of this embodiment, Z3 is a phenyl substituted with a derivatized amidine group which, upon hydrolysis, oxidation, reduction, or elimination, or any combination thereof, under physiological conditions yields an amidine group. In still another alternative of this embodiment, Z4 is phenyl substituted with R42 and R44 wherein R42 is amino and R44 is selected from the group consisting of hydrocarbyl, substituted hydrocarbyl, acetamidyl, alkoxy, hydroxy, amino, alkylsulfonyl, haloalkoxy, haloalkythio, alkoxycarbonyl, carboxy, sulfonamido, carboxamido and sulfonamidyl, optionally substituted with fluorine.

In another embodiment of compounds corresponding to formula (1), Z3 is phenyl substituted with an amidine group and optionally substituted at any substitutable position with fluorine, hydroxy, carboxy, alkoxycarbonyl, or hydrocarbyloxy. In one alternative of this embodiment (i. e. , when Z3 is substituted or unsubstituted

benzamidine), L1 is a bond, methylene or ethylene. In another alternative of this embodiment, Z, is Cl-C. alkyl optionally substituted at any substitutable position with fluorine, hydroxy, carboxy, or alkoxycarbonyl. In still another alternative of this embodiment, Z4 is phenyl substituted with R42 and R44 wherein R42 is amino and R44 is selected from the group consisting of hydrocarbyl, substituted hydrocarbyl, acetamidyl, alkoxy, hydroxy, amino, alkylsulfonyl, haloalkoxy, haloalkythio, alkoxycarbonyl, carboxy, sulfonamido, carboxamido and sulfonamidyl, optionally substituted with fluorine.

In yet another embodiment, Z4 corresponds to formula (b) wherein R42 is amino and R41, R43, R44 and R45 are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, heterocyclo, halogen, or a substituted or unsubstituted heteroatom selected from nitrogen, oxygen, sulfur and phosphorus, provided at least one of R41, R43, R44 or R45 is other than hydrogen. In one alternative of this embodiment (i. e. , when Z4 is disubstituted phenyl), L is a bond, methylene or ethylene. In another alternative of this embodiment, Z1 is Cl-C. alkyl optionally substituted at any substitutable position with fluorine, hydroxy, carboxy or alkoxycarbonyl. In another alternative of this embodiment, Z3 is phenyl substituted with an amidine group and optionally substituted at any substitutable position with fluorine, hydroxy, carboxy, alkoxycarbonyl, or hydrocarbyloxy. In another alternative of this embodiment, Z3 is a phenyl substituted with a derivatized amidine group which, upon hydrolysis, oxidation, reduction, or elimination, or any combination thereof, under physiological conditions yields an amidine group.

In a particularly preferred embodiment of compounds corresponding to formula (1), L, is a bond, Z1 is cyclopropyl or isopropyl optionally substituted with fluorine, hydroxy, carboxy, or alkoxycarbonyl, Z3 is

phenyl substituted with an amidine or derivatized amidine group and optionally further substituted at any substitutable position with fluorine, hydroxy, or carboxy and Z4 is formula (b) wherein R42 is amino and R44 is selected from the group consisting of sec-butylamide, carboxy, ethoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isopropylamide and hydroxy.

In another aspect of the invention, the heterocyclic ring forms a pyrazinone corresponding to formula (2): wherein X. is CH, C (Br), or C (F) and each of Z1, Z3, Z4, Ll, L3, R42, and R44 are as described above for formula (1). In one embodiment, Z1 is other than isopropyl or cyclobutyl.

In one embodiment of compounds corresponding to formula (2), L1 is a bond. In one alternative of this embodiment (i. e. , when L1 is a bond), X. is CH. In another alternative of this embodiment, one of the following conditions exist: (a) Z1 is other than unsubstituted cyclobutyl when X, is CH; (b) Z1 is other than unsubstituted isopropyl when (i) X5 is CH and (ii) Z4 is 3,5-diaminophenyl or 3-amino-5- (2,2, 2-trifluoroacetamide) phenyl; or (c) Z3 is other than 4-amidinobenzyl, 4-amidino-2-fluorobenzyl, or 4-amidino-3- fluorobenzyl. In still another alternative of this embodiment, Z1 is isopropyl or cyclobutyl substituted with fluorine, hydroxy, carboxy, or alkoxycarbonyl.

In a preferred embodiment of compounds corresponding to formula (2), Ll is a bond, Z1 is selected from the group

consisting of cyclopropyl, isopropyl, methyl, ethyl, cyclobutyl, isobutyl, tert-butyl, and sec-butyl optionally substituted at any substitutable position with fluorine, hydroxy, carboxy or alkoxycarbonyl, Z3 is phenyl substituted with an amidine group and optionally substituted with fluorine, hydroxy, carboxy, alkoxycarbonyl, or hydrocarbyloxy, and Z4 is formula (b) wherein R42 is amino and R44 is selected from the group consisting of hydrocarbyl, substituted hydrocarbyl, acetamidyl, alkoxy, hydroxy, amino, alkylsulfonyl, haloalkoxy, haloalkythio, alkoxycarbonyl, carboxy, sulfonamido, carboxamido and sulfonamidyl, optionally substituted with fluorine.

In yet another preferred embodiment, compounds corresponding to formula (2) may be represented by formula (2-a): wherein Z1 is isopropyl or cyclopropyl optionally substituted at any substitutable position with fluorine, hydroxy, carboxy or alkoxycarbonyl; R440 is Cl-C6 alkyl, aryl, aralkyl, carboxy, or carboxyalkyl, wherein said alkyl, aryl, aralkyl, carboxy, or carboxyalkyl is optionally further substituted with fluorine; and

R3, 0 and R311 are independently selected from the group consisting of hydrogen, fluorine, hydroxy, alkoxy, and carboxy.

In another aspect of the invention, the heterocyclic ring forms a pyridone having the following formula (3): wherein X5 is CH, C (Br), C (Cl), or C (F) and each of Z1, Z3, Z4, L1, R42, and R44 are as described above for formula (1).

In one embodiment, Z1 is other than isopropyl or cyclobutyl. In another embodiment, neither Z41 nor Z4. is sulfur when Z4 is thienyl.

In one embodiment for compounds corresponding to formula (3), L1 is a bond. In one alternative of this embodiment (i. e. , when L1 is a bond), Xs is CH. In still another alternative of this embodiment, one of the following conditions exist: (a) Z3 is other than 4- amidinobenzyl, 4-amidino-2-fluorobenzyl, and 4-amidino-3- fluorobenzyl; or (b) (i) Z1 is other than unsubstituted cyclobutyl and unsubstituted isopropyl when X, is CH or C (Cl) and (ii) neither Z41 nor Z4. is sulfur when Z4 is thienyl. In yet another alternative of this embodiment, Z1 is isopropyl or cyclobutyl substituted with fluorine, hydroxy, carboxy, or alkoxycarbonyl.

In a preferred embodiment of compounds corresponding to formula (3), Ll is a bond, Z1 is selected from the group consisting of cyclopropyl, isopropyl, methyl, ethyl, cyclobutyl, isobutyl, tert-butyl, and sec-butyl optionally substituted at any substitutable position with fluorine,

hydroxy, carboxy or alkoxycarbonyl, Z3 is phenyl substituted with an amidine group and optionally substituted with fluorine, hydroxy, carboxy, alkoxycarbonyl, or hydrocarbyloxy, and Z4 is formula (b) wherein R42 is amino and R44 is selected from the group consisting of hydrocarbyl, substituted hydrocarbyl, acetamidyl, alkoxy, hydroxy, amino, alkylsulfonyl, haloalkoxy, haloalkythio, alkoxycarbonyl, carboxy, sulfonamido, carboxamido and sulfonamidyl, optionally substituted with fluorine.

In another aspect of the invention, the heterocyclic ring forms a pyrimidinone corresponding to formula (4): wherein X6 is CH, C (Br), C (C1), or C (F) and each of Zl, Z3, Z4, Ll, R42, and R44 are as described above for formula (1).

In one embodiment, Z1 is other than isopropyl or cyclobutyl. In another embodiment neither Z41 nor Z4. is sulfur when Z4 is thienyl. In a preferred embodiment, X6 is CH.

In one embodiment of compounds corresponding to formula (4), Ll is a bond. In one alternative of this embodiment (i. e. , when L, is a bond), X6 is CH. In another alternative of this embodiment, Z. is other than unsubstituted cyclobutyl or unsubstituted isopropyl and neither Z41 nor Z45 is sulfur when Z4 is thienyl. In still another alternative of this embodiment, Zi is isopropyl or cyclobutyl substituted with fluorine, hydroxy, carboxy, or alkoxycarbonyl.

In a preferred embodiment of compounds corresponding to formula (4), L, is a bond, Z1 is selected from the group consisting of cyclopropyl, methyl, ethyl, isobutyl, tert- butyl, and sec-butyl optionally substituted at any substitutable position with fluorine, hydroxy, carboxy or alkoxycarbonyl, Z3 is phenyl substituted with an amidine group and optionally substituted by fluorine, hydroxy, carboxy, alkoxycarbonyl, or hydrocarbyloxy, and Z4 corresponds to formula (b) wherein R42 is amino and R44 is selected from the group consisting of hydrocarbyl, substituted hydrocarbyl, acetamidyl, alkoxy, hydroxy, amino, alkylsulfonyl, haloalkoxy, haloalkythio, alkoxycarbonyl, carboxy, sulfonamido, carboxamido and sulfonamidyl, optionally substituted with fluorine.

In another aspect of the invention, the heterocyclic ring forms a triazinone corresponding to formula (5): wherein each of Zl, Z3, Z4, Ll, R42, and R44 are as described above for formula (1). In one embodiment, Z1 is other than isopropyl or cyclobutyl. In another embodiment neither Z41 nor Z45 is sulfur when Z4 is thienyl.

In one embodiment of compounds corresponding to formula (5), L, is a bond. In one alternative of this embodiment (i. e. , when Li is a bond), Z1 is other than unsubstituted cyclobutyl or unsubstituted isopropyl and neither Z41 nor Z45 is sulfur when Z4 is thienyl. In another alternative of this embodiment, Z1 is isopropyl or

cyclobutyl substituted with fluorine, hydroxy, carboxy or alkoxycarbonyl.

In a preferred embodiment of compounds corresponding to formula (5), Li is a bond, Z1 is selected from the group consisting of cyclopropyl, methyl, ethyl, isobutyl, tert- butyl, and sec-butyl optionally substituted at any substitutable position with fluorine, hydroxy, carboxy or alkoxycarbonyl, Z3 is phenyl substituted with an amidine group and optionally substituted by fluorine, hydroxy, carboxy, alkoxycarbonyl, or hydrocarbyloxy, and Z4 corresponds to formula (b) wherein R42 is amino and R44 is selected from the group consisting of hydrocarbyl, substituted hydrocarbyl, acetamidyl, alkoxy, hydroxy, amino, alkylsulfonyl, haloalkoxy, haloalkythio, alkoxycarbonyl, carboxy, sulfonamido, carboxamido and sulfonamidyl, optionally substituted with fluorine.

Another aspect of the invention embraces compounds which correspond to formula (1) having the fused ring formula (6): wherein Zl, Z4, Z3, X5, X6 are as defined above for formula (1) and L1 contains a bond directly to X6 to form a fused ring with the heterocyclic ring. Exemplary linkages from L1 to X6 contain from one to six atoms forming an aryl, heteroaryl, heterocyclic or carbocyclic fused ring.

Preferred exemplary linkages form a five or six membered aryl, heteroaryl, heterocyclic or carbocyclic fused ring.

In one embodiment, compounds corresponding to formula (6), may be represented by formula (7):

wherein X. is nitrogen, CH, C (F), C (Cl), or C (Br) ; X6 is carbon or nitrogen, provided the dashed line represents a double bond when X6 is carbon and the dashed line represents a single bond when Xó is nitrogen; X7 and X8 are independently carbon, nitrogen, oxygen or sulfur; Z2 is a hydrogen bond acceptor covalently bonded to the carbon gamma to Xs ; n is 0 to 2; and Zl Z3 and Z4 are as defined for formula (1).

In one alternative of this embodiment (i. e., compounds corresponding to formula (7)), X6 is carbon, thereby making the dashed lines represent a double. bond.

In another alternative of this embodiment, X6 is nitrogen thereby making the dashed lines represent a single bond.

Generally, as used herein, hydrogen bond acceptors are heteroatoms that have a lone pair of electrons available for hydrogen bonding. When taken with the carbon to which Z2 is attached, suitable hydrogen bond acceptors are selected from the group consisting of C (O), C (S), C (C1), C (Br), C (F), C (OH), COCH3, COR, C (SH), CSR, and CNRlR2 wherein R, R1 and R2 are independently hydrogen, alkyl, aryl, and arylakyl, optionally substituted with halogen, hydroxy or alkoxy.

In another aspect of the invention, compounds corresponding to any of formulas (1)- (7), have no zwitterionic effect. In one alternative of this embodiment (i. e. , compounds having no zwitterionic effect) wherein Z4 is formula (b) and R42 is amino, R44 is selected from other than carboxy. It is hypothesized that compounds lacking a zwitterionic effect have increased solubility over analogous compounds possessing such zwitterionic effect.

Another aspect of the invention embraces intermediate compounds having either of two formulae. Compounds corresponding to one of the formulas may be represented by formula (8): wherein X, and X6 are independently nitrogen, CH, C (F) or C (Br) ; T3is hydroxy, alkoxy, substituted alkoxy, or substituted amino; T4 is Cl, Br, I, S (CH3), or OSO2 (CF3); Zl is Cl-C8 alkyl, C2-C8 alkenyl, or C2-C8 alkynyl, the alkyl, alkenyl, or alkynyl being optionally substituted with fluorine, hydroxy, carboxy, or alkoxycarbonyl; and Z2 is a hydrogen bond acceptor covalently bonded to the carbon gamma to X5.

Intermediate compounds represented by the other formula may be represented by formula (9):

wherein X5 and X6 are independently nitrogen, CH, C (F) or C (Br) ; Z, is C1-C8 alkyl, C-Cg alkenyl, or Ca-Ce alkynyl, the alkyl, alkenyl, or alkynyl being optionally substituted with fluorine, hydroxy, carboxy, or alkoxycarbonyl; Z2 is a hydrogen bond acceptor covalently bonded to the carbon gamma to X5 ; and Z4 is hydrocarbyl, substituted hydrocarbyl, or a 5- or 6-membered heterocyclic or carbocyclic ring, the ring atoms of the 5-or 6-membered heterocyclic or carboxylic ring of Z4 being carbon, nitrogen, oxygen, or sulfur.

In one embodiment of compounds corresponding to either formula (8) or (9), hydrogen bond acceptors are as defined above.

Among the preferred embodiments, therefore, are compounds corresponding to any of formulas (1)- (7), wherein Z., is selected from the group consisting of cyclopropyl, isopropyl, methyl, ethyl, cyclobutyl, isobutyl, and sec-butyl optionally substituted with fluorine, hydroxy, carboxy, or alkoxycarbonyl, L1 is a bond, Z3 is phenyl, thienyl, or furanyl ring substituted with an amidine or a derivatized amidine group and optionally further substituted at any position with fluorine, hydroxy, carboxy, alkoxycarbonyl, or hydrocarbyloxy and Z4 is a phenyl ring having two substituents, R42 and R44.

In another embodiment of compounds corresponding to any of formulas (1)- (7), Z4 is phenyl ring having two substituents, R42 and one of R4 ;, R43, R44, or R45. Preferred substituents of Z4 are R42 and R43. More preferred substituents of Z4 are R42 and R4,. The most preferred substituents of Z4 are R42 and R44. Preferred R42 and R44 groups are as described above. Particularly preferred R44 groups are sec-butylamide, carboxy, ethoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isopropylamide and hydroxy.

In another embodiment of compounds corresponding to any of formulas (1)- (7), Z4 is a 5-membered heteroaryl ring having two substituents, R42 and R44, provided neither Z41 nor Z4. is sulfur when Z4 is thienyl. Preferred R42 and R44 groups are as described above. Particularly preferred R44 groups are sec-butylamide, carboxy, ethoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isopropylamide and hydroxy.

A further aspect of the invention embraces compounds that are prodrugs of any of the compounds corresponding to formulas (1)- (7). Generally speaking, any prodrug compound of the present invention having one or more prodrug moieties as part of the compound, can be converted under physiological conditions to the biologically active drug by a number of chemical and biological mechanisms.

Typically, the prodrug compounds have phenyl or thienyl rings at position Z3 substituted with a derivatized amidine which, upon hydrolysis, oxidation, reduction or elimination yields an amidine group. For illustrative purposes, the following paragraphs detail conversion of the prodrug to the biologically active compound when the prodrug moiety is covalently bonded to the amidine group on Z3.

In one embodiment, conversion of the prodrug to the biologically active drug can be accomplished by hydrolysis of the prodrug moiety provided the prodrug moiety is

chemically or enzymatically hydrolyzable with water. The reaction with water typically results in removal of the prodrug moiety and liberation of the biologically active drug. By way of example, a hydrolyzable prodrug derivative at the amidine group may be a carbonyl derivative such as N-acyl. Hydrolysis results in freeing the amidine group of the drug by removal of the acyl as carbon acid. Other suitable hydrolyzable prodrug derivatives include carbonyl, thiocarbonyl, imine, enamine, and oxygenated sulfur.

Yet another aspect of the invention provides conversion of the prodrug to the biologically active drug by reduction of the prodrug moiety. Typically in this embodiment, the prodrug moiety is reducible under physiological conditions in the presence of a reducing enzymatic process. The reduction preferably results in removal of the prodrug moiety and liberation of the biologically active drug. An example of a reducible prodrug derivative at the amidine group is an oxygen containing group in which an oxygen is directly attached to the amidine. Reduction results in freeing the amidine group of the drug by removal of oxygen as water or an alcohol. Generally speaking, other suitable reducible prodrug derivatives include a nitrogen containing group, and a sulfur containing group, provided both nitrogen and sulfur are each preferably in their most reduced state.

In another embodiment, conversion of the prodrug to the biologically active drug can also be accomplished by oxidation of the prodrug moiety. Typically in this embodiment, the prodrug moiety is oxidizable under physiological conditions in the presence of an oxidative enzymatic process. The oxidation preferably results in removal of the prodrug moiety and liberation of the biologically active drug. An example of an oxidizable prodrug derivative at the amidine group is a hydrocarbyl containing unsaturation in the carbon beta to the carbon

directly connected to the amidine group. Oxidation results in forming an oxygenated intermediate that breaks down, thereby freeing the amidine group of the drug with concurrent hydrolysis of the oxygenated hydrocarbyl residue. Other suitable oxidizable prodrug derivatives of the amidine include saturated hydrocarbyl, unsaturated substituted hydrocarbyl, aryl, and aralkyl.

A further aspect of the invention encompasses conversion of the prodrug to the biologically active drug by elimination of the prodrug moiety. Generally speaking, in this embodiment the prodrug moiety is removed under physiological conditions with a chemical or biological reaction. The elimination results in removal of the prodrug moiety and liberation of the biologically active drug. By way of example, an eliminateable prodrug derivative at the amidine group is a hydrocarbyl containing an unsaturated electron withdrawing group bonded to the carbon beta to the carbon directly connected to the amidine. More specifically, for illustration purposes and exemplification, the hydrocarbyl group could have a cyano group beta to the carbon directly bonded to the amidino group. Elimination results in the freeing of the amidine group of the drug with concurrent removal of the unsaturated hydrocarbyl residue derived from the prodrug moiety. Other suitable eliminateable prodrug derivatives of the amidine include a hydrocarbyl substituted at the beta carbon with carbonyl, alkoxycarbonyl, amidocarbonyl, nitro, or sulfonyl or an alkyl group substituted with oxygen, nitrogen or sulfur at the carbon directly bonded to the amidine group.

Any prodrug compound of the present invention may undergo any combination of the above detailed mechanisms to convert the prodrug to the biologically active compound. For example, a particular compound may undergo hydrolysis, oxidation, elimination, and reduction to convert the prodrug to the biologically active compound.

Equally, a particular compound may undergo only one of these mechanisms to convert the prodrug to the biologically active compound.

A further embodiment embraces compounds having any of formulas (1)- (7) wherein Z3 is -R300C(=NR301)NR302R303, wherein R300 is a 6-membered carbocyclic aromatic ring, R301, R302r R303 are independently selected from the group consisting of hydrogen, halogen, optionally substituted hydrocarbyl, and an optionally substituted heteroatom selected from the group consisting of oxygen, nitrogen, phosphorus and sulfur, provided at least one of R301, R3021 R303 is other than hydrogen. In another alternative of this embodiment, Z3 is-R30oC (=NR3o1) NR302R303. wherein R300 is a 6-membered carbocyclic aromatic ring, and at least two of R301, R302, R303 are ring atoms of a heterocyclic ring. In another alternative of this embodiment, Z3 iS-R300C (=NR301) NR302R303 wherein R300 is a 6-membered carbocyclic aromatic ring, and at least one of R301, R302, R303 are ring atoms of a heterocyclic ring fused to R300.

Yet another embodiment encompasses compounds having any of formulas (1)- (7) wherein Z3 is a benzamidine derivatized with one or more groups selected from carbonyl, thiocarbonyl, imino, enamino, phosphorus, and sulfur, where the benzamidine derivative hydrolyzes under physiological conditions to form benzamidine. In a further embodiment, Z3 is a benzamidine derivatized with one or more groups selected from optionally substituted hydrocarbyl, provided that the carbon atom directly bonded to the amidine is Sp3 hybridized and aryl, where the benzamidine derivative is oxidized under physiological conditions to form benzamidine. In yet another embodiment, Z3 is a benzamidine derivatized with one or more heteroatoms selected from oxygen, nitrogen in its most reduced state, and sulfur in its most reduced state, where the benzamidine derivative is reduced under physiological conditions to form benzamidine. In still

another embodiment, Z3 is a benzamidine derivatized with one or more substituents selected from a hydrocarbyl substituted at the beta carbon with carbonyl, sulfonyl, sulfinyl, cyano, nitro and an alkyl, aryl, or heterocyclic group substituted with oxygen, nitrogen, or sulfur at the carbon directly bonded to the amidine group, where the benzamidine derivative undergoes elimination at physiological conditions to form benzamidine.

In a further embodiment for compounds having any of formulas (1)- (7), Z3 corresponds to formula (c): wherein: R301, R302, and R303 are independently selected from the group consisting of: (i) hydrogen, -C (=O) Ra,-C (=O) ORa,-S (=O) ORa, -S (=O) SRa,-S (=O) 2ORa,-S (=O) 2SRa and alkenyl, wherein Ra is selected from the group consisting of hydrocarbyl, substituted hydrocarbyl, and heterocylo, provided, however, that the carbon atom of R301, R302, and R303 directly bonded to the amidine is sp2 hybridized when R301, R302, and R303 is alkenyl, (ii) hydrogen, optionally substituted hydrocarbyl and aryl, provided, however, the carbon atom of R301, R302, and R303 directly bonded to the amidine is sp3 hybridized when R301, R302, and R303 is optionally substituted hydrocarbyl, (iii) hydrogen,-ORb,-SRb,-NRb, or-N (Rb) 21 wherein

each Rb is independently optionally substituted hydrocarbyl, and heterocylo, and (iv) hydrogen, substituted hydrocarbyl wherein the carbon bonded to the amidine group is substituted with -ORC,-SRC,-NRC, or-N (Rc) 2, wherein each Rc is <BR> <BR> <BR> independently-C (O) Rd, -C (O) NRd,-C (O) ORd,-C (O) N (Rd)2 and each Rd is independently hydrocarbyl, substituted hydrocarbyl or heterocyclo, and substituted alkyl with the carbon atom beta to the point of attachment to the amidine group being an unsaturated electron withdrawing group, provided, however, at least one of R301, R302, and R303 is other than hydrogen; R3. 4 is selected. from the group consisting of halogen, hydrogen, hydroxyl, alkyl, sulfhydryl, alkoxy, and alkylthio; R,,,, is selected from the group consisting of oxygen, sulfur, halogen, hydrogen, hydroxyl, alkyl, sulfhydryl, alkoxy, and alkylthio ; R306 is selected from the group consisting of halogen, hydrogen, hydroxyl, alkyl, sulfhydryl, alkoxy, and alkylthio; and R is selected from the group consisting of oxygen, sulfur, halogen, hydrogen, hydroxyl, alkyl, sulfhydryl, alkoxy, and alkylthio. wherein R301, R302, R303, R304, R305l R306 and R307 are as defined below for each prodrug conversion mechanism.

In one embodiment, the benzamidine derivative is hydrolyzed under physiological conditions to form benzamidine when Z3 is a benzamidine derivative having formula (c) and R301, R302, and R303 are independently selected from hydrogen,-C (=O) Ra,-C (=O) ORa,-S (=O) ORa, - S (=O) SRa,-S (=0) 2ORa,-S (=O) 2SRa and alkenyl, wherein Ra is selected from the group consisting of hydrocarbyl, substituted hydrocarbyl, and heterocylo, provided, however, that the carbon atom of R301, R302, and R303 directly bonded to the amidine is sp2 hybridized when Ruolz

R302, and R303 is alkenyl.

In a further embodiment, the benzamidine derivative is oxidized under physiological conditions to form benzamidine when Z3 is a benzamidine derivative having formula (c) and R301, R302, and R03 are independently selected from hydrogen, optionally substituted hydrocarbyl and aryl, provided, however, the carbon atom of R301, R302, and R303 directly bonded to the amidine is sp3 hybridized when R301, R302, and R303 is optionally substituted hydrocarbyl.

In still another embodiment, the benzamidine derivative is reduced under physiological conditions to form benzamidine when Z3 is a benzamidine derivative having formula (c) and R301, R302, and R31) 3 are independently selected from hydrogen,-ORb,-SRb,-NRb, or-N (Rb) 21 wherein each Rb is independently optionally substituted hydrocarbyl, and heterocylo.

In an alternative embodiment, the benzamidine derivative undergoes elimination at physiological conditions to form benzamidine when Z3 is a benzamidine derivative having formula (c) and R301, R302, and R303 are independently selected from hydrogen, substituted hydrocarbyl wherein the carbon bonded to the amidine group is substituted with -ORc, -SRc, -NRc, or-N (RC) 21 wherein each Rc is independently-C (O) Rd,-C (O) NRd,-C (O) ORd, -C(O) N (Rd) 2 and each Rd is independently hydrocarbyl, substituted hydrocarbyl or heterocyclo, and substituted alkyl with the carbon atom beta to the point of attachment to the amidine group being an unsaturated electron withdrawing group.

In a particularly preferred embodiment, the compound represented by any of formulas (1)- (7) is selected from the group of compounds illustrated in Table 1 below. Certain compounds listed in Table 1 are pharmaceutically acceptable salts of compounds having any of formulas (1)- (7). Some of the salts are depicted as the chemical

formula with the respective compound. For example, compound 1 has 2 molecules of CF3COOH salt per molecule of compound 1. Other salts are depicted as the structural formula with the respective compound. For example, compound 119 has 2.3 molecules of CF3COOH salt per molecule of compound 119. For each compound listed in.

Table 1, the compound number corresponds to the example number.

TABLE 1 Compound Compound No. 1. 0 2 CFCOOH U H N NH2 --N I N e NH H o)-NH\=/NH2 0 2. H o 2CF3COOH 0 H N NH2 nu H H -NH NH2 0 3. NH2 2 CFCOOH Bu Ber I N OH 1f 0 N i H kJNHz NH TABLE 1 Compound Compound No. 4. NH2 2CFaCOOH Bu ION 0 N O N NU NH NH 5. H2N 2CCOOH HAN- Ho N ZON 0 own NUS NH2 NH2 6. NHs 2CCOOH H N N I, N 0 H 0 N H NH2 NH NH 7. NHz 2CCOOH I H 'IN N N C) t J+-: Nez \ NH NH NH TABLE 1 Compound Compound No. 8. H2N 2 CF3COOH 0 HAN N HN-b-F -ly N zozo NHz i NH NHz 9. NHz 2CF, COOH H H N nô N O Nez H NH2 NH NH 10. NH2 FF 2 CFCOOH NHZ H N H N N H H 0 ci NU2 NU NH NH2 2 CF, COOH H H N N H « N'je /nu2 NH TABLE 1 Compound Compound No. 12. NH2 2 CF3COOH N I H N vSl J/N O N Ozon Nu2 NH 13. NH2 2 CF3COOH H H N N ; boy N H 0") . O O N \ A g A0 NH 14. NH2 2 CF3COOH H H ZOZO ; boy N YN 0 NH NU2 NH 15. NHz 2CCOOH H H N N No < xi H W H to NH TABLE 1 Compound Compound No. 16. NH2 2 CF3COOH N 0 N ON N H H W I NH2 NH 17. NH2 2 HCI f I N N N OH J'YN)"OH H 0'' O 0_''/ H \ I NH2 NH 18. F 3HCI F F If I \ O NH2 Non HN43) HAN HN NH 19. NHz 2 CF3COOH fus IF -"'14 0 NU 0 nu N Hz HN TABLE 1 Compound Compound No. 2 0. NH2 2 CF3COOH N ole O. N1 O H ODJ. NH zu F NU 21. NH2 2 CF3COOH N 01-1 N N 0 L) H N H O-'_NH NU NUS 22. NH2 2 CF3COOH Tl ° Neo , o 0 N 0 N H O ou N H NH2 NH 23. NH2 2 CF3COOH -10 N OH N N H 1 O-'N H NH2 NH TABLE 1 Compound Compound No. 24. NH2 2 CF3COOH Nl)/ IN HO N') y H ° O'_NH NU2 HAN NH2 25. NH 2 HCI 1 0 N N HN 0 0)", NH H O''NH H2N NH 2 6. NH2 2 CF3COOH I H H H"j N oui N H H O OXNH Han ITS NH2 TABLE 1 Compound Compound No. 27.'H2N 2 CF, COOH 0 Han Ho ZU HAN 0 own H /NH NH2 28. H2N 2 CF, COOH 0 N N N HAN ozon zon NU2 29. HgN 2CFaCOOH 0 HN H N ho nif ''O-''N I i NH NH2 H2 30. HN 2CFsCOOH 0 Han H\ /\ o 1 HN' O H OXNv NH2 NHz TABLE 1 Compound. Compound No. 31. NH2 2 CF3COOH ci N s N'Y.') 'NH NU H2N NH H2N 3 2. H2N 2 CF3COOH O HN N -OH HN-XIYN 0 0 own °'O''N NUS NHZ 3 3. H2N 2 CF3COOH - HN Han Han N HN /\ 00'-N w i NH NH2 34. HsN 2CCOOH O N O H'LNH H NU /\ OJN w i NH NH2 TABLE 1 Compound Compound No. 3 5. NH2 2 CF3COOH N NH2 I N NU NH2 HN 3 6. NH2 2 CF3COOH I I I O H I NH NU2 han HN HN 2 CF3COOH A N H YN 0 OH O \N H NHZ HN TABLE 1 Compound Compound No. 3 8. HN 2 CF3COOH 0 HN HO N HN NHz NHR 3 9. NH2 2 CF3COOH H ß H N O Nez H A 0"'NH han HO NUS 4 0. xjD 2 CF3COOH O Han-\, N N \__j HN'' own NHz /nu NHZ TABLE 1 Compound Compound No. 41. HN 2 CF3COOH 0 HO N I N HN O HN NU NU2 42. HN 2CCOOH \ O NH2 N HN-Jly N ZON H NH NH2 NH 43. H2N 2 CF3COOH OU HAN NHZ OU HNO N+ NH H NH NH2 44. H2N 2 CF3COOH 0 N N- N j A O H NU NH2 TABLE 1 Compound Compound No. 45. H2N 2 CF, COOH \ O HN N I-IN N OH -Y 0 0 N NU NH2 nus zozo HAN Zu I N HN O IHN 46. H NH2 H2N 2 CF3COOH 47. 0 NH2 N ZU H NU NU2 NH2 H /NH NH2 TABLE 1 Compound Compound No. 4 8. NH2 2 CF3COOH N oll, Nez H O ''NH ' F F F NH F H2N 49. H2N 2 CF, COOH F F N N H NH2 NEZ \ /NHZ "L. NH OH NH 50. H 2. 65 H20 H2N N O N<NH2NH N N Holy 00)", NUS NU O N I NH NH2 TABLE 1 Compound Compound No. 51. NHa 2. 5 CF3COOH F IF N \ v N'lu O NH H2N F NH F 52. NH2 3 CF3COOH + H20 N \ \ F N F H 0'IN H <syN H NH H" NU2 NH2 53. Oz 2CF3COOH N NH2 ZON 0 NH H O1NH nu2 NU NHa TABLE 1 Compound Compound No. 54. NH2 2 CF3COOH O ; NH N OH Nez H o O'_NH NH NH2 55. NH2 3 HCI + 3H20 N OH N ""OH H 0 NH i NH NH2 5 6. N H2 2 CF3COOH H N N 0 N Nay N 1 H O oo NH NH 57. NHZ 2 CF3COOH H N °ONY Nui NU N H I/NH NH TABLE 1 Compound Compound No. 58. NH2 2 CF, COOH H OXO "Y ° 1 0 "IJ"N YN H NHz NH 59. NH2 2 CF3COOH H N A "IN'N 0 NEZ H. W H /NH2 NH 60. l 4 I H N Ho H 0C) N H NHZ NH 61. NH2 2 CF3COOH NHZ N N N out N H 0 c N H NH2 NH TABLE 1 Compound Compound No. 62. NH2 2 CF3COOH H N N Zozo N-0 H i H NH2 NH 6 3. N H2 2 CF3COOH I H N N,,,,,- N O Nez NH O'_ N Fi I/NH NH 64. NH2 2 CF3COOH O NH JN flow H O J. NH nu NH NH 65. 3 CF3COOH NH2 N CF3 \ \ C 3 0"'W O HN 1 nu2 TABLE 1 Compound Compound No. NH2 2 CF, COOH 66. 1 OH OU Yin 0 N 1 JNH NH NH2 67. NH2 2 CF, COOH N CF3 N O N S NH NH2 68. NH2 3 HCI NH N NH2 In NHz Nu S 69. NH2 2 CF3COOH N Non H 0 0 N NHR NH2 TABLE 1 Compound. Compound No. 70. NH2 2 CF3COOH ANA t < Ho Nez NH i NH NHz 71. NH2 2 CF3COOH H I N' ! JLN o H H pN H'NH NHa 7 2. N H2 2 CF3COOH H vJ H H C 0), N H ON"Y H O. N H v NH NHz 73. NH2 2 CF3COOH H C N 0 N H 0 0 NH NU nu kJkNH NHz TABLE 1 Compound Compound No. 74. NH2 2 CF3COOH > - N p' H O NH NH NH2 NH2 3. 5 HCI 75. N N 0 H 0 H A H Nu NHz 76. NH2 2 CF3COOH i N Han °ONH 'fl NH NH 77. NH 3. 5 CF3COOH /I N 0 H tut H--in 00 N H O ON \ NH2 OH NH TABLE 1 Compound Compound No. 78. NH2 3. 5 CF3COOH 0 \ \ \ Jl--O NU2 H o H N H OH 4. 5 CF3COOH N NH2 OH H NHz N NH2 N N H O H NH OH OH 80. NHz 2CFaCOOH N w N N H VN (HNH2 0-nu NH2 NU 81. NH2 2 CF3COOH H C N N N 0 NN O H "% NH NH NHz TABLE 1 Compound Compound No. 82. NH2 2 CF3COOH H N N "°ONH Il 'NH i NH NHz 83. NHz 2CFsCOOH I H N N I H N hic 0 0 NH NH NH2 84. NH2 2 CF3COOH H N N il NN O H coH O ; NH NH w (NH NH2 85. NHz 2CCOOH I H N NUA N. 'N O H co2H H ( ° O NH NH NUS NHZ TABLE 1 Compound Compound No. 8 6. N H2 2 CF3COOH H I H N N Hop ou nu NH2 8 7. NH2 2 CF3COOH H N N s _ 0 H 02CH3 H 00 NH nu NU NH2 88. n. 2CFCOOH Ó ANH2 ag NH 0 nu2 N 0 ! N0 ANX SNH+NH NHz 8 CF 2 CF, COOH 1-3 S N 4 NH2 N 0 Nu HAN NHz TABLE 1 Compound Compound No. 90. 2 CF, COOH Oh - N Nu2 , p N \/ nu2 91., X 2 CFCOOH 0 H S 0 -NHz N 0 NH 1 NHz O 92. 2 CF, COOH I, S N "S-N 6 nu2 Nu nu \/ Nu2 - NHs 93. F 2 CF, COOH p Nu 0 nu2 I _ -YN-"-NH NH N WJON+NH2 - NHz TABLE 1 Compound Compound No. 94. F F 2 CF, COOH zoo , Zkll 0 ry-NH2 v'S NH (5 nu2 Non J, N . J - nez O NH2 9 5. 2 CF3GOOH NH 0 NH2 N 0 NNNH NH H p nu2 96. eo NH 2 CF, COOH SO Nu . N0 NHz N--NH NH N NH2 9 7. NH2 2 CF3COOH z NON zu H r-OH ou NHZ NH2 TABLE 1 Compound Compound No. 9 . HN 3 CF3COOH RAZ NNH2 zu "Y 'ion N \ nu2 nu Nu 99. H2N H 2 CF3COOH NIZ___o H) 9 /. N \ O Nu nu NHZ - NH2 10 0. 2 CF3COOH H2N H P ,,, O Ici NNNH NH nu2 101.'3 CF3COOH HN N NH2 ZON -LU H 0 0 N 0''N H NH2 NH TABLE 1 Compound Compound No. 102. 3 HCI HNz do N NH2 ZON H-ly H 0 H NHZ NH 103. HN 3 CF, COOH r ff N NH2 ) Y N) Nez H nu NH NH 104. X H 2 HCL N N 0 0 0 I NH NH Nu2 105. H2N H 2 HCI p O I 0 0 'NH NH NH2 N-'y--NH NH TABLE 1 Compound Compound No. 10 6. > T 2 CF3COOH AN) N N 0 0 Nu2 H 0 -ONH2 10 7. H2N H 2 CF3COOH \ N//1 y <N+NH O NN NH NH nu2 10 8. H2N H 2 CF3COOH I \ N- zozo 0 HJV Ns+NH H nu2 109. 2 CF, COOH H2N H 2 N Fizz "'NH NH -J'NH NHz TABLE 1 Compound Compound No. 110. 3 CF, COOH HN"-o HAN N NH2 N Her 0 0,)"N NH H I/NH2 NH HN 3 CF, COOH I N NH2 N H A 1 ZON \ NH NH 112. H2N H 2 CF3COOH N N 0 0 NH NH Nu2 - NHz 113. 0 2 CF3COOH N NH \ nu2 N 0 11 N II NN H 0 H NU NH2 TABLE 1 Compound Compound No. 114. 2 CF, COOH 0 N NH NU2 N 0 NN-T l lI J H H ( NH NH2 115. NH2 2 CF3COOH / w 0 N HAN N H tHNH 0 0 NH NH2 116. NHz 2 CF3COOH I N CF3 Zon N' O OH 0 N I H /NHZ F NH 117. NHZ 2 CF3COOH N NH2 NY J 'N H N H NU F NNz TABLE 1 Compound Compound No. 118. F NH Oh/ OH I oh N H O H 00 N NHz H NH NH / O N N N oll, ho O H H-ly NHZ NH F o/kF 2. 3 F OH 120. H, N O F F . 0 2. 3 F OH T') \ A ° HA H /NU NH TABLE 1 Compound Compound No. 121. NH2 F N 0 F F N \ p F_F N Hly H 0 NH2 O \ I NH u O OH NH F 0 OH NH 2. 35 OH F 122. 0 ""'0 O NU N NH2 0 NHa O I N Ho'cl ° HDF H 0 C) IN H NU NHZ NH NHZ NH N OCH3 N °r H nu 123. HCI TABLE 1 Compound Compound No. 1-HN zu c /O F N +2. 4 F YKOH. HN N han' /\ O/ OHz NH /NH NH 12 S. OU 125. NH, F N F +0. 75 H20 Her ON Hz NU nu2 NHz 12 6. nu2 NHa F N F F /N N F OU H NH Hui HCI F F N-H H TABLE 1 Compound Compound No. 127. NHZ /I H 1NA N 4 OqXFF Hz 2. 4 F OH NHZ NH NH 128. 0 0 NH Ti HC HO-_CF3 N NH2 0 H Nay H) NEZ H NH NH 129. NH / Her N N O N H II 0"NH H-a H-cul H-Cl f t ! H-C ! nu H NH OH TABLE 1 Compound Compound No. 130. 0 0 O ; NHa . L HOCF, N \ I NHZ Hop H 0 OIN H NH NH NH 0 Nu HO'k CF, I NHZ O NYNH, 0 H II \ H I NH NHZ 132. 0 NH 0 HO CF3 N NH2 0 NHR H 0 0 N HO NH H I/ NH NH TABLE 1 Compound Compound No. 133. 0 nu ici Nô. N-NH2 0 134. o H 0 01 N H NH H I/ nu NHz 134. 0 __ /HO_'CF, N \ I NHZ O HO_ _CF3 Her 0 0IN H NH NH 135. 0 NH Fio CF3 /HO-_CF3 N \ NHZ HO CF3 H H H 0 01 N H I/ NH NHa TABLE 1 Compound Compound No. 136. 0 0 NH NH HO CF3 /I O N NH,, 0N /\¢4NH H IN \ NH NU NH2 137. NH HO CF3 NH HO_ _CF3 'N \ NHz HO CF3 0 H ATX O Hz NH 138. 0 Nu 0 NH HOCF, N NH2 0 N \ v NHz O Ho HOACF3 H II \ NI NH NH TABLE 1 Compound Compound No. 139. nu 0 nu /HO'_CF3 1 tNH2 O N H IN \ NH NH 140. 140. O ° H < NH2 H H HO 11 CF3 \ I NHZ O 'IN'y HO CF, H IN O'-N NU NU NHa 141. O < NH A /HO'_CF3 O HO 11 CF3 H NH2 0 N H I Nu NHZ TABLE 1 Compound Compound No. 142. O N NH 0 ZON /HO-'CF3 O HOI _CF3 H II H I nu NH 143. 0 nu /HO_ _CF HO CF3 N NH2 0 HO CF, Nu NHZ NH 144. 0 ° HN I HO'j CF3 NHR O N ° oY 144. HO CF3 NH 0'_N Nu NU NHZ TABLE 1 Compound Compound No. 145. HN N-YNH, (N O 0 0 A i F3CJTOH A 0 u i F3C) tOH H2NANH 146. NH I J NH2 NHZ 0 NH 0 O NU 0 F3cAOH A I H2N NH TABLE 1 Compound Compound No. 147. HC\. N H N 0NH2 NHZ I N O HO 0 nu O F3C OH t o D Nd JAZZ HAN NU 0 0 NH NU NHZ O H II O nu 0 0/ A f F, C OH b p A"r F3cAOH H 2NH TABLE 1 Compound Compound No. 149. / NHz O NJ. ,-- NU 0 O ! 1 F3C'_OH 1 NH2 150. hex "czar Han J 150. 0 NHZ H N H ! ! \ F, jazz NH F3C'_OH F3C) t'OH \ A FC-"OH) H2N NH TABLE 1 Compound Compound No. 151. 0 HN NH N NHa c ho jj r" F3C'_OH/ F3C OH H2N NH 152. 0 F HO Fuzz F N O NHz 152. N ICI zea 0 F "5'NH .-6 HAN NH TABLE 1 Compound Compound No. 153. it un F HO Ou /I N NU NHR N H il p nu O/ F I O H2N NH 154. NHZ Hui HCI N Her NF H O NH NU2 nu 0 NHR 155. F 1 0 F F Zur O N NHZ CF3''OH J I N N H Of-I "N _I_rN H NHz H NH FEZ TABLE 1 Compound Compound No. NH 156. H /nez O _ H H ft NH N 0 ci J\-oH OH F 'NH HCI NHZ NH F F N9NX O ° oD SNA F N N 0 (H F_ N N OH H 0 N II F_F O N H NU Nu F OU NHZ F-F 158. NH2 NH I I N N N O-HCI NH 0 0'IN H I NH HCI F NH2 TABLE 1 Compound Compound No. 159. F H NH F I N NH2 F N off O NH OH ici NH NH 160. NH2 NHa F N N 0 \ I N \ I O N "2. 65 OH F F O/ NH NU nu 161. NH2 N N N J I N O N H II O N I NU2 0 N OH NU 2. 65 OH F F TABLE 1 Compound Compound No. 162. NHZ F H N 0 U V /\N J N I 1. 9 F OH H II F H F 0 0)"N I NH2 OH NH OH NH 163. F NHz 0 F N NH2 0 OH Oh F O F NU NU2 NU NH 164. NH CH H Nr H tf ; H 0 F Ft NH -"LiOH CM H2 F NHa C1N

TABLE 1 Compound Compound No. 165. NHz J sas N "OH NH 1-CL O NU /NU 166. NH HO CF3 NU, 166. Nui2 N OH \ \ I N \ I N" OH 'N 0 H O O O NH O HO CF3 > HO CF3 /NH NH TABLE 1 Compound Compound No. 167. NH 1 0 N N HN N , p 7 F ! s NH HO NU HO NHZ 168. HCI NH N OCH3 N I N O'_N ou / N H F NH2 HCI 169. NH2 O N I H I N 0 -lu "° A 2 NH HO CF3 NH N HZ TABLE 1 Compound Compound No. 170. Me Me N HHCCI k H--4 H N N NU HCI HCI HC ! ! i H2N NH 171. NH2 0 w I N H O 00 INH 0 ONH o ZEA OH NH HO''CF3 /NH NHZ 172. NHZ OH N OUZO O ) HO CF, O NH HOU'CE NU2 /NH HOI'CF NHZ 3 TABLE 1 Compound Compound No. 173. NH H N O- I N NH OH 1 ß o cri H N-H , 0 H 174. NH2 ,, ou NN N °ONH ZOZO NH 0 NH2 NH 0 jj O 0 u HO CF3 TABLE 1 Compound Compound No. 175. NHz tS N OU - dz H IN -ly O N I NH2 0 F NU ou F F 176. NH2 OH H II N IO H 0 0 nu 0 0 NH HOXCF3 ANH NH NHZ NH 11 Hao, N N Ap No O O b-Y NH z HO- i NH NH TABLE 1 Compound Compound No. 178. NHz CI | C 4 F t N OH F 'IN F Hz NH OU O NU NU NHz 179. HO NHR N Oh ! Hz p nu F F OH OH HAN NH F 2 p F F if OU OH TABLE 1 Compound Compound No. 180. NHZ N OH F NNYN 2 F HN 0 2 OH F /\ nu OU NHZ F NH 181. NH /I O N ° N), IYF F F F NH OH NH NHZ 182. NH2 I H H"J t 0 F- OH H 0 NH2 < NH O NHZ TABLE 1 Compound Compound No. 183. H N H ""Y 0 _ 0 N 0 N HUI HCI H2NNH 184. Ha 4 e e t N\/ Nez H N F F F F/ F F O F O F \ I OH OH H2 N NH 185. NH2 NH / N HO) H 0 0IN OH H HUI HCI F /NU HCI F NHZ TABLE 1 Compound Compound No. N 186. NH O/F N N OH F Oh 001 N 2. 45 0/F H \ I NHa OH NH 187. F LU NHZ 1. 9 F OU N N N 0 Zozo H ! ! J Nu2 NU NH nu 18 8'O HzN OH F O 00 NH2 O \ I NHz O F OH F TABLE 1 Compound Compound No. 189. O B) SNG OH 0 N O \ I NHz Zou FOH NH F 190. HN H NEZ N 0 H 0 N F F/ F FF F O OH OH H2N NH 191. H2N Y N = I N N 0 N 0 H 0 N H O wF O F \ ou han nu TABLE 1 Compound Compound No. 192. H2N H N \ O _ II N O H F F 0 OqXF 9 Hj Y OH OH H2N NH 193. NHa / N N \ \ I N I N o _ N H O NH OH I nu NH NHZ 2 HCI 194. ~ HX Nez N c N // r N / F F F F \ I F F OH OH H2N NH TABLE 1 Compound Compound No. 195. NH / N O N N H 0 0 nu 0 (\ HA NH2 2 HCI 196. NHZ H N \ \ I N oui _ H il I NU O NH O \ NH2 O NHZ 2 HCI 197. NH, I H N Holy I N H O i O NH O nu 0 NHZ 2 HCI TABLE 1 Compound Compound No. 198. NH / H N N O N NI II ,"nay O NH OH I NU /nu NU2 NHZ 2 HCI 199. NH2 A H H-ly I N O N H II O O NH OH I NU HO 3by 2 HCI 200. NH N N N 0 F H) Y F N II N O F H IZk O H I 2. 25 F \ NHa OH NH TABLE 1 Compound Compound No. 201. NH HW0 o1 F N 0 H F F Hz 0 N 2. 6 F NH nu2 NU 202. H2N NEZ _ O --H OakF O NU F/ O F F F F OH pH HN NH2 203. H, N Nez N N 0 O N II Nu F/ if \1N X N ( OH OH HN NHZ TABLE 1 Compound Compound No. 204. H2N 0 F OH KIF ou 0 oh NI y OU O I NHZ NH 205. H2N 0 OH \/F \/ 2. 650F N 0 I'H 0 Nul nu 206. Hz F OU < 2. 25 F N 0 H I \ I NHz NH TABLE 1 Compound Compound No. 207. NHZ N V Zozo v H N \ nu /NH NHz F F 2. 4 F OH 208. han F k O N w 0 HON N O HO N 0 H F/ < if OH HN NH2 TABLE 1 Compound Compound No. 209. NH2 / N 0 /\ N O N c'i NH CF3 OH zea ZON °-NH, CF3'_OH 210. NH2 1 0 O N 0-"-) N CF, 1OH N--'y Hz N p O O N H H N H CF3) OH NHz 211. NH2 o N 1 0 CF3''OH N H--if 0 0 0'in H k NH CF3J4OH NH2 TABLE 1 Compound Compound No. 212. NHa fS r\ N'y N N O H ! t N N H O O N H 1 X N CF3/VOH NH2 213. NH2 Ruz ,- N'Y N H t ! NU2 214. NH2 O N H \ I NH CF3''OH NHz 914 ""'NH2 S ! N 0 CF3OH N) y N Cru oh zon H H O N H NH CFs'OH NH2 TABLE 1 Compound Compound No. 215. NH2 1 0 O N-r N n ! ! N N p O O N H H MNH CF3X0H NH2 216. NH2 1 0 \ N SS CF3J4OH N H--Iy 0 0 O N H O N MNH CF3J4OH NH2 217. NH2 1 0 O N 0 N CF3) tOH I N I N H 0 0 Hz H NH CF3J4OH NH TABLE 1 Compound Compound No. 2 1 8. 1 N A J° 9 CF3J4OH 218. NH2 1 0 N 0 CF3'iOH N'y N H) t N NU2 219. NH2 O N Nus 719 H--Iy 219."NH2 O \ H) t N N H O O N H 1 J CF3J4OH NH2 220. NH2 1 0 GF3''OH 'li-IN Nez p /O NH CF3 OH NH2 TABLE 1 Compound Compound No. 221. NHZ O N N CF3'iOH H-r 0 0 0,)"N NH H2 NH CF3''OH nu2 222. NH2 O N O N N CF3'IOH N H) Y 0 ouzo NH \N CF3J4OH NHz 223. nu2 NHz O 'IN YN v CF3''OH w" O /O H CF3''OH NH2 TABLE 1 Compound Compound No. 924 Nu2 f ! N CF3'iOH N Nez 00 N NH CFgOH NH2 225. NH2 ""NHR N oD CF3'iOH N NEZ 2 00 N 0 / NH CF3''OH NHZ 226. NH2 i NH2 IN NHZ ff 226. NH2 F NIF r OH NHZ TABLE 1 Compound Compound No. 227. NH N-N N ii /\ N \ \ _N N N H O OH/ \ NHa NH NH ZU F OH 228. NHZ 228. Nu2 OH °ONH F \ NH NHZ 2 2 9. NHZ N / H O ANH 0 FOC H2 FOC NH F3C NHZ TABLE 1 Compound Compound No. 230. NH2 w O 0 2 3 0. l N q F2C S /'I O 3 Nu :, nu 3 NH N HZ 231. NHZ O 0 H II N p' FsC/'OH O ONH O F3C OH NU NH 232. NH2 0 0 OH Foc N N Fi NU N H NH N HZ TABLE 1 Compound Compound No. 233. NHz o w, s N H ! FUZZ O NH NH 234. NU, N ho Mc t\ j N - J-LnH 0 °ONH Y C NH 234. NH 234. NU2 Fui O ONH O F3C OH nu NH NHZ 2 NHZ zozo N I SO F C'OH 3 o N 6s"0 F3c-OH ANH nu2 NHz 236. NHz NU2 OH NI F3C 3 ANH N 0 , NH NH /NH NHZ TABLE 1 Compound Compound No. 237. NHZ o 0 O 238. o H2N N X n A 3 NU NHZ NH, OH Fla NI vJ N O 0ON NH F AH ) *-"OH H i FOH \/ O NI vJ 0 0 NH2 O F OH 0 Y OH TABLE 1 Compound Compound No. 240. N HZ 1 0 N NN HN Hazy ! NH Fuzz NH F NH2 Ho \ N Hz F 241. NH, F F / OU I\ N'N O H \ I NHz NH 242. NHz H 2 HCI NH "oil Nay Nez NH 2 ho /NHZ hui TABLE 1 Compound Compound No. 243. NH N CF3 I N F H il OH 0 OH F NH 0 F HA HO CF3 ho 244. NHa / HOLY N N O Nez O NH OH HO 1 HA ß O NH F F OH OH TABLE 1 Compound Compound No. 245. F OH F N OH NHZ LIY Nui y 0 nu2 NAH F F oh \ I N HZ 0 NH FOH F 246. NHZ. NI N 0 N \ \ I OOi 0 01 NH NEZ ° NU F F OH NU OH NH 247. NH / 'Y\°' H 0 N H NH2 Nu NU /NHa nu OH F q. F OH --| TABLE 1 Compound Compound No. 248. H2N Hz N Yl in N F F I F OH HN NH OH 2 O 1 F3C''OH / N O I S O. N X JS N X N a N <XS N NH H F nu NHZ NH p HN tr- Fla N \ Ni nu N N 0 0 NH2 F NH

TABLE 1 Compound Compound No. 251. Nu, N F F 0 0 H 0 Yl- 0 N OH w NH2 NH NH NHZ N OII/ . F 0 Fui F FO NH NH , F F F F TABLE 1 Compound Compound No. 253. 0 0 F Ho HOOF U N NH 2 OH 0 0 NU Nu2 N N H Q NH N H NH 254. S H N v 2. 6 H- HX HCNH2 3. 0 H H 254. H. 6 H - N 2. 6 H-cl N Zu "NN O 3. 0 Hi vH NH 0 cl, 3 CF TABLE 1 Compound Compound No. 255. NH2 zu H HIER N O N H II ° O l NH OH , by N p/NH nu2 2 HCI 256. NHZ H N 4 H - XN 0' u ! tr\ H~í l, NH H NU NH2 TABLE 1 Compound. Compound No. 257. NH2 I H N W w I N - N 0 H0 OU /NU NHz 258. > N ß zN l ° < O N = NH NH2 H N N O 2 TUFA O N NH NU2

Following the processes described in the Schemes, Examples or elsewhere herein, compounds corresponding to each of formulae A, B, C, and D and having any of the combinations of substituents identified in Table 2 may be prepared.

TABLE 2 Z1 R44 Z3 methyl, ethyl, propyl, hydroxy benzamidine-4-yl butyl, isopropyl, cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, hydroxy 3-hydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, hydroxy 3, 5-dihydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, hydroxy 2-hydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, hydroxy 3, 5, 6-trifluoro- butyl, isopropyl, 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, hydroxy 2, 5, 6-trifluoro- butyl, isopropyl, 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, isobutyl-benzamidine-4-yl butyl, isopropyl, sulfonyl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutyl-3-hydroxy- butyl, isopropyl, sulfonyl benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutyl-3, 5-dihydroxy- butyl, isopropyl, sulfonyl benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutyl-2-hydroxy- butyl, isopropyl, sulfonyl benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl

TABLE 2 Z, R 44 Z3 methyl, ethyl, propyl, isobutyl-3, 5, 6-trifluoro- butyl, isopropyl, sulfonyl 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, isobutyl-2, 5, 6-trifluoro- butyl, isopropyl, sulfonyl 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, trifluoro-benzamidine-4-yl butyl, isopropyl, methyl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, trifluoro-3-hydroxy- butyl, isopropyl, methyl benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, trifluoro-3, 5-dihydroxy- butyl, isopropyl, methyl benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, trifluoro-2-hydroxy- butyl, isopropyl, methyl benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, trifluoro-3, 5, 6-trifluoro- butyl, isopropyl, methyl 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, trifluoro-2, 5, 6-trifluoro- butyl, isopropyl, methyl 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, carboxamido-benzamidine-4-yl butyl, isopropyl, benzyl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, carboxamido-3-hydroxy- butyl, isopropyl, benzyl benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl

TABLE 2 Zl R44 z3 methyl, ethyl, propyl, carboxamido-3, 5-dihydroxy- butyl, isopropyl, benzyl benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, carboxamido-2-hydroxy- butyl, isopropyl, benzyl benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, carboxamido-3, 5, 6-trifluoro- butyl, isopropyl, benzyl 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, carboxamido-2, 5, 6-trifluoro- butyl, isopropyl, benzyl 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, carboxamido-benzamidine-4-yl butyl, isopropyl, butyl-2-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, carboxamido-3-hydroxy- butyl, isopropyl, butyl-2-yl benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, carboxamido-3, 5-dihydroxy- butyl, isopropyl, butyl-2-yl benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, carboxamido-2-hydroxy- butyl, isopropyl, butyl-2-yl benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, carboxamido-3, 5, 6-trifluoro- butyl, isopropyl, butyl-2-yl 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, isobutyramido 2, 5, 6-trifluoro- butyl, isopropyl, 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl

TABLE 2 Z1 R44 z3 methyl, ethyl, propyl, isobutyramido benzamidine-4-yl butyl, isopropyl, cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutyramido 3-hydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutyramido 3, 5-dihydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or'cyclobutyl methyl, ethyl, propyl, isobutyramido 2-hydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutyramido 3, 5, 6-trifluoro- butyl, isopropyl, 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, isobutyramido 2, 5, 6-trifluoro- butyl, isopropyl, 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, isobutoxy benzamidine-4-yl butyl, isopropyl, cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutoxy 3-hydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutoxy 3, 5-dihydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutoxy 2-hydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl

TABLE 2 Z1 R 44 Z3 methyl, ethyl, propyl, isobutoxy 3, 5, 6-trifluoro- butyl, isopropyl, 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, isobutoxy 2, 5, 6-trifluoro- butyl, isopropyl, 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, carboethoxy benzamidine-4-yl butyl, isopropyl, cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, carboethoxy 3-hydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, carboethoxy 3, 5-dihydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, carboethoxy 2-hydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, carboethoxy 3, 5, 6-trifluoro- butyl, isopropyl, 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, carboethoxy 2, 5, 6-trifluoro- butyl, isopropyl, 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, carboxyl benzamidine-4-yl butyl, isopropyl, cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, carboxyl 3-hydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl

TABLE 2 Z1 R44 Z3 methyl, ethyl, propyl, carboxyl 3, 5-dihydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, carboxyl 2-hydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, carboxyl 3, 5, 6-trifluoro- butyl, isopropyl, 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, carboxyl 2, 5, 6-trifluoro- butyl, isopropyl, 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, amino benzamidine-4-yl butyl, isopropyl, cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, amino 3-hydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, amino 3, 5-dihydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, amino 2-hydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, amino 3, 5, 6-trifluoro- butyl, isopropyl, 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, amino 2, 5, 6-trifluoro- butyl, isopropyl, 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl

TABLE 2 Z1 R 44 Z3 methyl, ethyl, propyl, 3-benzamidine-4-yl butyl, isopropyl, aminomethyl- cyclopropyl, sec-thiphene butyl, or cyclobutyl methyl, ethyl, propyl, 3-3-hydroxy- butyl, isopropyl, aminomethyl-benzamidine-4-yl cyclopropyl, sec-thiphene butyl, or cyclobutyl methyl, ethyl, propyl, 3-3, 5-dihydroxy- butyl, isopropyl, aminomethyl-benzamidine-4-yl cyclopropyl, sec-thiphene butyl, or cyclobutyl methyl, ethyl, propyl, 3-2-hydroxy- butyl, isopropyl, aminomethyl-benzamidine-4-yl cyclopropyl, sec-thiphene butyl, or cyclobutyl methyl, ethyl, propyl, 3-3, 5, 6-trifluoro- butyl, isopropyl, aminomethyl-2-hydroxy- cyclopropyl, sec-thiphene benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, 3_ 2, 5, 6-trifluoro- butyl, isopropyl, aminomethyl-3-hydroxy- cyclopropyl, sec-thiphene benzamidine-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, benzylamine benzamidine-4-yl butyl, isopropyl, cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, benzylamine 3-hydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, benzylamine 3, 5-dihydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl

TABLE 2 Z1 R44 z3 methyl, ethyl, propyl, benzylamine 2-hydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, benzylamine 3, 5, 6-trifluoro- butyl, isopropyl, 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, benzylamine 2, 5, 6-trifluoro- butyl, isopropyl, 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, phenethyl-benzamidine-4-yl butyl, isopropyl, amine cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, phenethyl-3-hydroxy- butyl, isopropyl, amine benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, phenethyl-3, 5-dihydroxy- butyl, isopropyl, amine benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, phenethyl-2-hydroxy- butyl, isopropyl, amine benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, phenethyl-3, 5, 6-trifluoro- butyl, isopropyl, amine 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, phenethyl-2, 5, 6-trifluoro- butyl, isopropyl, amine 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl

TABLE 2 Z1 R44 z3 methyl, ethyl, propyl, isobutylamine benzamidine-4-yl butyl, isopropyl, cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutylamine 3-hydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutylamine. 3, 5-dihydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutylamine 2-hydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutylamine 3, 5, 6-trifluoro- butyl, isopropyl, 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, isobutylamine 2, 5, 6-trifluoro- butyl, isopropyl, 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, methoxy-benzamidine-4-yl butyl, isopropyl, methylamide cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, methoxy-3-hydroxy- butyl, isopropyl, methylamide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, methoxy-3, 5-dihydroxy- butyl, isopropyl, methylamide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl

TABLE 2 Z1 R44 methyl, ethyl, propyl, methoxy-2-hydroxy- butyl, isopropyl, methylamide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, methoxy-3, 5, 6-trifluoro- butyl, isopropyl, methylamide 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, methoxy-2, 5, 6-trifluoro- butyl, isopropyl, methylamide 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, 1-carboxyl-benzamidine-4-yl butyl, isopropyl, benzylamide cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, 1-carboxyl-3-hydroxy- butyl, isopropyl, benzylamide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, 1-carboxyl-3, 5-dihydroxy- butyl, isopropyl, benzylamide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, 1-carboxyl-2-hydroxy- butyl, isopropyl, benzylamide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, 1-carboxyl-3, 5, 6-trifluoro- butyl, isopropyl, benzylamide 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, 1-carboxyl-2, 5, 6-trifluoro- butyl, isopropyl, benzylamide 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl

TABLE 2 zl R44 Z3 methyl, ethyl, propyl, p-fluoro-benzamidine-4-yl butyl, isopropyl, benzylamide cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, p-fluoro-3-hydroxy- butyl, isopropyl, benzylamide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, p-fluoro-3, 5-dihydroxy- butyl, isopropyl, benzylamide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, p-fluoro-2-hydroxy- butyl, isopropyl, benzylamide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, p-fluoro-3, 5, 6-trifluoro- butyl, isopropyl, benzylamide 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, p-fluoro-2, 5, 6-trifluoro- butyl, isopropyl, benzylamide 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, cyclobutyl-benzamidine-4-yl butyl, isopropyl, amide cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, cyclobutyl-3-hydroxy- butyl, isopropyl, amide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, cyclobutyl-3, 5-dihydroxy- butyl, isopropyl, amide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl

TABLE 2 l R44 Z3 methyl, ethyl, propyl, cyclobutyl-2-hydroxy- butyl, isopropyl, amide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, cyclobutyl-3, 5, 6-trifluoro- butyl, isopropyl, amide 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, cyclobutyl-2, 5, 6-trifluoro- butyl, isopropyl, amide 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, m-fluoro-benzamidine-4-yl butyl, isopropyl, benzylamide cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, m-fluoro-3-hydroxy- butyl, isopropyl, benzylamide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, m-fluoro-3, 5-dihydroxy- butyl, isopropyl, benzylamide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, m-fluoro-2-hydroxy- butyl,. isopropyl, benzylamide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, m-fluoro-3, 5, 6-trifluoro- butyl, isopropyl, benzylamide 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, m-fluoro-2, 5, 6-trifluoro- butyl, isopropyl, benzylamide 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl

TABLE 2 Z1 R44 Z3 methyl, ethyl, propyl, 1-methyl-benzamidine-4-yl butyl, isopropyl, benzylamide cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, 1-methyl-3-hydroxy- butyl, isopropyl, benzylamide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, 1-methyl-3, 5-dihydroxy- butyl, isopropyl, benzylamide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, 1-methyl-2-hydroxy- butyl, isopropyl, benzylamide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, 1-methyl-3, 5, 6-trifluoro- butyl, isopropyl, benzylamide 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, 1-methyl-2, 5, 6-trifluoro- butyl, isopropyl, benzylamide 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, sec-benzamidine-4-yl butyl, isopropyl, butylamide cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, sec-3-hydroxy- butyl, isopropyl, butylamide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, sec-3, 5-dihydroxy- butyl, isopropyl, butylamide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl

| TABLE 2 Z1 R44 Z3 methyl, ethyl, propyl, sec-2-hydroxy- butyl, isopropyl, butylamide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, sec-3, 5, 6-trifluoro- butyl, isopropyl, butylamide 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, sec-2, 5, 6-trifluoro- butyl, isopropyl, butylamide 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, benzylacyl-benzamidine-4-yl butyl, isopropyl, amine cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, benzylacyl-3-hydroxy- butyl, isopropyl, amine benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, benzylacyl-3, 5-dihydroxy- butyl, isopropyl, amine benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, benzylacyl-2-hydroxy- butyl, isopropyl, amine benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, benzylacyl-3, 5, 6-trifluoro- butyl, isopropyl, amine 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, benzylacyl-2, 5, 6-trifluoro- butyl, isopropyl, amine 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl

TABLE 2 Z, R44 Z3 methyl, ethyl, propyl, isobutylamide benzamidine-4-yl butyl, isopropyl, cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutylamide 3-hydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutylamide 3, 5-dihydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutylamide 2-hydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutylamide 3, 5, 6-trifluoro- butyl, isopropyl, 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, isobutylamide 2, 5, 6-trifluoro- butyl, isopropyl, 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, sec-benzamidine-4-yl butyl, isopropyl, pentylamine cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, sec-3-hydroxy- butyl, isopropyl, pentylamine benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, sec-3, 5-dihydroxy- butyl, isopropyl, pentylamine benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl

TABLE 2 Z1 R44 z3 Z, R44 Z3 methyl, ethyl, propyl, sec-2-hydroxy- butyl, isopropyl, pentylamine benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, sec-3, 5, 6-trifluoro- butyl, isopropyl, pentylamine 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, sec-2, 5, 6-trifluoro- butyl, isopropyl, pentylamine 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, cyclopentyl-benzamidine-4-yl butyl, isopropyl, acylamine cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, cyclopentyl-3-hydroxy- butyl, isopropyl, acylamine benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, cyclopentyl-3, 5-dihydroxy- butyl, isopropyl, acylamine benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, cyclopentyl-2-hydroxy- butyl, isopropyl, acylamine benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, cyclopentyl-3, 5, 6-trifluoro- butyl, isopropyl, acylamine 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, cyclopentyl-2, 5, 6-trifluoro- butyl, isopropyl, acylamine 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl

TABLE 2 Z1 R44 z3 zu methyl, ethyl, propyl, 1-carboxyl, benzamidine-4-yl butyl, isopropyl, 2-methyl- cyclopropyl, sec-butylamide butyl, or cyclobutyl methyl, ethyl, propyl, 1-carboxyl, 3-hydroxy- butyl, isopropyl, 2-methyl-benzamidine-4-yl cyclopropyl, sec-butylamide butyl, or cyclobutyl methyl, ethyl, propyl, 1-carboxyl, 3, 5-dihydroxy- butyl, isopropyl, 2-methyl-benzamidine-4-yl cyclopropyl, sec-butylamide butyl, or cyclobutyl methyl, ethyl, propyl, 1-carboxyl, 2-hydroxy- butyl, isopropyl, 2-methyl-benzamidine-4-yl cyclopropyl, sec-butylamide butyl, or cyclobutyl methyl, ethyl, propyl, 1-carboxyl, 3, 5, 6-trifluoro- butyl, isopropyl, 2-methyl-2-hydroxy- cyclopropyl, sec-butylamide benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, 1-carboxyl, 2, 5, 6-trifluoro- butyl, isopropyl, 2-methyl-3-hydroxy- cyclopropyl, sec-butylamide benzamidine-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, isobutyl-benzamidine-4-yl butyl, isopropyl, acylamine cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutyl-3-hydroxy- butyl, isopropyl, acylamine benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutyl-3, 5-dihydroxy- butyl, isopropyl, acylamine benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl

TABLE 2 Z, R 44 Z3 methyl, ethyl, propyl, isobutyl-2-hydroxy- butyl, isopropyl, acylamine benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutyl-3, 5, 6-trifluoro- butyl, isopropyl, acylamine 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, isobutyl-2, 5, 6-trifluoro- butyl, isopropyl, acylamine 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, isobutyl-benzamidine-4-yl butyl, isopropyl, sulfoxyl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutyl-3-hydroxy- butyl, isopropyl, sulfoxyl benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutyl-3, 5-dihydroxy- butyl, isopropyl, sulfoxyl benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutyl-2-hydroxy- butyl, isopropyl, sulfoxyl benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutyl-3, 5, 6-trifluoro- butyl, isopropyl, sulfoxyl. 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, isobutyl-2, 5, 6-trifluoro- butyl, isopropyl, sulfoxyl 3-hydroxy-. cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl

TABLE 2 Zi R44 Z3 methyl, ethyl, propyl, 2-cyclohexyl-benzamidine-4-yl butyl, isopropyl, amide cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, 2-cyclohexyl-3-hydroxy- butyl, isopropyl, amide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, 2-cyclohexyl-3, 5-dihydroxy- butyl, isopropyl, amide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, 2-cyclohexyl--2-hydroxy- butyl, isopropyl, amide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, 2-cyclohexyl-3, 5, 6-trifluoro- butyl, isopropyl, amide 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, 2-cyclohexyl-2, 5, 6-trifluoro- butyl, isopropyl, amide 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, methoxyl benzamidine-4-yl butyl, isopropyl, cyclopropyl, sec- butyl,. or cyclobutyl methyl, ethyl, propyl, methoxyl 3-hydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, methoxyl 3, 5-dihydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl

TABLE 2 Zi a methyl, ethyl, propyl, methoxyl 2-hydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, methoxyl 3, 5, 6-trifluoro- butyl, isopropyl, 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, methoxyl 2, 5, 6-trifluoro- butyl, isopropyl, 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, sulfonamide benzamidine-4-yl butyl, isopropyl, cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, sulfonamide 3-hydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, sulfonamide 3, 5-dihydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, sulfonamide 2-hydroxy- butyl, isopropyl, benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, sulfonamide 3, 5, 6-trifluoro- butyl, isopropyl, 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, sulfonamide 2, 5, 6-trifluoro- butyl, isopropyl, 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl

TABLE 2 Z1 R44 z3 methyl, ethyl, propyl, isobutyl-benzamidine-4-yl butyl, isopropyl, sulfonamide cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutyl-3-hydroxy- butyl, isopropyl, sulfonamide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutyl-3, 5-dihydroxy- butyl, isopropyl, sulfonamide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutyl-2-hydroxy- butyl, isopropyl, sulfonamide benzamidine-4-yl cyclopropyl, sec- butyl, or cyclobutyl methyl, ethyl, propyl, isobutyl-3, 5, 6-trifluoro- butyl, isopropyl, sulfonamide 2-hydroxy- cyclopropyl, sec-benzamide-4-yl butyl, or cyclobutyl methyl, ethyl, propyl, isobutyl-2, 5, 6-trifluoro- butyl, isopropyl, sulfonamide 3-hydroxy- cyclopropyl, sec-benzamidine-4-yl butyl, or cyclobutyl For convenience, each of the substituents identified for R44 and Z3 in Table 2 is set forth below. OH SO2SO CF3 i hydroxy trifluoromethyl isobutylsulfonyl O 0 H , KN /H H N" carboxamidobenzyl carboxamidobutyl-2-yi isobutyramido 0 JX X0, CO2H W NH2 2'2. 0 carboxyl amino isobutoxy carboethoxy SHNr HN < tHNx -S I-N 3-aminomethylthphene benzylamine phenethylamine O O CO2H ZON , NOw N \ H H isobutylamine methoxyethylamide 1-carboxylbenzylamide R or S ISOMERS 'WN'WN N t'N \/ O cydobutytamide H /H 'N F cyclobutylamide H p-fluorobenzylamide/ m-fluorobenzylamide . N O O Hz H 1-methylbenzylamide sec-butylamide benzylacylamine RACEMIC or R or S R or S ISOMERS O O o 0 --%' N -HN H ?-HN isobutylamide sec-pentylamine cyclopentylacylamine O CO2H ll-o 13k N H H N 1-carboxyl, 2-methylbutylamide isobultylacylamine O CH3 0 N % loCH3 kas H methoxyl isobutylsulfoxyl 2-cyclohexylamide R or S ISOMERS O Z, S NU N 2 H sulfonamide isobutylsulfonamide OH OH 1. 1-by NH2 NH NH"jH NH NH (NH benzamidine-4-yl 3-hydroxybenzamidine4-yl 3, 5-dihydroxybenzamidine-4-yl F OH OH NH NH2 F F NH NH 3, 5, 6-trifluoro-2-hydroxybenzamidine-4-yl 2-hydroxybenzamidine-4-yl OH F F F NH 2, 5, 6-trifluoro-3-hydroxybenzamidine-4-yl

As a further embodiment, compounds of the present invention or a pharmaceutically-acceptable salt thereof, comprise a treatment and prophylaxis for thrombotic events resulting from coronary artery disease, cerebrovascular disease and other coagulation cascade related disorders in a subject, comprising administering to the subject having such disorder a therapeutically-effective amount of compounds the present invention or a pharmaceutically- acceptable salt thereof.

In another aspect of the invention, the compounds may also be used whenever inhibition of blood coagulation is required such as to prevent coagulation of stored whole blood and to prevent coagulation in other biological samples for testing or storage. Thus coagulation inhibitors of the present inhibition can be added to or contacted with stored whole blood and any medium containing or suspected of containing plasma coagulation factors and in which it is desired that blood coagulation be inhibited, e. g. when contacting the mammal's blood with material selected from the group consisting of vascular grafts, stents, orthopedic prothesis, cardiac prosthesis, and extracorporeal circulation systems.

Compounds of the invention are capable of inhibiting activity of serine proteases related to the coagulation cascade, and thus could be used in the manufacture of a medicament, a method for the prophylactic or therapeutic treatment of diseases mediated by coagulation cascade serine proteases, such as inhibiting the formation of blood platelet aggregates, inhibiting the formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, in blood, in blood products, and in mammalian organs. The compounds also can be used for treating or preventing unstable angina,

refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels in a mammal. The compounds also can be used to study the mechanism of action of coagulation cascade serine proteases to enable the design of better inhibitors and development of better assay methods. The compounds would be also useful in prevention of cerebral vascular accident (CVA) or stroke. Also included in the family of compounds are the pharmaceutically-acceptable salts thereof. The term"pharmaceutically-acceptable salt" embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases.

The nature of the salt is not critical, provided that it is pharmaceutically acceptable. Suitable pharmaceutically- acceptable acid addition salts of compounds of formulas (1)- (7) may be prepared from inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucoronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, salicylic, p-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethylsulfonic, benzenesulfonic, sulfanilic, stearic, cyclohexylaminosulfonic, algenic, galacturonic acid.

Suitable pharmaceutically-acceptable base addition salts

of compounds of any of formulas (1)- (7) include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N, N'-dibenzylethyleneldiamine, choline, chloroprocaine, diethanolamine, ethylenediamine, meglumine (N- methylglucamine) and procain. All of these salts may be prepared by conventional means from the corresponding compound by reacting, for example, the appropriate acid or base with the compound of the present invention.

The present invention also comprises a pharmaceutical composition comprising a therapeutically-effective amount of the compound in association with at least one pharmaceutically-acceptable carrier, adjuvant or diluent.

Pharmaceutical compositions of the present invention can comprise the active compounds in association with one or more non-toxic, pharmaceutically-acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as"carrier"materials) and, if desired, other active ingredients. The active compounds of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended.

The active compounds and composition may, for example, be administered orally, intravascularly, intraperitoneally, subcutaneously, intramuscularly, oculary, or topically. For treating ocular build up of fibrin, the compounds may be administered intraocularly or topically as well as orally or parenterally.

The compounds can be administered in the form of a depot injection or implant preparation which may be formulated in such a manner as to permit a sustained release of the active ingredient. The active ingredient

can be compressed into pellets or small cylinders and implanted subcutaneously or intramusculary as depot injections or implants. Implants may employ inert materials such as biodegradable polymers or synthetic silicones, for example, Silastic, silicone rubber or other silicon containing polymers.

The compounds can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

The compounds may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds may also be coupled with soluble polymers as targetable drug carriers.

Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or ployethyleneoxide- polylysine substituted with palmitoyl residues.

Furthermore, the compounds may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphitpathic block copolymers of hydrogels.

For oral administration, the pharmaceutical composition may be in the form of, for example, tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixers, tinctures, suspensions, liquids including

syrups, and emulsions. The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are tablets or capsules. The active ingredient may also be administered by injection as a composition wherein, for example, saline, dextrose or water may be used as a suitable carrier.

The amount of therapeutically active compounds which are administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, sex and medical condition of the subject, the severity of the disease, the route and frequency of administration, and the particular compound employed, and thus may vary widely.

The pharmaceutical compositions may contain active ingredients in the range of about 0.1 to 2000 mg, and preferably in the range of about 0.5 to 500 mg. A daily dose of about 0.01 to 100 mg/kg body weight, and preferably between about 0.5 and about 20 mg/kg body weight, may be appropriate. The daily dose can be administered in one to four doses per day.

The compounds may be formulated in topical ointment or cream, or as a suppository, containing the active ingredients in a total amount of, for example, 0.075 to 30% w/w, preferably 0.2 to 20% w/w and most preferably 0.4 to 15% w/w. When formulated in an ointment, the active ingredients may be employed with either paraffinic or a water-miscible ointment base.

Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base. If desired, the aqueous phase of the cream base may include, for example at least 30% w/w of a polyhydric alcohol such

as propylene glycol, butane-1, 3-diol, mannitol, sorbitol, glycerol, polyethylene glycol and mixtures thereof. The topical formulation may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas.

Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogs. The compounds of this invention can also be administered by a transdermal device. Preferably topical administration will be accomplished using a patch either of the reservoir and porous membrane type or of a solid matrix variety. In either case, the active agent is delivered continuously from the reservoir or microcapsules through a membrane into the active agent permeable adhesive, which is in contact with the skin or mucosa of the recipient. If the active agent is absorbed through the skin, a controlled and predetermined flow of the active agent is administered to the recipient. In the case of microcapsules, the encapsulating agent may also function as the membrane.

The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner.

While the phase may comprise merely an emulsifier, it may comprise a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat.

Together, the emulsifier (s) with or without stabilizer (s) make-up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations. Emulsifiers and emulsion stabilizers suitable for use in the formulation of the

present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate, and sodium lauryl sulfate, among others.

The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations is very low. Thus, the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono-or dibasic alkyl esters such as diisoadipate, isocetylstearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters may be used. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.

For therapeutic purposes, the active compounds of the present invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration.

Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active

compound in hydroxypropylmethyl cellulose. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.

Compounds of the present invention can exist in tautomeric, geometiric or stereoisomeric forms. The present invention contemplates all such compounds, including cis-and trans-geometric isomers, E-and Z- geometric isomers, R-and S-enantiomers, diastereomers, d-isomers, 1-isomers, the racemic mixtures thereof and other mixtures thereof, as falling within the scope of the invention. Pharmaceutically acceptable salts of such tautomeric, geometric or stereoisomeric forms are also included within the invention.

The terms"cis"and"trans", as used herein, denote a form of geometric isomerism in which two carbon atoms connected by a double bond will each have a hydrogen atom on the same side of the double bond ("sis") or on opposite sides of the double bond ("trans").

Some of the compounds described contain alkenyl groups, and are meant to include both cis and trans or"E" and"Z"geometric forms.

Some of the compounds described contain one or more stereocenters and are meant to include R, S, and mixtures or R and S forms for each stereocenter present.

In addition to a compound having any of formulas (1)- (7), the composition of the invention may also comprise any agent, which when administered as part of a combination therapy with a compound having any of formulas (1)- (7), provides enhanced treatment options as compared to administration of either agent alone for the particular indication being treated. These indications are referred to herein as"thrombolytic conditions"and the agent administered with a compound having formula (1)- (7) is referred to as a"thrombolytic agent."Generally speaking, the term"thrombolytic condition,"as used herein, encompasses vaso-occlusive events or related disorders including but not limited to, myocardial infarction, stroke, transient ischemic attacks including myocardial infarction and stroke, amaurosis fugax, aortic stenosis, cardiac stenosis, coronary stenosis and pulmonary stenosis. Stenosis is the narrowing or stricture of a duct or canal. Coronary stenosis is the narrowing or stricture of a coronary artery. Cardiac stenosis is a narrowing or diminution of any heart passage or cavity. Pulmonary stenosis is the narrowing of the opening between the pulmonary artery and the right ventricle. Aortic stenosis is narrowing of the aortic orifice of the heart or of the aorta itself. Moreover, the term"thrombolytic agent, "as used herein unless otherwise indicated, includes anti-platelet agents, anticoagulation agents, and cardiovascular therapeutic agents.

In one embodiment, when general thrombolytic condition are being treated, the thrombolytic agent may

belong to a class of compounds that cause a reduction in platelet aggregation and thereby diminishes the size of or prevents the formation of a thrombus or occlusion. One such class of compounds are anti-platelet inhibitors that ameliorate prostaglandin synthesis. These agents include salicylates (e. g. aspirin) and other NSAIDS, ticlopidine, or clopidrogel. In a further embodiment, the anti- platelet inhibitor is a GP IIb/IIIa inhibitor.

In yet another embodiment, when indications such as unstable angina, thrombolytic occlusions or prevention of reocculsion after angioplasty and restenosis are being treated, the thrombolytic agent co-administered along with compounds having any of formulas (1)- (7) include fibrinogen receptor antagonists, anti-coagulants such as warfarin or heparins, and plasminogen activators, such as tissue plasminogen activator (tPA) or streptokinase. In still another embodiment, when the indication being treated is coronary artery disease or patients subjected to angioplasty procedures, suitable agents include antihypercholesterolemics (e. g. HMG CoA reductase inhibitors such as mevastatin, lovastatin, simvastatin, pravastatin, and fluvastatin, HMG CoA synthatase inhibitors, etc. ), anti-diabetic drugs, or other cardiovascular agents (e. g. loop diuretics, thiazide type diuretics, nitrates, aldosterone antagonistics (e. g. spironolactone and epoxymexlerenone), angiotensin converting enzyme (e. g. ACE) inhibitors, angiotensin II receptor antagonists, beta-blockers, antiarrythmics, anti- hypertension agents, and calcium channel blockers to treat or prevent atheriosclerosis.

Generally speaking, the pharmacokinetics of the particular agent to be administered will dictate the most preferred method of administration and dosing regiment.

For example, when the thrombolytic agent has a rapid plasma clearance time and a short half-life, a preferred mode of administration is as a bolus injection followed by an intravenous infusion. Alternatively, when the thrombolytic agent has a lower plasma clearance time and a longer half-life, a preferred mode of administration is as a single bolus injection.

Additionally typical doses of compounds of the present invention with other suitable thrombolytic agents may be the same as those doses of compounds having formula (1)- (7) without coadministration of the thrombolytic agent, or may be substantially less than those doses of compounds having formula (1)- (7) administered without coadministration of the thrombolytic agents and will vary depending on a subject's therapeutic needs. Those skilled in the art will appreciate that dosages may also be determined with guidance from Goodman & Goldman's The Pharmacological Basis of Therapeutics, Ninth Edition (1996), Appendix II, pp. 1707-1711 and from Goodman & Goldman's The Pharmacological Basis of Therapeutics, Tenth Edition (2001), Appendix II, pp. 475-493.

The timing of the administration of the compound having formula (1)- (7) in relation to the administration of the thrombolytic agent may also vary from subject to subject and depend upon the thrombolytic condition being treated. In one embodiment of the invention, the compound of formula (1)- (7) and thrombolytic agent may be administered substantially simultaneously, meaning that both agents may be administered. to the subject at approximately the same time. For example, the compound of formula (1)- (7) or pharmaceutically acceptable salt or prodrug thereof is administered during a continuous period beginning on the same day as the beginning of the

thrombolytic agent and extending to a period after the end of the thrombolytic agent. Alternatively, the compound of formula (1)- (7) and thrombolytic agent may be administered sequentially, meaning that they are administered at separate times during separate treatments. In one embodiment, for example, the compound of formula (1)- (7) or a pharmaceutically acceptable salt or prodrug thereof is administered during a continuous period beginning prior to administration of the thrombolytic agent and ending after administration of the thrombolytic agent. Of course, it is also possible that the compound of formula (1)- (7) may be administered either more or less frequently than the thrombolytic agent. One skilled in the art can readily design suitable treatment regiments for a particular subject depending on the particular thrombolytic condition being treated. Moreover, it will be apparent to those skilled in the art that it is possible, and perhaps desirable, to combine various times and methods of administration in the practice of the present invention.

In some aspects, the invention provides treatment for subjects who are at risk of a thrombolytic condition.

These subjects may or may not have had a previous thrombolytic condition. The invention embraces the treatment of subjects prior to a thrombolytic condition, at a time of a thrombolytic condition and following a thrombolytic condition. Thus, as used herein, the "treatment"of a subject is intended to embrace both prophylactic and therapeutic treatment, and can be used either to limit or to eliminate altogether the symptoms or the occurrence of a thrombolytic condition. In one embodiment, the subject may exhibit symptoms of a thrombolytic condition.

The invention also embraces the treatment of a subject that has an abnormally elevated risk of a thrombolytic condition. The subject may have vascular disease. The vascular disease may be selected from the group consisting of arteriosclerosis, cardiovascular disease, cerebrovascular disease, renovascular disease, mesenteric vascular disease, pulmonary vascular disease, ocular vascular disease or peripheral vascular disease.

In one embodiment, however, the subject has had a primary thrombolytic condition. The composition of the invention may be administered to a subject following such a primary thrombolytic condition. The method of the invention also embraces treatment of a subject to reduce the risk of a secondary thrombotic event or to inhibit the propagation of an existing thrombotic event. By way of example, the thrombotic event may be selected from the group consisting of arterial thrombosis, coronary thrombosis, heart valve thrombosis, coronary stenosis, stent thrombosis and graft thrombosis. The thrombolytic condition also includes disorders or conditions that may arise from a thrombotic event or a thromboembolic event and in this regard a thrombolytic condition includes, but is not limited to myocardial infarction, stroke and transient ischemic attack. In one embodiment, the thrombolytic condition is myocardial infarction. In yet another embodiment, the subject has had a myocardial infarction. A subject who has hypercholesterolemia, hypertension or atherosclerosis also can be treated by the methods of the invention.

In yet another embodiment, the subject is one who will undergo an elective surgical procedure. The composition of the invention may be administered to such a subject prior to the elective surgical procedure. The

method of the invention can also be directed towards a subject who has undergone a surgical procedure. As used herein, a"surgical procedure"is meant to embrace those procedures that have been classically regarded as surgical procedures as well as interventional cardiology procedures such as arteriography, angiography, angioplasty and stenting. Thus, the surgical procedure, whether elective or not, can be selected from the group consisting of coronary angiography, coronary stent placement, coronary by-pass surgery, carotid artery procedure, peripheral stent placement, vascular grafting, thrombectomy, peripheral vascular surgery, vascular surgery, organ transplant, artificial heart transplant, vascular angioplasty, vascular laser therapy, vascular replacement, prosthetic valve replacement and vascular stenting.

The present novel methods preferably employ compounds which selectively inhibit human TF-VIIA over the inhibition of both human Thrombin II and human factor Xa.

Preferably, the compounds have a human TF-VIIA ICsoof less than 0.5 mM and also have a selectivity ratio of TF-VIIA inhibition over both human Thrombin II and human factor Xa inhibition of at least 10, and more preferably at least 100. Even more preferably, the compounds have a human TF- VIIA IC. 50 of less than 0.1 mM and also have a selectivity ratio of TF-VIIA inhibition over both human Thrombin II and human factor Xa inhibition of at least 1000, and most preferably at least 10,000.

All mentioned references are incorporated by reference as if here written.

Although this invention has been described with respect to specific embodiments, the details of these embodiments are not to be construed as limitations.

Without further elaboration, it is believed that one

skilled in the art can, using the preceding descriptions, utilize the present invention to its fullest extent.

Compounds containing multiple variations of the structural modifications illustrated in the Schemes are also contemplated. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds.

GENERAL SYNTHETIC PROCEDURES AND SPECIFIC EXAMPLES The compounds of the present invention can be synthesized, for example, according to the following procedures and Schemes given below.

Abbreviations used in the schemes and tables include :"AA"represents amino acids,"AcCN"represents acetonitrile,"AcOH"represents acetic acid,"BINAP" represents 2,2'-bis (diphenylphosphino)-1, 1'-binaphthyl, "BnOH"represents benzyl alcohol,"BnCHO"represents 2- phenylethanal, "BnSO2Cl"represents benzylsulfonyl chloride,"Boc" represents tert-butyloxycarbonyl,"BOP"represents benzotriazol-1-yl-oxy-tris- (dimethylamino),"bu" represents butyl, "dba"represents dibenzylidene-acetone, "DCC"represents 1,3-dicyclohexylcarbodiimide,"DCM" represents dichloromethane or methylene chloride,"DIBAH" or"DIBAL"represents diisobutylaluminum hydride,"DMF" represents dimethylformamide,"DMSO"represents dimethylsulfoxide, "DPPA"represents diphenylphosphoryl azide", "EDC"represents 1- [3- (dimethylamino) propyl]-3- ethylcarbodiimide hydrochloride,"Ex. No. "represents Example Number,"Fmoc"represents 9- fluorenylmethoxycarbonyl,"HOBt"represents hydroxybenzoltriazole","LDA"represents lithium

diisopropylamide,"MW"represents molecular weight,"NMM" represents N-methylmorpholine,"Ph"represents phenyl or aryl,"PHTH"represents a phthaloyl group,"pnZ" represents 4-nitrobenzyloxy-carbonyl, "PTC"represents a phase transfer catalyst,"py"represents pyridine," RNH2"represents a primary organic amine,"SEM"represents 2- (trimethylsilyl) ethoxy-methyl chloride,"p-TsOH" represents paratoluenesulfonic acid,"TBAF"represents tetrabutylammonium fluoride,"TBTU"represents 2- (1H- benzotriozole-1-yl)-1, 1, 3,3-tetramethyl uronium <BR> <BR> <BR> <BR> tetrafluoroborate, "TEA"represents triethylamine,"TFA" represents trifluoroacetic acid,"THF"represents tetrahydrofuran, "TMS"represents trimethylsilyl,"TMSCN" represents trimethylsilyl cyanide, and"Cbz"or"Z" represents benzyloxycarbonyl.

As used in the schemes and examples, Ll, Zu, Z3, Z4, R44, and Rgo along with any other variable depicted, encompasses every group described for each particular variable for each embodiment of compounds having any of the formulas detailed herein. Further, R4a and R4b are hydrogen, Z. and Z6 are independently hydrogen or halogen, and L6 is a bond.

Scheme 1: Pyrimidone (I) H3CO ° Y ! ! 3CO.. k OCHs li O LEZ O R NH-HCI L6Z6 ° R4a 1 OCH3 > H2N t ly OCH3 Lil, Pyridine H CO I N oc3 'OH 0 0 R" Z6L6\4 O O Ra 4 OCHg DPP A, TEA Ho N Benzyl alcohol OC3 0 0 R Oc3 T"Y OCHs ! ! 1. 1N HC ! ! HN OCH3 2. NaCl02 Rua 0 Scheme 1 : Pyrimidone (I) (continued) Z4 O (CICO) 2, t-BuOH, N pyridine o HN/9 \OH r Y t 26L64 R4a O O I N O H N w0 \ t Rua 0 Z6L6 N Z4 0 ZlLl =0 NaBH (OAc) 3 H2N 0 H2N il _0 Z6L6 R4a Z6L6 N Z4 0 HCI N Z1 L1 _HN II w0 R4a Scheme 1: Pyrimidone (I) (continued)

Scheme 2: Pyrimidone (II) Scheme 2 : Pyrimidone (II) (continued) SEM 1. TBAF, THF N O Z6L6 2. PhNMe2, POC13 N CONH-Z3-Cbz H 11 o O N\ CI II I Z4-B (OH) 2, Pd (PPh3) 4, N CONH-Z3-Cbz Na2CO3 H o DEPROTECTION Z6L6 N Z4 H2, Pd/C, HCI, MeOH N CONH-Z3-Cbz H I H Z6L6 YNYZ4 Z L I N CONH-Z3 H 11 o 0

Scheme 3: Pyrimidone (III) LJ N S 6 6 _ CH3 Br2 NH NAOH ACOH nu I O O N\ SCHg CaH2 THF NH t-butyl bromoacetate Br U N SCHg _ Z L-NH2, Pd (OAc) 2 BINAP, N CsCO3 Toluene, heat 0 N N SCHg o Pd (PPh3) 4, 1. 4 equiv Cu (1)-TC ZOLL-HAN Z4-B (OH) 2 o 0 Scheme 3 : Pyrimidone (III) (continued) Scheme 4: Triazinone 0 + 0 1. TEA, DCM 2. (CH3) 3 +BF4- H2N/Z4 Lawessonws Reagent 0 '7\ Z4 N 0 SCH3 o Z4 N Ethyl Thiooxamate 0 NH H2N /N Z4 N O Z1=O J) /NaBH (OAc) s H2N II \O o 0 Scheme 4: Triazinone (continued) Scheme 5 : Pyrazinone (I)

Scheme 5: Pyrazinone (I) (continued) Scheme 5: Pyrazinone (I) (continued) Scheme 6: Pyrazinone (II) Z5 25 N AtN Z1-NH2 N/; NBS (2. 0 eg. L hea I N DMSO/H20 CI Z-hiN Ber bu Z5 . Br KOH/H20, heat t4 Z1-HN/9N Br 5 R = t-butyl, benzyl or Br similar group gCOR Br uurt CaH2 THF /2 OH Z5 Br Z Z4-Leaving Group N C02R Metal Catalyzed Coupling Han Zi 0 Z O Scheme 6: Pyrazinone (II) (continued) Z5 z5 Hydrolysis . J-. N COzR HN N C02R H I II Zozo Z5 Z 'f f ? NH2-Z3-Cbz, íl I 11 NH2~Z3~CbZx o (N Coupling Agent o 0 Z5 Z4 N 4 O Deprotection : H2, Pd/C or LiOH, H20, MeOH Z1-HN Y NH-Z3-Cbz Il 0 Z5 Z N ir"o I N Z-HN'NH-Z3 0 Scheme 7 Pyrazinone (III)

Scheme 7 : Pyrazinone (III) (continued)

Z5 Z 4 N Y O +. I Z1-HN/S 0- ? o R4a +NH3 D-x Rinse away by-products from resin-bound D-x KCI + Z1-NH3+CI-+ RE-OH Z5 Z oh HCI N J. 0-+nu3 lu O rua Oh OH N \ z4 \ N\N N O +/N ZI-HN t4 OH II R4a/ D-1 B-2 Cbz-Z,-NH2 NC N DMF DCM,, _ or [NMM] R-2 Boc-Z,-NH2 Scheme 7 : Pvrazinone (III) (continued

z5 N 0 NH I N J-han 0 R4a D-i bound to R-2 OH N\ OH N B-2 (remaining) Zs E-i N 0 I N-E. ZI-HN NH-Z3-Cbz (Boc) 0 R4a E-i CHO NH2 N 2 H H R-3 R-1 Scheme 7 : Pyrazinone (III) (continued)

Scheme 7 : Pyrazinone (III) (continued) Z5 Z4 N 0 O e NH-Z3-Cbz (Boc) raya E-i 0 RW4a Cbz or Boc protected E-i Cbz-protected E-i/\ 1. Nal/TMS-CI 10% Pd/C with 2. N, N-dimethylamino- +/\ methylpolystyrene or H2 Z5 Z N 4 O or N ZI-HN NH-Z3 Z-i 0 R 4a Scheme 8: Pyridone (I) (CH30) 2CHN (CH3) 2 z) C Z5 2-Cyanoacetamide Z4 Z5 z4 HBr/AcOH Reflux 12 hrs 0 O Z5 z5 1. DPPA/TEA/Dioxane N 2. t-BuOH, reflux HOOCH Z5 Zs o 1. NaH Nu 2. BrCH2C (O) NH-Z3-Cbz Boc-HN 11/H Z5 Zs z4 0 TFA Cbz Boc-HN \N/ I H H Scheme 8 : Pyridone (I) (continued) Scheme 9 : Pyridone (II) Z6 Z6 6 Z5 02N Z5 Z6 Z6 Fe Br \N Br gr \N Br Z6 vs H2N Z5 H2N Z5 NaOCH3 ZIL1=0 "Y"NaOCH3 T"r ZiLi=0 Dioxane I NaHB (OAc) 3 Br \N gr H3C0 \N Br Z6 Z5 ,/\ BBr3 Z, L,-HN Br BBr3 N H3CO Z6 Z5 /CaH2 THF Z1L1-HN/\Br Br/\CO2R R = t-butyl, benzyl or /similar group HO Scheme 9: Pyridone (II) (continued) z5 NaHC03 Pd (PPh3) 4 Z4-B (OH) 2 HN N C02R H I il LZ 0 Z5 L1Z1 ° z 15 Z6 Z4 1. Deprotection-TFA 2. NH2-Z3-Cbz, HN/\II/NC°2R Coupling Agent P 9 HN L1Z1 0 z5 Deprotection : H2, Pd/C /or LiOH, H20, MeOH N Z1L1 HN 11 NH-Z3-CbZ 0 Z5 Z5 0 ZlLl-HN * NH-Z3 0 Scheme 10: 0 0 c A A ammonium-2-nitroacetamide _ , Z4 O Boc Box /\0 BOC CH33°+BF4 I N 02N \ H o 0 /\0 BOC Z4 0 Z4 DIBAL/DCM In On OCH3 OH Boc Z4 Kl4 /N DMSO N OCH3 Scheme 10: (continued) Scheme 10: (continued) Boc R80 Z4 I NU Z N Z, N 0 1. NaH NaH /\NaH 2. BrCH2C (O) NH-Z3-Cb THF /\Br CO2-t-Bu boy Toc \ Z-Cbz Z N N 3 Boc H H Ruz I N 1. H2, Pd/C Z, N 0-t-Bu 2. TFA 0 1. Deprotection TFA R80 Z4 2. NH2-Z3-Cbz, t coupling agent zon Z \N \N H H 0 R80 Z4 H2, Pd-C N/Z3-Cbz Z N N H H < Z1 H,, J ! sx,,. 1 J oZ3-Cbz 0 Scheme 11: 0 0 Z4-ammonium 2-nitroacetamide I Cbz Cbz Cbz HO Z4 POC13 Acetonitrile TEA OZN H o Cbz I NaH/THF Br/\CO-t-Bu z o 1 0 Cbz Rso 0 + Z,--X7-H p'lus Base O O 02N f O-t-Bu \/ o Scheme 11: (continued) Cbz R80 I x' 4 TFA/H20 o , O O 02N 0-t-Bu 0 Cbz Rso R80 I H2, Pd/C x, z4 0 Z1 VU 0 02N OH 0 1. Deprotection TFA o 2. NH2-Z3-Cbz, Coupling Agent o H 0 o H, Pd/C Z3-Cbz R8o X7 Z4 H i H H H H H R80 X7 Z4 0 Z N N/ H I H o H H 0

Assays for Biological Activity TF-VIIa Assay In this assay 100 nM recombinant soluble tissue factor and 2 nM recombinant human factor VIIa are added to a 96-well assay plate containing 0.4 mM of the substrate, N-methylsulfonyl-D-phe-gly-arg-p-nitroaniline and either inhibitor or buffer (5 mM CaCl2, 50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0.1% BSA). The reaction, in a final volume of 100 ul is measured immediately at 405 nm to determine background absorbance. The plate is incubated at room temperature for 60 min, at which time the rate of hydrolysis of the substrate is measured by monitoring the reaction at 405 nm for the release of p-nitroaniline.

Percent inhibition of TF-VIIa activity is calculated from OD405 nm value from the experimental and control sample.

Xa Assay Human factor Xa (0.3 nM) and 0.15 mM-a- Benzyloxycarbonyl-D-arginyl-L-glycyl-L-arginine-p- nitroaniline-dihydrochloride (S-2765) are added to a 96-well assay plate containing either inhibitor or buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0. 1% BSA). The reaction, in a final volume of 100 ul is measured immediately at 405 nm to determine background absorbance.

The plate is incubated at room temperature for 60 min, at which time the rate of hydrolysis of the substrate is measured by monitoring the reaction at 405 nm for the release of p-nitroaniline. Percent inhibition of Xa activity is calculated from OD405 nm value from the experimental and control sample.

Thrombin Assay Human thrombin (0.28 nM) and 0.06 mM H-D- Phenylalanyl-L-pipecolyl-L-arginine-p-nitroaniline dihydrochloride are added to a 96-well assay plate containing either inhibitor or buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0. 1% BSA). The reaction, in a final volume of 100 ul is measured immediately at 405 nm to determine background absorbance. The plate is incubated at room temperature for 60 min, at which time the rate of hydrolysis of the substrate is measured by monitoring the reaction at 405 nm for the release of p-nitroaniline.

Percent inhibition of thrombin activity is calculated from OD405 nm value from the experimental and control sample.

Trypsin Assay Trypsin (5 ug/ml; type IX from porcine pancreas) and 0.375 mM N-a-Benzoyl-L-arginine-p-nitroanilide (L-BAPNA) are added to a 96-well assay plate containing either inhibitor or buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0. 1% BSA). The reactions, in a final volume of 100 ul are measured immediately at 405 nm to determine background absorbance. The plate is incubated at room temperature for 60 min, at which time the rate of hydrolysis of the substrate is measured by monitoring the reaction at 405 nm for the release of p-nitroaniline. Percent inhibition of trypsin activity is calculated from OD405 nm value from the experimental and control sample.

Recombinant soluble TF, consisting of amino acids 1-219 of the mature protein sequence was expressed in E. coli and purified using a Mono Q Sepharose FPLC.

Recombinant human VIIa was purchased from American Diagnostica, Greenwich CT and chromogenic substrate N- methylsulfonyl-D-phe-gly-arg-p-nitroaniline was prepared

by American Peptide Company, Inc. , Sunnyvale, CA. Factor Xa was obtained from Enzyme Research Laboratories, South Bend IN, thrombin from Calbiochem, La Jolla, CA, and trypsin and L-BAPNA from Sigma, St. Louis MO. The chromogenic substrates S-2765 and S-2238 were purchased from Chromogenix, Sweden.

Prothrombin Time Assay The prothrombin time (PT) assay is a clotting assay that is used to determine deficiencies of clotting factor activity in the extrinsic pathway. The assay measures time to clotting after the addition of thromboplastin (human tissue factor). Normal human pooled plasma is incubated with 100uM compound or saline in a coagulation machine. Thromboplastin is added and time to clotting is measured. Compounds with greater than 3x normal PT of 11.0 seconds are further analyzed by concentration response to determine at what concentration the prothrombin time is prolonged by 2x normal.

Using the bioassay procedures described herein, the biological activity of the compounds of Table 1 are summarized below in Table 3. While all of the compounds in Table 3 exhibit activity towards TF-VIIa, a compound selective for TF-VIIa preferably possesses an ICso value of less than 0.1 uM for TF-VIIa and greater than 30.0 uM against thrombin and/or factor Xa. Compounds meeting these criteria are at least 300x more selective against TF-VIIa than against other proteases along the extrinsic coagulation pathway. Additionally, in general, compounds that selectively inhibit TF-VIIa at a concentration of less than 0.1 uM effect a 2x prolongation of prothrombin time at a concentration of less than 50 uM. Accordingly,

the data for each compound in Table 3 is reported as less than or greater than 0.1 uM for TF-VIIa, as less than or greater than 30 uM for both thrombin and factor Xa, and as less than or greater than 50 uM for prothrombin time. As used herein, the term"ND"is used to indicate that no' data is available.

Table 3 Example TF-VIIa Thrombin Factor Xa PT No. ICsa (II) (II) (Prothrombin (uM) IC50 (uM) IC50 (uM) time) 2xPT (uM) 1 <0. 1 >30. 0 >30.0 ND 2 <0. 1 >30.0 >30. 0 ND 3 <0. 1 >30.0 >30. 0 <50. 0 4 <0. 1 >30.0 >30. 0 >50. 0 5 <0. 1 <30. 0 >30.0 ND 6 <0. 1 >30.0 >30.0 <50.0 7 <0. 1 <30. 0 >30. 0 <50. 0 8 <0. 1 >30.0 >30.0 ND 9 <0. 1 <30.0 >30.0 ND 10 <0. 1 >30. 0 >30.0 <50. 0 11 <0.1 <30.0 <30. 0 ND 12 <0. 1 >30. 0 >30.0 ND 13 <0. 1 <30. 0 >30. 0 ND 14 ND ND ND ND 15 <0.1 <30.0 >30.0 <50.0 16 <0. 1 >30. 0 >30.0 <50.0 17 <0. 1 >30. 0 >30.0 <50.0 18 <0. 1 >30. 0 >30.0 <50.0 19 ND ND ND ND 20 >0.1 >30.0 >30.0 ND 21 <0.1 >30.0 >30.0 ND 22 >0. 1 >30. 0 >30.0 ND 23 >0.1 >30. 0 >30. 0 ND 24 <0.1 >30.0 >30. 0 <50. 0 25 <0.1 <30.0 >30. 0 ND 26 <0.1 >30.0 >30.0 <50.0 27 <0. 1 >30. 0 >30. 0 ND 28 <0. 1 >30. 0 >30. 0 <50.0 29 <0. 1 >30. 0 >30.0 <50.0 30 >0. 1 >30. 0 >30.0 ND

Table 3 Example TF-VIIa Thrombin Factor Xa PT No. IC50 (II) (II) (Prothrombin (uM) ICso (uM) ICso (uM) time) 2xPT (uM). 31 >0. 1 >30. 0 >30. 0 ND 32 >0. 1 >30. 0 >30. 0 ND 33 <0. 1 >30. 0 >30. 0 ND 34 ND ND ND ND 35 <0. 1 >30. 0 >30. 0 <50. 0 36 >0. 1 >30. 0 >30. 0 ND 37 >0. 1 >30. 0 >30. 0 ND 38 <0. 1 ND >30. 0 ND 39 <0. 1 ND >30. 0 ND 40 <0. 1 ND >30. 0 ND 41 <0. 1 ND >30. 0 ND 42 <0. 1 ND >30. 0 ND 43 <0. 1 ND >30. 0 ND 44 <0. 1 ND >30. 0 ND 45 <0. 1 ND >30. 0 ND 46 <0. 1 ND >30. 0 ND 47 <0. 1 ND >30. 0 ND 48 >0. 1 >30. 0 >30. 0 ND 49 >0. 1 >30. 0 >30. 0 <50. 0 50 <0. 1 <30. 0 >30. 0 <50. 0 51 >0. 1 >30. 0 >30. 0 <50. 0 52 <0. 1 <30. 0 >30. 0 ND 53 <0. 1 >30. 0 >30. 0 <50. 0 54 <0. 1 >30. 0 >30. 0 <50. 0 55 <0. 1 >30. 0 >30. 0 ND 56 <0. 1 <30. 0 >30. 0 <50. 0 57 <0. 1 <30. 0 >30. 0 <50. 0 58 <0. 1 <30. 0 >30. 0 <50. 0 59 >0. 1 >30. 0 >30. 0 >50. 0 60 <0. 1 <30. 0 >30. 0 <50. 0 61 <0. 1 >30. 0 >30. 0 <50. 0 62 <0. 1 <30. 0 >30. 0 <50. 0 63 <0. 1 >30. 0 >30. 0 <50. 0 64 <0. 1 >30. 0 >30. 0 <50. 0 65 >0. 1 >30. 0 >30. 0 >50. 0 66 <0. 1 >30. 0 >30. 0 <50. 0 67 <0. 1 >30. 0 <30. 0 <50. 0 68 <0. 1 >30. 0 <30. 0 <50. 0 69 <0. 1 >30. 0 >30. 0 <50. 0 70 <0 1 >30. 0 >30. 0 <50. 0

Table 3 Example TF-VIIa Thrombin Factor Xa PT No. Also (II) (II) (Prothrombin (uM) IC50 (uM) IC50 (uM) time) 2xPT (uM). 71 <0. 1 <30. 0 >30. 0 <50. 0 72 <0. 1 <30. 0 >30. 0 <50. 0 73 <0. 1 >30. 0 >30. 0 <50. 0 74 <0. 1 >30. 0 >30. 0 <50. 0 75 ND ND ND ND 76 <0. 1 >30. 0 >30. 0 <50. 0 77 >0. 1 >30. 0 >30. 0 <50. 0 78 >0. 1 >30. 0 >30. 0 <50. 0 79 >0. 1 >30. 0 >30. 0 <50. 0 80 <0. 1 >30. 0 >30. 0 >50. 0 81 <0. 1 <30. 0 >30. 0 <50. 0 82 <0. 1 <30. 0 >30. 0 <50. 0 83 <0. 1 >30. 0 >30. 0 <50. 0 84 <0. 1 >30. 0 >30. 0 <50. 0 85 <0. 1 >30. 0 >30. 0 <50. 0 86 <0. 1 <30. 0 >30. 0 <50. 0 87 <0. 1 <30. 0 >30. 0 <50. 0 88 >0. 1 >30. 0 >30. 0 <50. 0 89 <0. 1 >30. 0 >30. 0 <50. 0 90 <0. 1 >30. 0 >30. 0 <50. 0 91 <0. 1 >30. 0 >30. 0 <50. 0 92 <0. 1 >30. 0 >30. 0 <50. 0 93 <0. 1 >30. 0 >30. 0 <50. 0 94 <0. 1 >30. 0 >30. 0 <50. 0 95 <0. 1 >30. 0 >30. 0 <50. 0 96 <0. 1 >30. 0 >30. 0 <50. 0 97 >0. 1 >30. 0 >30. 0 ND 98 <0. 1 >30. 0 >30. 0 <50. 0 99 <0. 1 >30. 0 >30. 0 <50. 0 100 <0. 1 <30. 0 >30. 0 <50. 0 101 <0. 1 <30. 0 >30. 0 <50. 0 102 <0. 1 <30. 0 >30. 0 <50. 0 103 <0. 1 >30. 0 >30. 0 <50. 0 104 <0. 1 <30. 0 >30. 0 <50. 0 105 <0. 1 >30. 0 >30. 0 <50. 0 106 <0. 1 >30. 0 >30. 0 <50. 0 107 <0. 1 >30. 0 >30. 0 <50. 0 108 <0. 1 <30. 0 >30. 0 <50. 0 109 <0. 1 <30. 0 >30. 0 <50. 0 110 <0. 1 >30. 0 >30. 0 c50. 0

Table 3 Example TF-VIIa Thrombin Factor Xa PT No. Also (II) (II) (Prothrombin (uM) ICsa (uM) ICso (uM) time) 2xPT (uM)' 111 <0. 1 >30. 0 >30. 0 <50. 0 112 <0. 1 <30. 0 >30. 0 <50. 0 113 <0. 1 >30. 0 >30. 0 <50. 0 114 <0. 1--->30. 0 >30. 0 <50. 0 115 <0. 1 ND ND <50. 0 116 >0. 1 >30. 0 <30. 0 <50. 0 117 ND ND ND <50. 0 118 <0. 1 >30. 0 >30. 0 <50. 0 119 <0. 1 <30. 0 >30. 0 <50. 0 120 ND ND ND ND 121 <0. 1 <30. 0 >30. 0 ND 122 ND ND ND ND 123 <0. 1 >30. 0 >30. 0 <50. 0 124 <0. 1 >30. 0 >30. 0 <50. 0 125 ND ND ND ND 126 <0. 1 <30. 0 >30. 0 ND 127 <0. 1 <30. 0 >30. 0 <50. 0 128 <0. 1 >30. 0 >30. 0 <50. 0 129 <0. 1 >30. 0 >30. 0 ND 130 <0. 1 <30. 0 >30. 0 <50. 0 131 <0. 1 <30. 0 >30. 0 <50. 0 132 <0. 1 <30. 0 >30. 0 ND 133 <0. 1 <30. 0 >30. 0 <50. 0 134 <0. 1 <30. 0 >30. 0 <50. 0 135 <0. 1 <30. 0 >30. 0 <50. 0 136 <0. 1 <30. 0 >30. 0 <50. 0 137 <0. 1 <30. 0 >30. 0 <50. 0 138 <0. 1 <30. 0 >30. 0 ND 139 <0. 1 <30. 0 >30. 0 <50. 0 140 <0. 1 <30. 0 >30. 0 <50. 0 141 <0. 1 <30. 0 >30. 0 <50. 0 142 <0. 1 >30. 0 >30. 0 <50. 0 143 <0. 1 <30. 0 >30. 0 <50. 0 144 <0. 1 >30. 0 >30. 0 <50. 0 145 <0. 1 ND ND <50. 0 146 <0. 1 ND ND <50. 0 147 <0. 1 ND ND <50. 0 148 <0. 1 ND ND <50. 0 149 >0. 1 ND ND ND 150 <0. 1 ND ND ND

Table 3 Example TF-VIIa Thrombin Factor Xa PT No. icso (II) (II) (Prothrombin (uM) IC50 (uM) ICso (uM) time) 2xPT (uM)' 151 <0. 1 ND ND ND 152 ND ND ND <50. 0 153 ND ND ND <50. 0 154 ND ND ND >50. 0 155 ND ND ND ND 156 ND ND ND ND 157 ND ND ND ND 158 ND ND ND ND 159 ND ND ND ND 160 ND ND ND ND 161 <0. 1 >30. 0 >30. 0 <50. 0 162 <0. 1 >30. 0 >30. 0 <50. 0 163 >0. 1 >30. 0 >30. 0 ND 164 <0. 1 >30. 0 >30. 0 <50. 0 165 <0. 1 >30. 0 >30. 0 <50. 0 166 <0. 1 >30. 0 >30. 0 <50. 0 167 <0. 1 <30. 0 >30. 0 <50. 0 168 >0. 1 >30. 0 >30. 0 ND 169 <0. 1 <30. 0 >30. 0 <50. 0 170 <0. 1 >30. 0 >30. 0 <50. 0 171 <0. 1 >30. 0 >30. 0 <50. 0 172 <0. 1 >30. 0 >30. 0 <50. 0 173 <0. 1 >30. 0 >30. 0 ND 174 <0. 1 >30. 0 >30. 0 <50. 0 175 <0. 1 >30. 0 >30. 0 <50. 0 176 <0. 1 >30. 0 >30. 0 <50. 0 177 <0. 1 >30. 0 >30. 0 <50. 0 178 <0. 1 >30. 0 >30. 0 <50. 0 179 <0. 1 >30. 0 >30. 0 <50. 0 180 >0. 1 >30. 0 >30. 0 ND 181 >0. 1 >30. 0 >30. 0 >50. 0 182 <0. 1 <30. 0 >30. 0 <50. 0 183 <0. 1 <30. 0 >30. 0 ND 184 <0. 1 <30. 0 >30. 0 <50. 0 185 <0. 1 >30. 0 >30. 0 <50. 0 186 <0. 1 >30. 0 >30. 0 <50. 0 187 <0. 1 >30. 0 >30. 0 <50. 0 188 ND ND ND ND 189 ND ND ND ND 190 <0. 1 <30. 0 >30. 0 <50. 0

Table 3 Example TF-VIIa Thrombin Factor Xa PT No. IC50 (II) (II) (Prothrombin (uM) IC50 (uM) ICso (uM) time) 2xPT (uM) 191 <0. 1 <30. 0 >30. 0 <50. 0 192 <0. 1 <30. 0 >30. 0 <50. 0 193 >0. 1 >30. 0 >30. 0 <50. 0 194 <0. 1 >30. 0 >30. 0 <50. 0 195 <0. 1 >30. 0 >30. 0 <50. 0 196 >0. 1 >30. 0 >30. 0 ND 197 >0. 1 >30. 0 >30. 0 ND 198 <0. 1 >30. 0 >30. 0 <50. 0 199 <0. 1 >30. 0 >30. 0 <50. 0 200 <0. 1 >30. 0 >30. 0 ND 201 <0. 1 >30. 0 >30. 0 ND 202 <0. 1 <30. 0 >30. 0 <50. 0 203 <0. 1 <30. 0 >30. 0 <50. 0 204 <0. 1 >30. 0 >30. 0 <50. 0 205 ND ND ND ND 206 ND ND ND ND 207 <0. 1 >30. 0 >30. 0 <50. 0 208 <0. 1 <30. 0 >30. 0 ND 209 <0. 1 >30. 0 >30. 0 50 210 <0. 1 >30. 0 >30. 0 <50. 0 211 <0. 1 >30. 0 >30. 0 <50. 0 212 <0. 1 >30. 0 >30. 0 <50. 0 213 <0. 1 >30. 0 >30. 0 <50. 0 214 <0. 1 >30. 0 >30. 0 <50. 0 215 <0. 1 >30. 0 >30. 0 <50. 0 216 <0. 1 >30. 0 >30. 0 <50. 0 217 <0. 1 <30. 0 >30. 0 <50. 0 218 <0. 1 >30. 0 >30. 0 <50. 0 219 <0. 1 >30. 0 >30. 0 <50. 0 220 <0. 1 >30. 0 >30. 0 <50. 0 221 <0. 1 >30. 0 >30. 0 >50. 0 222 <0. 1 >30. 0 >30. 0 <50. 0 223 <0. 1 >30. 0 >30. 0 <50. 0 224 <0. 1 >30. 0 >30. 0 <50. 0 225 <0. 1 >30. 0 >30. 0 >50. 0 226 <0. 1 >30. 0 >30. 0 ND 227 <0. 1 >30. 0 >30. 0 <50. 0 228 <0. 1 >30. 0 >30. 0 <50. 0 229 <0. 1 >30. 0 >30. 0 <50. 0 230 <0. 1 >30. 0 >30. 0 <50. 0

Table 3 Example TF-VIIa Thrombin Factor Xa PT No. ICso (II) (II) (Prothrombin (uM) ICso (uM) ICso (uM) time) 2xPT (uM). 231 <0. 1 >30. 0 >30. 0 <50. 0 232 <0. 1 >30. 0 >30. 0 <50. 0 233 <0. 1 >30. 0 >30. 0 <50. 0 234 <0. 1 >30. 0 >30. 0 <50. 0 235 <0. 1 >30. 0 >30. 0 <50. 0 236 <0. 1 >30. 0 >30. 0 <50. 0 237 <0. 1 >30. 0 >30. 0 <50. 0 238 <0. 1 >30. 0 >30. 0 <50. 0 239 <0. 1 >30. 0 >30. 0 <50. 0 240 <0. 1 >30. 0 >30. 0 <50. 0 241 ND ND ND ND 242 <0. 1 >30. 0 >30. 0 ND 243 >0. 1 >30. 0 ND ND 244 >0. 1 >30. 0 ND ND 245 ND ND ND ND 246 ND ND ND ND 247 ND ND ND ND 248'<0. 1<30. 0'NDND 249 <0. 1 >30. 0 ND <50. 0 250 ND ND ND ND 251 <0. 1 >30. 0 ND <50. 0 252 ND ND ND ND 253 >0. 1 <30. 0 ND <50. 0 254 <0. 1 >30. 0 ND <50. 0 255 >0. 1 >30. 0 ND ND 256 <0. 1 <30. 0 >30. 0 ND 257 <0. 1 >30. 0 >30. 0 ND 258 <0. 1 <30. 0 ND Example 1

Prepared as described in the schemes above, Example 1 was obtained: 1H NMR (300 MHz, CD30D) 5 8.76 (t, 1 H), 7.75 (d, J = 6.3 Hz, 2 H), 7.49 (s, (2 H), 7.47 (d, J = 6.3 Hz, 2 H), 7.41 (s, 1 H), 7.14 (s, 1 H), 7.01 (t, J = 1.2 Hz, 1 H), 4.69 (s, 2 H), 4.49-4. 51 (m, 2 H), 3.86 (s, 3 H), 3.62 (septet, J = 4.5 Hz, 1 H), 1.27 (d, J = 4.5 Hz, 6 H); LRMS (ESI) [M + Ho 492.

Example 2 Using the product of Example 1, hydrolysis was used to obtain Example 2 : 1H NMR (300 MHz, CD30D) 5 7.76 (d, J =

6.3 Hz, 2 H), 7.54 (apparent t, J = 1.8 Hz, 1 H), 7.46 (d, J = 6.3 Hz, 2 H), 7. 46 (s, 1 H), 7.14 (s, 1 H), 7.04 (apparent t, J = 1.8 Hz, 1 H), 4.72 (s, 2 H), 4.49 (s, 2 H), 3.63 (septet, J = 4.5 Hz, 1 H), 1.28 (d, J = 4.5 Hz, 6 H); LRMS (ESI) [M + H] + = 478.

Example 3 <BR> <BR> 3-Amino-5-[1-[2-({4-Eamino (imino) methyl] benzyl} amino)-2- oxoethyl]-3-bromo-5-(isopropylamino)-6-oxo-1, 6- dihydropyrazin-2-yl] benzoic acid Ex-3) The crude product from Ex-4 (0.21 g, 0.37 mmol) was taken up in 2.5 mL of MeOH. Water (1.1 mL) was added, followed by LiOH (82 mg, 2 mmol) in 1.85 mL of water. The reaction was stirred for 3.5 h.

The volatiles were removed under reduced pressure.

The crude residue was purified by reverse-phase HPLC with a gradient of 5/95%-95/5% acetonitrile/water (+ 0. 1% TFA). The product-containing fractions were concentrated and dried under high vacuum to give 80 mg of an off-white solid: LRMS m/z 556,558 (M+ + H); HPLC purity (retention time): >99% (2.3 min); 3, H NMR (400 MHz, CD30D) # 1.25 (d, 6H, J = 6.8 Hz), 4.16 (m, 1H), 4.32-4. 55 (m, 4H), 7.21 (m, 1H), 7.40 (d, 2H, J = 8.4 Hz), 7.60 (m, 1H), 7.71 (d, 2H, J = 8.4 Hz), 7.79 (m, 1H).

Example 4 Methyl 3-amino-5- [l- [2- ( {4- [amino (imino) methyl] benzyl} amino)-2-oxoethyl]-3-bromo-5- <BR> <BR> (isopropylamino)-6-oxo-1, 6-dihydropyrazin-2-yl] benzoate Methyl 3- (hydroxymethyl)-5-nitrobenzoate Ex-4a) Anhydrous THF (600 mL) was cooled in a salt/ice bath under N2. Mono-methyl-5-nitroisophthalate (175 g, 777 mmol) was added and the solution was cooled to-10 °C. BH3. THF (800 mL of a 1M solution) was added dropwise over 1 h 20 mins. The solution was warmed to room temperature, then heated to 35 °C. The reaction slowly exothermed to 61 °C. The reaction was stirred at 55 °C overnight.

The reaction solution was diluted with 200 mL of EtOAc and concentrated under reduced pressure. The yellow residue was diluted with 800 mL of EtOAc and washed with aqueous saturated NaHC03 2 x 450 mL, brine 1 x 450 mL, to give 146.02 g (89%) of a pale yellow solid: LRMS m/z 212.0 (M+ + H); HPLC purity (retention time): >80% (2. 3 min) ; 1H NMR (300 MHz, CDC13) 5 2. 52 (s, 1H), 3.93 (s, 3H), 4.82 (s, 2H), 8.28 (s, 1H), 8.37 (s, 1H), 8.67 (s, 1H).

Methyl 3-formyl-5-nitrobenzoate Ex-4b) CH2Cl2 was cooled to-78 °C under N2 in a 5-L flask equipped with an overhead stirrer. Oxalyl chloride (69 mL, 791 mmol) was added in a steady stream to the CH2C12.

DMSO (91 mL, 1282 mmol) in 400 mL of CH2Cl2 was added rapidly dropwise over 45 mins, keeping the reaction temperature below-70 °C. The reaction was stirred at- 78 °C for 10 mins. The product from Ex-4a (132.6 g, 628 mmol) in 850 mL of CH2C12 was added dropwise over 55 mins, keeping the reaction temperature below-70 °C. The reaction was stirred at-78 °C for 30 mins.

Triethylamine (350 mL, 2511 mmol) was added in a steady stream to the reaction, keeping the temperature below-60 °C. The reaction was warmed to room temperature overnight.

The layers were allowed to separate. The CH2Cl2 layer was washed with 2 L of 1M KHSO4, aqueous saturated NaHCO3, brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to give 126.4 g (96%) of a yellow solid : 1H NMR (300 MHz, CDC13) 8 4. 01 (s, 3H), 8.82 (m, 1H) 8.86 (m, 1H), 9.06 (m, 1H), 10.14 (s, 1H).

Methyl 3- [ [ [ (benzyloxy) carbonyl] (methyl) amino] (cyano) methyl)-5- nitrobenzoate Ex-4c) Glycine benzyl ester hydrochloride. (38.14 g, 189 mmol) was dissolved in 250 mL of aqueous saturated Na2CO3 and 500 mL of brine. The aqueous phase was extracted with EtOAc 2 x 500 mL. The combined organics were dried over Na2CO3, concentrated under reduced pressure, dissolved in CH2C12 and concentrated again to give 29.9 g (96%) of a pale yellow oil which was used directly in the next step.

The glycine benzyl ester (29.9 g, 181 mmol) was dissolved in 80 mL of CH2C12. The product from Ex-4b (32.9 g, 157 mmol) was added, followed by 10 mL of CH2C12.

TMSCN (25 g, 252 mmol) was, added neat, dropwise, over 20 mins. The reaction exothermed from 26 to 38 °C. The reaction was stirred at room temperature for 3 h.

The reaction solution was washed with brine 1 x 350 mL, dried over MgS04, and the volatiles were removed under reduced pressure to give 83.78 g of a crude orangish- yellow oil, which was carried on without purification to the next step.

Methyl 3- {l- [2- (benzyloxy)-2-oxoethyl]-3, 5-dibromo-6-oxo- 1, 6-dihydropyrazin-2-yl}-5-nitrobenzoate Ex-4d) The crude product from Ex-4c (24.3 g, 63 mmol) was dissolved in 75 mL of CH2C12 and added dropwise to a solution of oxalyl bromide (59.7 g, 277 mmol) in 30 mL of CH2Cl2. The temperature during the addition was kept below 40 °C. The reaction was stirred at 50-55 °C for 2 h.

The reaction solution was cooled, then washed with water 1 x 150 mL, brine 1 x 150 mL, dried over MgS04, filtered, and concentrated. The residue was dried under high vacuum and stored under N2 to give 34.8 g of the crude, desired product: LRMS m/z 580,582, 584 (M+ + H) ; HPLC purity (retention time): <50% (4.3 min).

Methyl 3- [I- [2- (benzyloxy)-2-oxoethyll-3-bromo-5- (isopropylamino)-6-oxo-1, 6-dihydropyrazin-2-yl]-5- nitrobenzoate Ex-4e) The crude product from Ex-4d (33 g crude, 57 mmol) was dissolved in 100 mL of EtOAc. Isopropylamine (20 mL 235 mmol) was added rapidly dropwise. The reaction exothermed from 33 to 55 °C. The reaction was stirred at room temperature for 1 h 15 mins.

The reaction mixture was filtered through a pad of Celite, then washed with brine 1 x 125 mL, dried over MgS04, and concentrated under reduced pressure. The crude, reddish-brown residue was purified by normal phase HPLC using 30/70% EtOAc/hex, isocratic. The product- containing fractions were concentrated, then triturated with Et20 to give 3.6 g of a yellow solid: LRMS m/z 559, 561 (M+ + H); HPLC purity (retention time): >95% (4.5 min).

Methyl 3-amino-5- [1- [2- (benzyloxy)-2-oxoethyl]-3-bromo-5- (isopropylamino)-6-oxo-1, 6-dihydropyrazin-2-yl] benzoate Ex-4f) The product from Ex-4e (2.93 g, 5.24 mmol) was taken up in 40 mL of 50/50% EtOH/H20 (w/w) and 10 mL of ACN and heated to 55 °C. Another 40 mL of 50/50% EtOH/H20 (w/w), 60 mL of ACN, and 40 mL of 100% EtOH were added.

Iron powder (4.16 g, 74 mmol) and 12M HC1 (1.44 mL, 17 mmol, in 50/50% EtOH/H20) were added portion-wise to the 55 °C reaction over two days.

The reaction mixture was cooled, filtered through a pad of Celite, and partially concentrated under reduced pressure. The solid that precipitated was filtered and dried under high vacuum overnight to give 2.50 g (90%) of desired product: LRMS m/z 529,531 (M+ + H); HPLC purity (retention time): >99% (3.8 min).

[6- [3-amino-5- (methoxycarbonyl) phenyl]-5-bromo-3- (isopropylamino)-2-oxopyrazin-1 (2H)-yl] acetic acid Ex-4g) The product from Ex-4f (0.52 g, 0.98 mmol) was taken up in 5 mL of CH2Cl2. TFA (0.5 mL, 6.5 mmol) was added, followed by triflic acid (0.42 mL, 4.7 mmol) and anisole (0.15 mL, 1.4 mmol). The biphasic solution was stirred vigorously for 15 mins.

The solution was extracted with water 3 x 15 mL and aqueous saturated NaHC03 2 x 10 mL. The combined aqueous extracts were acidified with 2 M HC1, then extracted with EtOAc 2 x 25 mL. The combined organic extracts were dried over MgS04, filtered, and concentrated under reduced pressure. The yellow residue was dissolved in Et2O and concentrated. The resulting solid was dissolved in MeOH and filtered. The filtrate was concentrated and dried under high vacuum for 30 mins to give 0.41 g (96%) of a pale yellow solid: LRMS m/z 439,441 (M+ + H); HPLC purity (retention time): >99% (2.8 min).

Methyl 3-amino-5- [l- (2- { [4- ( (Z)- aminofE (benzyloxy) carbonyl] imino} methyl) benzyl] amino}-2- oxoethyl)-3-bromo-5- (isopropylamino)-6-oxo-1, 6- dihydropyrazin-2-yljbenzoa. te Ex-4h) LRMS m/z 704,706 (M+ + H); HPLC purity (retention time) : >95% (3. 2 min).

Ex-4) The crude product from Ex-4h (0.64 g, 0.91 mmol) was dissolved in 10 mL of CH2C12. Triflic acid (0.60 mL, 6.8 mmol) and anisole (0.15 mL, 1.4 mmol) were added, followed by TFA (0.44 mL, 5.7 mmol). After stirring for 1 h 10 mins, another 0.6 mL of TFA (7.8 mmol) and 0.3 mL (3.4 mmol) of triflic acid were added. The reaction was stirred another 15 mins.

The reaction solution was extracted with water 5 x 30 mL. The combined aqueous extracts were neutralized with aqueous saturated NaHC03, then extracted with EtOAc 2 x 75 mL. The combined organics were washed with brine 1 x 50 mL, dried over MgS04, concentrated under reduced pressure and stored under N2 to give 0.32 g of a pale yellow residue: LRMS m/z 570,572 (M+ + H); HPLC purity (retention time): >95% (2.6 min).

One third of the residue was purified by reverse-phase HPLC with a gradient of 5/95%-95/5% acetonitrile/water (+ 0. 1% TFA) over 10 mins. Product eluted at 4.9 mins, giving 59 mg of a pale yellow solid : LRMS m/z 570,572 (M+ + H); HPLC purity (retention time) : >99% (2.6 min) ; 1H NMR (400 MHz, CD30D) # 1. 25 (d, 6H, J = 6.5 Hz), 3.86 (s, 3H), 4.16 (m, 1H), 4.33-4. 52 (m, 4H), 7.19 (m, 1H), 7.40 (d, 2H, J = 8.5 Hz), 7.56 (m, 1H), 7.70-7. 72 (m, 3H).

Amide Library NH H 1 0 N OH 'l) fi ° O NHn N \ I NH WNH Ol, NH o Scaffold R NH2 Generic Amine Scaffold (0.1 mmol) was reacted. Each well contained the scaffold (0.1 mmol), P-CD resin (0.2 gram, 1 meq/g), HOBT (13.5 mg), NMM (0.20 mL), Generic Amine (0.1 mmol), and DCM (6.0 mL). Each well was shaken for 6 hours. DCM (3.0 mL) was added along with PolyAmine Resin (200 mg, 230 meq/g) and Aldehyde Resin (75 mg). The wells were shaken for 0.5 hours. Each well was filtered and the solution was dried under Nitrogen stream. Each well was re-dissolved in DCM (3.0 mL) and TFA (0.5 mL). The wells were shaken (2 hours), and then dried under a Nitrogen stream. Each well was re-dissolved in methanol and purified as fractions on the Gilson as needed.

General: HPLC purities were determined with a Hewlett Packard HP1100 using an XDB-C18 3.5 ? M 2.1 x 30 mm column, eluting with a gradient system 5/95% to 95/5% acetonitrile/H2O (+0.1% TFA buffer) over 4.5 min at 1 mL/min, and detected by W at 254 nm using a diode array detector.

Example 5 LC/MS Purity->80%, Retention Time-2.136, M+H-533.3 Example 6 LC/MS Purity->80%, Retention Time-2.371, M+H-547.5 LC/MS Purity->80%, Retention Time-2.093, M+H-533.4 Example 8 LC/MS Purity-58%, Retention Time-2.350, M+H-585.4 Example 9 LC/MS Purity->80%, Retention Time-2.594, M+H-573.0 Example 10 LC/MS Purity->80%, Retention Time-2.599, M+H-635.1 Example 11 LC/MS Purity->80%, Retention Time-2.190, M+H-545.4 Example 12 LC/MS Purity->80%, Retention Time-2.479, M+H-563.2 Example 13 LC/MS Purity->80%, Retention Time-2.582, M+H - 595. 4 Example 14 LC/MS Purity->80%, Retention Time-2.199, M+H-533.5 Example 15 LC/MS Purity-90%, Retention Time-1.395, M+H-531.2 Examples 16/17 3-amino-5-[1-[2-({4-[amino (imino) methyl] benzyl} amino)-2- oxoethyl]-5- (isopropylamino)-6-oxo-1, 6-dihydropyrazin-2- yl] benzoic acid trifluoracetate methyl 3- [1- (2-tert-butoxy-2-oxoethyl)-5- (isopropylamino)-6-oxo-1, 6-dihydropyrazin-2-yl]-5- nitrobenzoate Ex-17a) A solution of tert-butyl [6-bromo-3- (isopropylamino)-2-oxopyrazin-1 (2H) -yl] acetate (50.0 g, 144.4 mmol), 3- (methoxycarbonyl)-5-nitrophenylboronic acid (35.7 g, 158.9 mmol), and sodium carbonate (61.2 g, 0.6 mol) in 2 L THF and 200 mL DI H20 stirred in a 3 neck flask equipped with a cold water condenser, heating mantle and stir bar stirred for 1 h while N2ng) bubbled through the solution.

Tetrakis (triphenylphospine) palladium (0) (16.7 g, 14.4 mmol) under a blanket of N3 (3), and the reaction was warmed to reflux (64 °C) for 16 h. The reaction mixture cooled to room temperature, filtered, reduced, diluted with 1 L ethyl acetate and washed with 2 x 500 mL DI H20. The organic portion was dried over Magnesium sulfate, filtered and concentrated to give 80 g crude brown oil.

The crude product was chromatographed on silica, eluted with 20% ethyl acetate/80% hexanes. 26.0 g (40.3%) of yellow solid was recovered.

LRMS m/z 447.2 (M+ + H).

'H NMR (300 MHz, CDC13) 8 1.30 (d, 6H, J = 6.3 Hz), 1.46 (s, 9H), 4.00 (s, 3H), 4.09-4. 23 (m, 1H), 4.38 (s, 2H), 5.31 (s, 2H), 6.85 (s, 1H), 8.38 (s, 1H), 8.44 (s, 1H), 8.90 (s, 1H).

[3- (isopropylamino)-6- [3- (methoxycarbonyl)-5- nitrophenyl]-2-oxopyrazin-1 (2H)-yl] acetic acid Ex-17b) 3.2 g (7.2 mmol) of the product of 17a was hydrolyzed with stirring in 50 mL TFA and 50 mL CH2C12 for 2 h. The solvents were evaporated to give 2.3 g (81%) of brown foam.

1H NMR (400 MHz, CD3COCD3) 5 1.46 (d, 6H, J = 6.4 Hz), 3.96 (s, 3H), 4.22-4. 38 (m, 1H), 4.59 (s, 2H), 7.01 (s, 1H), 8.42 (s, 1H), 8.59 (s, 1H), 8.82 (s, 1H).

LRMS m/z 391.4 (M+ + H) methyl 3- [I- [2- ( {4- [{[(benzyloxy)carbonyl]amino}(imino)methyl]benzyl}amino)- 2-oxoethyl]-5-(isopropylamino)-6-oxo-1, 6-dihydropyrazin- 2-yl]-5-nitrobenzoate Ex-17c) A solution of 17b (36.3 g, 59.0 mmol), benzyl [4- (aminomethyl) phenyl] (imino) methylcarbamate dihydrochloride (23.1 g, 64.9 mmol), HOBt (4.0 g, 29.5 mmol), and NMM (38.9 mL, 353.9 mmol) with 500 mL CH2C12 and 200 mL DMF was shaken in a glass bottle for 30 min.

Polystyrene resin bound carbodiimide (73.1 g, 88.4 mmol) was added and the reaction shook for 12 h. PS-diethylene triamine (21.0 g, 59.0 mmol) and Aldehyde wang (20.7 g, 59.0 mmol) scavenging resins were added and shook for 30 min. Reaction mixture was filtered, resins rinsed with copious amounts of CH2C12 and DMF, and solvents evaporated in vacuo to afford a brown semi-solid. No yield determined, >95% pure by HPLC and 1H NMR.

'H NMR (400 MHz, CD30D) 6 1. 28 (d, 6H, J = 6.4 Hz), 3. 96 (s, 3H), 4.10-4. 19 (m, 1H), 4.43 (s, 2H), 4.55 (s, 2H), 6.82 (s, 1H), 7.33-7. 79 (m, 9H), 8.42 (s, 1H), 8.54 (s, 1H), 8.80 (s, 1H).

LRMS m/z 656. 2 (M+ + H) Ex-17) Crude product 17c (36.7 g, 56.0 mmol) was dissolved in 1 L methanol and 4 eq. of 2M LiOH in H20. In addition, Pd/C (10%, 3.6 g) was added, and the reaction hydrogenated with a H2 (g) balloon, room temperature, stirring overnight. The reaction filtered through Celite 545, neutralized to pH 7 with 6 M HC1, and reduced in vacuo. Crude material was purified by reverse phase HPLC with 5-20% acetonitrile/water with 0.1 % TFA over 30 min.

Product collected at 8-12 min, yield 19.8 g (48%).

1H NMR (300 MHz, CD30D) 8 1.42 (d, 6H, J = 6.6 Hz), 4.03- 4.17 (m, 1H), 4.46 (s, 2H), 4.62 (s, 2H), 6.71 (s, 1H), 7.39-7. 86 (m, 7H).

"C NMR (300 MHz, CD30D) 8 20.23, 42.60, 45.74, 108.72, 121.63, 125.58, 127.72, 127.21, 127.93, 128.04, 128.97, 132.03, 133.16, 145.10, 146.33, 152.58, 167. 04, 167.11, 167.44.

LRMS m/z 478.2 (M+ + H).

Two salts were prepared for this compound and data for each is reported in Table 3.

Examples 18/19 HPLC/LRMS: >97%, 502 (M+H) + ;'7F NMR (DMF-d7, 375MHz) a- 63.28ppm ; 1H NMR (DMF-d7, 400MHz) # 9.99 (2H, s), 9.75 (2H, s), 9.44 (1H, br s), 9.05 (1H, m), 8.00 (2H, m), 7.42 (2H, m), 7.34 (1H, s), 7.16 (1H, s), 7.04 (1H, s), 6.71 (1H, s), 4.66 (3H, m), 4.43 (2H (, m), 1.38 (6H, d); HRMS (ES+) calcd. for C24H27N7O2 502.2178, found 502.2214.

Two salts were prepared for this compound and data for each is reported in Table 3.

Example 20 LCMS (RP, 5-90% acetonitrile in 0. 1% TFA over 14 min): retention time: 3.63 min; (M+H) + = 562.

1H-NMR, 400 MHz, CD30D, # 7.50 (s, 1H), 7.35 (s, 1H), 6.98 (s, 1 H), 6.60 (s, 1 H), 4.46 (s, 2 H), 4.43 (s, 2 H), 4.03 (septet, J = 6.4 Hz, 1 H), 3.86 (s, 3H), 1.36 (d, J = 6.4 Hz, 6 H).

19F-NMR, 376 MHz, CD30D, 6-77. 6 (TFA), -142. 64 (d, J = 13.5 Hz, 1 H),-146. 10 (dd, J = 13.5 Hz, J = 21.4 Hz, 1 H), -152.81 (d, J = 21.4 Hz, 1 H).

Example 21 methyl 3-amino-5 w [2- ( {4- [amino (imino) methyl] benzyl} amino)-2-oxoethyl]-5- (isopropylamino)-6-oxo-1, 6-dihydropyrazin-2-yl] benzoate trifluoroacetate H NMR (300 MHz, CD30D) 8 1.39 (d, 6H, J = 6.6 Hz), 3.87 (s, 3H), 4. 03-4. 17 (m, 1H), 4. 49 (s, 2H), 4.62 (s, 2H), 6. 65 (s, 1H), 6. 91-7. 79 (m, 7H).

LRMS m/z 492.2 (M+ + H).

Example 22 Methyl {3-amino-5-[1-[2-({4- [amino (imino) methyl] benzyl} amino)-2-oxoethyl]-5- (isopropylamino)-6-oxo-1, 6-dihydropyrazin-2-yl]-4- methoxyphenyl} acetate Methyl 4-Hydroxy-3-iodo-5-nitrophenylacetate Ex-22a) 4-Hydroxy-3-iodo-5-nitrophenylacetic acid (2.48 g, 7.68 mmol) was taken up in 14 mL of MeOH. H2SO4 (18M, 1.4 mL, 25 mmol) in 4 mL of MeOH was added, along with 2.5 mL of THF. The mixture was heated to 60 °C, and another 1 mL of THF was added to make the reaction homogeneous. The reaction was stirred for 50 mins.

The reaction was cooled to 30 °C, then cooled in an ice bath. The bright yellow solid was filtered, washed. with water until the pH was neutral, then dried under high vacuum at 40 °C to give 2.55 g (95%) of a bright yellow solid: LRMS m/z 337.9 (M+ + H); HPLC purity (retention time): >98% (3.4 min) ; 1H NMR (400 MHz, CDC13) 0. 3.57 (s, 2H), 3.70 (s, 3H), 8.00 (d, 1H, J = 1.9 Hz), 8. 02 (d, 1H, J = 1.6 Hz).

Methyl 3-iodo-4-methoxy-5-nitrophenylacetate Ex-22b) The product from Ex-22a (2.50 g, 7.42 mmol) was dissolved in 33 mL of acetone. K2CO3 (5.13 g, 37.1 mmol) and CH3I (4.62 mL, 74.2 mmol) were added and the reaction mixture was stirred at 50 °C for 3 h 20 mins.

The reaction was cooled, then diluted with 50 mL of water. The acetone was removed under reduced pressure.

The remaining aqueous mixture was acidified with 2 M HC1.

The mixture was extracted with EtOAc 2 x 75 mL. The combined organic extracts were washed with brine 1 x 75 mL, dried over MgS04, concentrated, and dried under high vacuum for 3 h to give 2. 60 g (99%) of a yellow solid: 1H NMR (400 MHz, CDC13) 83. 59 (s, 2H), 3.71 (s, 3H), 3.94 (s, 3H), 7.71 (d, 1H, J = 2.2 Hz), 7. 92 (1H, d, 2.2 Hz).

Methyl [4-methoxy-3-nitro-5- (tributylstannyl) phenyl] acetate Ex-22c) The product from Ex-22b (3.02 g, 8. 60 mmol) was dissolved in 15 mL of toluene. The solution was evacuated, then flushed with N2. Repeated 4x.

Bis (tributyl) tin (13 mL, 25.7 mmol) was added, followed by Pd (PPh3) 4 (105 mg, 0.09 mmol). The homogeneous solution was evacuated and flushed with N2. Repeated 4x.

The solution was stirred at 90 °C under N2 until the reaction was complete by TLC (2 days).

The reaction solution was cooled and diluted with EtOAc. The solution was washed with brine 1 x 50 mL, aqueous saturated KF 1 x 30 mL, brine 1 x 30 mL, dried over MgS04, and concentrated under reduced pressure. The crude was purified on silica, eluting with 10/90% EtOAc/hex, to give 2.64 g (60%) of a yellow oil : 1H NMR (400 MHz, CDC13) 8 0. 82-0. 92 (m, 9 H), 1.02-1. 11 (m, 6H), 1.25-1. 38 (m,-6H), 1.45-1. 56 (m, 6H), 3.61 (s, 2H), 3.70 (s, 3H), 3.77 (s, 3H), 7.42 (d, 1H, J = 2.3 Hz), 7.69 (d, 1H, J = 2.1 Hz).

Methyl {3-[1-(2-tert-butoxy-2-oxoethyl)-5- (isopropylamino)-6-oxo-1, 6-dihydropyrazin-2-yl]-4- methoxy-5-nitrophenyl} acetate Ex-22d) The product from Ex-22c (0.60 g, 1.2 mmol) was dissolved in 5 mL of N2-flushed DMF. tert-Butyl [6-bromo- 3-(isopropylamino)-2-oxopyrazin-1 (2H)-yl] acetate (1.14 g, 3.3 mmol), PPh3 (60 mg, 0.23 mmol), Cu (I) Br (82 mg, 0.57 mmol), 2,6-di-t-butyl-4-methylphenol (14 mg, 0.06 mmol), and Pd (PPh3) 4 (117 mg, 0.10 mmol) were added, along with another 5 mL of N2-flushed DMF. The reaction was stirred at 110 °C for 3.5 h.

The dark red solution was cooled to room temperature, then diluted with 100 mL of EtOAc and washed with aqueous KF 1 x 100 mL, aqueous saturated NaHC03 1 x 75 mL, and brine 1 x 75 mL. The organic phase was dried over MgS04, filtered, and concentrated.

The residue was purified on silica, eluting with 30/70% EtOAc/hexanes, to give 0.24 g (41%) of a yellow film: LRMS m/z 491.2, 533.3 (dimer) (M+ + H), (M+ + H) ; HPLC purity (retention time): 80% (3.2 min), 20% (3.4 min, dimer).

[3- (Isopropylamino)-6- [2-methoxy-5- (2-methoxy-2- oxoethyl)-3-nitrophenyl]-2-oxopyrazin-1 (2H)-yl] acetic acid Ex-22e) The product from Ex-22d (43 mg, 0.09 mmol) was dissolved in 0.5 mL of CH2C12. TFA (0.05 mL, 0.65 mmol), triflic acid. (0.044 mL, 0. 5 mmol) and anisole (0. 016 mL, 0. 15 mmol) were added and the reaction was stirred at room temperature for 15 mins.

The reaction solution was extracted with water 2x, then aqueous saturated NaHC03 2x. The combined aqueous extracts were acidified with 2 M HC1 and extracted with EtOAc 3x. The combined organic extracts were washed with brine, dried over MgS04 and concentrated to give 38 mg of a yellow film: LRMS m/z 435.1 (M+ + H) ; HPLC purity (retention time) : 90% (1.9 min).

Methyl {3- [l- (2- { [4- ( (Z)- amino {[(benzyloxy) carbonyl] imino} methyl) benzylzamino}-2- oxoethyl)-5- (isopropylamino)-6-oxo-1, 6-dihydropyrazin-2- yl]-4-methoxy-5-nitrophenyl} acetate Ex-22f) 38 mg (0.086 mmol) Ex-22e, 4.4 mg (0.03 mmol) HOBt, 28 mg (0. 07 mmol) benzyl [4- (aminomethyl) phenyl] (imino) methylcarbamate dihydrochloride, 57 OL (0. 52 mmol) NMM, 127 mg (0. 13 mmol) PS-carbodiimide, 1.5 mL CH2C12, and 0.3 mL DMF.

Agitated for 1.5 h, then added 20 mg (0. 06 mmol) PS- diethylenetriamine and 120 mg (0. 3 mmol) Wang aldehyde scavenging resins for 2 h to give 0. 11 g of orude, desired product: LRMS m/z 700.2 (M + H); HPLC purity (retention time): >85% (2.7 min).

Ex-22) 0.11 g of the crude product from Ex-22f, 20 mg (0.009 mmol) of 10% Pd/C (50% water-wet) and 1 mL of MeOH. The reaction was stirred overnight.

The crude residue was purified by reverse-phase HPLC with a gradient of 15/85%-85/15% acetonitrile/water (+ 0. 1% TFA) over 10 min. Product eluted at 2.8 min, giving 20 mg of an off-white solid: LRMS m/z 536.2 (M+ + H); HPLC purity (retention time) : 97% (1.8 min) ; 1H NMR (400 MHz, CD30D) 61. 41 (m, 6H), 3.52 (m, 2H), 3.66 (2 s, 6H), 4.04 (m, 1H), 4.31-4. 43 (m, 3H), 4.90-4. 94 (m, 1H), 6.61 (m, 1H), 6.73 (s, 1H), 7.01 (m, 1H), 7.40 (d, 2H, J = 8.4 Hz), 7.74 (d, 2H, J = 8.4 Hz).

Example 23 <BR> <BR> <BR> <BR> <BR> <BR> {3-Amino-5-[1-[2-({4-[amino (imino) methyl] benzyl} amino)-2-<BR> <BR> <BR> <BR> <BR> oxoethyl]-5- (isopropylamino)-6-oxo-1, 6-dihydropyraziin-2- yl]-4-methoxyphenyl} acetic acid Ex-23) The crude product from Ex-22f (150 mg crude, 0.22 mmol crude) was dissolved in 1 mL of MeOH. LiOH (55 mg, 1.3 mmol) in 0. 5 mL of water and a 0. 5 mL MeOH rinse were added. Pd/C (10% Pd/C, 50% water-wet, 48 mg, 0. 02 mmol) in N2-flushed water was added. The mixture was evacuated, then flushed with N2. Repeated several times with N2, then H2. Stirred under a H2 balloon for 3 h. The mixture was filtered through a 0.2 ; j. M frit, then concentrated.

The crude residue was purified by reverse-phase HPLC with a gradient of 15/85%-40/60% acetonitrile/water (+ 0. 1% TFA) over 10 mins. Product eluted at 2.4 mins, giving 46 mg of an off-white solid: LRMS m/z 522.2 (M+ + H); HPLC purity (retention time): >95% (1.6 min) ; 1H NMR (400 MHz, CD30D) 8 1.38 (m, 6H), 3.45 (s, 2H), 3.64 (s, 3H), 4.02 (m, 1H), 4.29-4. 41 (m, 2H), 4.91 (m, 2H), 6.59 (m, 1H), 6.72 (s, 1H), 7.00 (m, 1H), 7.38 (d, 2H, J = 8.3 Hz), 7.72 (d, 2H, J = 8.4 Hz).

Examples 24/25 LC/MS Purity-99%, Retention Time-2.089, M+H-567.2 Two salts were prepared for this compound and data for each is reported in Table 3.

Example 26 3-amino-5-[1-[2-({4-[amino(imino)methyl]benzyl}amino)-2- oxoethyl]-5- (isopropylamino)-6-oxo-1, 6-dihydropyrazin-2- yl]-N- (2-methoxyethyl) benzamide MS-ESI (M+H) = 699.

Example 27 The compound of Example 27 was prepared in an analogous manner to that of Example 186.

Example 28 LC/MS Purity->80%, Retention Time-2.354, M+H-581.3 Example 29 LC/MS Purity->80%, Retention Time-2. 370, M+H-585.4 Example 30 LC/MS Purity->80%, Retention Time-1.492, M+H-522.6 Example 31 The compound of Example 31 was prepared in an analogous manner to that of Example 3.

Example 32 Example 33 LC/MS Purity->80%, Retention Time-2.484, M+H-600.9 Example 34 LC/MS Purity->80%, Retention Time-2.213, M+H-652.0 Example 35 HPLC/LRMS: >96%, 421 (M+H) +; HRMS (ES+) calcd. for C2lH25N802 421.2100, found 421.2112.

Example 36 HPLC/LRMS: >98%, 464 (M+H) +; HRMS (ES+) calcd. for C23H26N704 464.2046, found 464.2065.

Example 37 Ex-36 (500mg) was stirred in MeOH/H2O and LiOH- H20 (Approxiately 5eq., 167mg). Purged mixture with nitrogen and added excess palladium on activated carbon, 10% wt. by dry basis. The reaction vessel was capped with a septum and a hydrogen balloon added. After 18 hrs reaction was filtered through Celite, the filtrae concentrated invacuo, and the residue chromatographed on Gilson HPLC-RP system with 0. 1% TFA (H20/AN). HPLC/LRMS: >98%, 450 (M+H) +; HRMS (ES+) calcd. for C22H249N704 450. 1890, found 450.1930.

Example 38 The compound of Example 38 was prepared in an analogous manner to that of Example 186.

Example 39 The compound of Example 39 is a salt of the compound of Example 26.

Example 40 The compound of Example 40 was prepared in an analogous manner to that of Example 186.

Example 41 The compound of Example 41 was prepared in an analogous manner to that of Example 186.

Example 42 The compound of Example 42 was prepared in an analogous manner to that of Example 186.

Example 43 The compound of Example 43 was prepared in an analogous manner to that of Example 186.

Example 44 Ex-44a) m/z (M+H) +640 Ex44) m/z (M+H) +506 Analysis: C26H31N704 + 2. 30 TFA + 0.80 H2O calcd: C, 46.99; H, 4.50 ; N, 12.53 ; found: C, 46.97 ; H, 4.47 ; N, 12.55.

HRMS calcd: 506.2510 ; Found: 506.2479 1H NMR (400MHz, DMSO): 1.22 (6H, d), 1.28 (3H, t), 4.09 (1H, m), 4.25 (2H, q), 4.36 (2H, d), 4.39 (2H, s), 6.71 (1H, s), 6. 78 (1H, t), 7. 11 (1H, t), 7.28 (1H, t), 7.39 (2H, d), 7.50 (1H, br s), 7.73 (2H, d), 8.69 (1H, t), 9.14 (2H, br s), 9.27 (2H, br s).

Example 45 LC/MS Purity-99%, Retention Time-1.500, M+H-563.3 Example 46 LC/MS Purity-99%, Retention Time-1.414, M+H-521.6 Example 47 LC/MS Purity-99%, Retention Time-1.243, M+H-478.3 Example 48 LCMS (RP, 5-90% acetonitrile in 0. 1% TFA over 14 min): retention time: 3.80 min; (M+H) + = 564, (M + Na) + = 586.

Example 49 Ex-49a) m/z (M+H) +516 Ex-49) To the product from 49a (3.0 g, 5.35 mmol) in 60 ml of ethanol was added 1.2 g of 10% palladium on carbon and 1.5 ml of hydrogen chloride (conc.). The mixture was shaken on the Parr apparatus under 40 Psi of hydrogen for 2 hours. The mixture was filtered and concentrated in vacuo to give 3.0 g of a tan foam. A portion of this material (400 mg, 0. 71 mmol) was then purified by reverse phase chromatography with 5-60% CH3CN/H20 to give 260 mg (46% yield) of a white solid. m/z (M+H) +518 Analysis : C24H26N703 + 2.35 TFA + 0.55 H20 calcd: C, 43.34 ; H, 3.73 ; N, 12.33 ; found: C, 43.39 ; H, 3.80 ; N, 12.28.

HRMS calcd: 518.2122 ; Found : 518.2107 1H NMR (400MHz, DMSO): 1.22 (6H, d), 4.09 (1H, m), 4.23 (2H, d), 4.34 (2H, s), 6.72 (1H, s), 6.77-6. 80 (3H, m), 6.9 (2H, s), 7.45 (1H, d), 7.48 (1H, br s), 8.69 (1H, t), 8.96 (4H, br s).

Example 50 N-{3-amino-5-[1-[2-({4-[amino(imino)methyl]benzyl}amino)- <BR> <BR> 2-oxoethyl]-5- (isopropylamino)-6-oxo-1, 6-dihydropyrazin-<BR> <BR> <BR> 2-yl] phenyl}-2-methylpropanamide HRMS calcd for C27H34F3N803 (M+H): 519.2827. Found: 519.2816.

Anal. Calcd for C27H34F3Ns03 + 3.45TFA+2. 65H20: C: 42.42 ; H: 4.48 ; N: 11.67.

Found: C: 42.38 ; H: 4.37 ; N: 11.79.

1H NMR (DMSO-d6, 300 MHz) 8 1.10 (d, 6H), 1.24 (d, 6H), 2.59 (m, 1H), 4.11 (m, 1H), 4.39 (m, 2H), 4.46 (s, 2H), 6.35 (s, 1H), 6.68 (s, 1H), 6.87 (s, 1H), 7.16 (s, 1H), 7.43 (d, 2H), 7.76 (d, 2H), 8.70 (t, 1H), 9.13 (s, 2H), 9. 28 (s, 2H), 9. 77 (s, 1H).

Example 51 Ex-51a) A mixture of di- (tert-butyl) 4-cyano-2,'3- difluorobenzylimidodicarbonate (0.5 g, 1.4 mmol), hydroxylamine hydrochloride (0.28 g, 4.1 mmol), and triethylamine (0. 57 ml, 4.1 mmol) in ethanol was heated to reflux for 1 hour. The reaction was concentrated in vacuo and the residue mixed with ethyl acetate, washed with 1N potassium hydrogen sulfate, saturated sodium bicarbonate, brine, dried over magnesium sulfate, filtered, and evaporated in vacuo to give 0. 5 g of Ex-51a (89% yield). LCMS (M+H) m/z 402. 1HNMR (300 MHz, CDC13) 8 1.50 (s, 18 H), 4.92 (s, 2H), 5.56 (br s, 2H), 7.05- 7.14 (m, 1H), 7.42-7. 53 (m, 1H). 19FNMR (282 MHz, CDC13) 6-142. 53 to-142.32 (m, 1F),-141. 3 to-141.0 (m, 1F).

LCMS (ES+) m/z M+H 402.

Ex-51b) To a stirred solution of 51a (0.45 g, 1.1 mmol) in pyridine (0.35 ml) and dichloromethane (0.5 ml) was added trifluoroacetic acid anhydride (0.35 ml, 2.5 mmol) while cooling in a water bath and stirring was continued at ambient temperature for 20 minutes. The reaction was concentrated in vacuo and the residue dissolved in ethyl acetate and washed with 1N sodium hydrogen sulfate, brine, dried over magnesium sulfate, filtered, and concentrated in vacuo to gave 0. 43 g as an off-white solid. 1HNMR (300 MHz, CDC13) 8 1.52 (s, 18H), 4.99 (s, 2H), 7.19-7. 26 (m, 1H), 7.82-7. 90 (m, 1H). 19FNMR (282 MHz, CDC13) 8-141.8 to-141.6 (m, 1F),-133. 2 to-132.9 (m, 1F),-65. 6 (s, 3F). Ex-51c) LCMS (M+H) m/z 280. 1HNMR (300 MHz, DMSO-d6) 8 4.25 (s, 2H), 7.68-7. 75 (m, 1H), 7.97-8. 05 (m, 1H), 8.73 (br s, 3H). 19FNMR (282 MHz, DMSO-d6) 5-139. 5 to-139.4 (m, 1F),-134. 7 to-134.6 (m, 1F),-65. 0 (s, 3F).

Ex-51d) 1HNMR (300 MHz, DMSO-d6) 8 1.23 (d, J = 6.3 Hz, 6H), 4.05-4. 20 (m, 1H), 4.41 (s, 2H), 4.46 (d, J = 5. 7 Hz, 2H), 5.81 (s, 2H), 6.72 (s, 1H), 6.80 (s, 1H), 6.89- 6.95 (m, 2H), 7.33 (t, J = 6.7 Hz, 1H), 7. 82-7. 90 (m, 1H), 8.78 (t, J = 5.8 Hz, 1H). 19FNMR (282 MHz, DMSO-d6) 5-142. 7 to-142.5 (m, 1F),-135. 4 to-135.2 (m, 1F),- 65.0 (s, 3F), -62. 0 (s, 3F). HRMS (ES) calcd for C26H22N703F8 (M+H): 632.1651. Found: 632.1674. Anal.

Calcd for C26H2lN703F8 + 0. 15 CH40H : C, 49.36 ; H, 3.42 ; N, 15.40. Found: C, 49.47 ; H, 3.33 ; N, 15.27.

Ex-51) A suspension of 51d (67 mg, 0.10 mmol) and 10% palladium on carbon (100 mg) in ethanol (30 ml) was shaken under hydrogen at 40 psi for 1.25 hr. The reaction was filtered and concentrated under a nitrogen stream. Purification by reverse phase HPLC (10-60% acetonitrile/water) followed by concentration in vacuo.

The residue was dissolved in methanol and concentrated in vacuo to give 46 mg (51% yield) of an off-white solid.

1HNMR (300 MHz, DMSO-d6) 5 1.25 (d, J = 6.6 Hz, 6H), 4.07- 4.20 (m, 1H), 4.40 (s, 2H), 4.44 (d, J = 5.4 Hz, 2H), 6.73-6. 85 (m, 3H), 6.94 (s, 1H), 7.22-7. 42 (m, 2H), 7.44- 7.52 (m, 1H), 8.85 (t, J = 5.7 Hz, 1H), 9.41-9. 61 (m, 3H). 19FNMR (282 MHz, DMSO-d6) 8-142. 9 to-142.7 (m, 1F), - 13 9. 3 to-139. 1 (m, 1 F),-6 2. 0 (s, 3F). HRMS (ES) calcd for C24H25N702F5 (M+H): 538.1984. Found: 538.1950. Anal.

Calcd for C24H24N702F5 + 2.5 TFA + 0.5 CH30H : C, 41.31 ; H, 3.34 ; N, 11.43. Found : C, 41.35 ; H, 3.30 ; N, 11.36.

Example 52 Tributyl (3-fluoro-5-nitrophenyl) stannane Ex-52a) 1-Fluoro-3-iodo-5-nitrobenzene (1.02 g, 3.8 mmol) was dissolved in 5 mL of toluene. The system was evacuated, then flushed with N2. Repeated 4x. Pd (PPh3) 4 (47 mg, 0. 041 mmol) and bis (tributyltin) (5.7 mL, 11.3 mmol) were added. The system was evacuated, then flushed with N2. The reaction was stirred at 90 °C under N2 until TLC showed disappearance of starting material (overnight).

The reaction solution was cooled to room temperature and diluted with 25 mL of EtOAc. The solution was washed with brine lx, aqueous saturated KF Ix, and brine lx.

The organic phase was dried over MgSO4 and concentrated under reduced pressure.

The residue was purified on silica, eluting with a 5/95%-10/90% EtOAc/hexanes gradient, to give 1.46 g (91%) of a yellow oil: IH NMR (400 MHz, CDC13) 80. 82-0.91 (m, 9H), 1. 09-1.15 (m, 6H), 1.23-1. 38 (m, 6H), 1.42-1. 55 (m,.

6H), 7. 46 (m, 1H), 7. 79 (m, 1H), 8. 06 (m, 1H) ; 19F NMR (375 Hz, CDC13) 6-111 (m). tert-Butyl [6- (3-fluoro-5-nitrophenyl)-3- (isopropylamino)-2-oxopyrazin-1 (2H)-yl] acetate Ex-52b) A flask containing 5 mL of DMF was evacuated and flushed with N2. Repeated 4x. tert-Butyl [6-bromo-3- (isopropylamino)-2-oxopyrazin-1 (2H)-yl] acetate (1.12 g, 3.23 mmol), PPh3 (54 mg, 0.21 mmol), and 2,6-di-t-butyl-4- methylphenol (13 mg, 0. 06 mmol) were added in one portion. The system was evacuated and flushed with N2.

Repeated 3x. Cu (I) Br (61 mg, 0.43 mmol), Pd (PPh3) 4 (134 mg, 0.12 mmol), the product from Ex-52a (0.48 g, 1.1 mmol), and 2.5 mL of DMF were added. The system was evacuated and flushed with N2. Repeated 3x. The reaction was stirred at 110 °C under positive N2 pressure until TLC showed disappearance of starting material (1 h 15 mins).

The dark red solution was cooled and diluted with 40 mL of EtOAc, then washed with aqueous KF 1 x 100 mL, aqueous saturated NaHC03 1 x 75 mL, and brine 1 x 75 mL.

The organic phase was dried over MgS04 and concentrated.

The dark orange oil was purified on silica, eluting with 20/80% EtOAc/hexanes, to give 0.2 g (44%) of an orange solid:. LRMS m/z 407.1 (M+ + H); HPLC purity (retention time): 90% (3.5 min).

[6- (3-Fluoro-5-nitrophenyl)-3- (isopropylamino)-2- oxopyrazin-l (2H)-yl] acetic acid Ex-52c) The product from Ex-52b (0.2 g, 0.5 mmol) was dissolved in 2 mL of CH2C12. Triflic acid (88 J. L, 1 mmol) and TFA (60 pL, O. 78 mmol) were added. The reaction was stirred for 20 mins.

The solid that precipitated out was filtered and dried under house vacuum to give 168 mg (96%) of an off- white solid: LRMS m/z 351.1 (M+ + H) ; HPLC purity (retention time): >99% (2.3 min).

4-((Z)-Amino{[(benzyloxy)carbonyl]imino}methyl) benzyl [6- <BR> <BR> (3-fluoro-5-nitrophenyl)-3-(isopropylamino)-2-oxopyrazin- 1 (2H)-yl] acetate Ex-52d) 147 mg (0.42 mmol) of the product from Ex-52c; 8 mg (0.06 mmol) HOBt, 129 mg (0.36 mmol) benzyl [4- (aminomethyl) phenyl] (imino) methylcarbamate dihydrochloride; 0.30 mL (2.7 mmol) NMM, 0.71 g (0.75 mmol) PS-carbodiimide, 6 mL CH2C12, and 2 mL DMF.

Agitated for 2.5 h, then added 0. 15 g (0. 42 mmol) PS- diethylenetriamine and 0. 17g (0. 48 mmol) Wang aldehyde scavenging resins for 1 h 10 mins to give 0. 37 g of crude, desired product: LRMS m/z 616.2 (M+ + H) ; HPLC purity (retention time): >90% (2.9 min).

Ex-52) 0.37 g of crude product from Ex-52d; 94 mg (0.04 mmol) of 10% Pd/C (50% water-wet) and 5 mL of MeOH.

Stirred overnight.

The mixture was filtered through a 0. 2 OM frit and concentrated. The crude residue was purified by reverse- phase HPLC with a gradient of 5/95%-60/40% acetonitrile/water (+ O. 1% TFA) over 10 mins. The product-containing fractions were concentrated and dried under high vacuum for 6 h to give 92 mg of a pale yellow solid: LRMS m/z 452.1 (M+ + H) ; HPLC purity (retention time): >95% (1.8 min) ; HRMS (M + H): Calc'd for C23H26FN702 : 452.2210 ; Found: 452.2225 ; 1H NMR (400 MHz, CD30D) D. 1.39 (m, 6H), 4.02 (m, 1H), 4.48 (d, 2H, J = 4.3 Hz), 4.60 (s, 2H), 6.37-6. 39 (m, 1H), 6.51-6. 56 (m, 2H), 6.61-6. 62 (m, 1H), 7.46 (d, 2H, J = 8.2 Hz), 7.77 (d, 2H, J = 8.4 Hz).

Example 53 N- {4- [Amino (imino) methyl] benzyl}-2- [6- (3-amino-5- methoxyphenyl)-3- (isopropylamino)-2-oxopyrazin-1 (2H) - yl] acetamide [3- (Isopropylamino)-6- (3-methoxy-5-nitrophenyl)-2- oxopyrazin-1 (2H)-yl] acetic acid Ex-53a) The product from Ex-52b (180 mg, 0.44 mmol), NaOCH3 (250 mg, 4.6 mmol) and 3 mL of MeOH were stirred at 75 °C overnight.

The MeOH was removed under reduced pressure. The dark brown residue was dissolved in 20 mL of EtOAc. The product was extracted with aqueous saturated NaHC03 4 x 10 mL. The combined aqueous extracts were acidified to pH-2 with 2 M HC1, then extracted with EtOAc 4 x 50 mL. The combined organic extracts were washed with brine Ix, dried over MgSO4, filtered, and concentrated to give 140 mg (88%) of a brown solid: LRMS m/z 363.1 (M+ + H) ; HPLC purity (retention time) : >80% (2.3 min).

Benzyl (1Z)-amino{4-[({[3-(isopropylamino)-6-(3-methoxy- 5-nitrophenyl)-2-oxopyrazin-1 (2H) - yl] acetyl} amino) methyl] phenyl} methylidenecarbamate Ex-53b) 55 mg (0.15 mmol) of the product from Ex-53a; 3.4 mg (0.02 mmol) HOBt ; 48 mg (0.13 mmol) benzyl [4- (aminomethyl) phenyl] (imino) methylcarbamate dihydrochloride; 0.10 mL (0.91 mmol) NMM; 0.23 g (0.24 mmol) PS-carbodiimide, 3 mL CH2C12, and 0.7 mL DMF.

Agitated for 1.5 h, then added 60 mg (0. 17 mmol) PS- diethylenetriamine and 50 mg (0.14 mmol) Wang aldehyde scavenging resins for 1.5 h to give 0. 11 g of crude, desired product: LRMS m/z 628.2 (M+ + H) ; HPLC purity (retention time): >85% (2.75 min).

Ex-53) 0.11 g of crude product from Ex-53b; 40 mg (0.02 mmol) of 10% Pd/C (50% water-wet) ; 1.5 mL of MeOH, and enough THF to dissolve the pyrazinone (2.5 mL). Stirred for 3.5 h The mixture was filtered through a 0. 2 3M frit and concentrated. The crude residue was purified by reverse- phase HPLC with a gradient of 10/90%-50/50% acetonitrile/water (+ O. 1% TFA) to give 54 mg of a yellow, glassy solid: LRMS m/z 464.2 (M+ + H) ; HPLC purity (retention time): 97% (1.6 min) ; HRMS (M + H): Calc'd for C24H29N7O3 : 464.2405 ; Found : 464.2379; H NMR (400 MHz, CD30D) # 1.38 (d, 6H, 6.6 Hz), 3.74 (s, 3H), 4.04 (m, 1H), 4. 48 (d, 2H, J = 5.5 Hz), 4.59 (s, 2H), 6.55-6. 56 (m, 2H), 6.63-6. 65 (m, 2H), 7.47 (d, 2H, J = 8.2 Hz), 7.76 (d, 2H, J = 8.3 Hz), 8.82 (br t, 1H).

Examples 54/55 4- [Amino (imino) methyl] benzyl [6- (3-amino-5- hydroxyphenyl)-3- (isopropylamino)-2-oxopyrazin-1 (2H) - yl] acetate 4-((Z)-amino{[(benzyloxy)carbonyl]imino}methyl) benzyl [6- <BR> (3-hydroxy-5-nitrophenyl)-3-(isopropylamino)-2-<BR> <BR> oxopyrazin-1 (2H)-yl] acetate Ex-54a) LRMS m/z 614.2 (M+ + H); HPLt pit} tiëtio time): >90% (1.9 min).

Ex-54) 0.31 g of crude product from Ex-54a: 160 mg (0. 08 mmol) of 10% Pd/C (50% water-wet) and 5 mL of MeOH.

Stirred for 3.5 h.

The mixture was filtered through a 0. 2 µM frit and concentrated. The crude oil was purified by reverse- phase HPLC with a gradient of 5/95%-30/70% acetonitrile/water (+ 0. 1% TFA) to give 58 mg of a pale yellow solid: LRMS m/z 450.2 (M+ + H) ; HPLC purity (retention time): >99% (1.0 min) ; HRMS (M + H): Calc'd for C23H27N703 : 450.2248 ; Found: 450.2270 ; 1H NMR (400 MHz, CD3OD) # 1. 37 (d, 6H, 6.4Hz), 4.04 (m, 1H), 4.49 (d, 2H, J = 4.2 Hz), 4. 60 (s, 2H), 6. 46-6. 64 (m, 4H), 7. 47 (d, 2H, J = 8.2 Hz), 7.76 (d, 2H, J = 8.3 Hz), 8.79 (br t, 1H).

Two salts were prepared for this compound and data for each is reported in Table 3.

Amide Library 3-amino-5- [I- [2- ( {4- [ [ (tert- butoxycarbonyl) amino] (imino) methyl] benzyl} amino)-2- oxoethyl]-5- (isopropylamino)-6-oxo-1, 6-dihydropyrazin-2- yl] benzoic acid LRMS m/z 578.2 (M+ + H).

Amine 1 (+/-)-alpha-Methylbenzylamine Amine 2 (S)- (-)-alpha-Methylbenzylamine Amine 3 (R)- (+)-alpha-Methylbenzylamine Amine 4 3.5-Bis (trifluormethyl) benzylamine Amine 5 Isopropylamine Amine 6 3- (Aminomethyl) pyridine Amine 7 3-Phenyl-1-propylamine Amine 8 Ethylamine Intermediate A (154 mg, 0.3 mmol), amines 1 through 8 (0.3 mmol), HOBt (34 mg, 0.3 mmol), NMM (0.5 mL, 4.

5mmol), PS-carbodiimide resin (480 mg, 0.5 mmol), PS- diethylene triamine (88 mg, 0. 3 mol), Aldehyde wang (88 mg, 0.3 mmol).

(0.3 mmol), TFA (1.5 mL), CH2C12 (5 mL). Reverse phase HPLC conditions 5-45% acetonitrile/water with 0. 1% TFA over 10 min. to afford an average yield of 54 mg (27%).

Example 56 NHR = (+/-)-alpha-Methylbenzylamine LRMS m/z 581. 3 (M+ + H).

Example 57 NHR = (S)- (-)-alpha-Methylbenzylamine LRMS m/z 581.3 (M+ + H).

Example 58 NHR = (R)- (+)-alpha-Methylbenzylamine LRMS m/z 581. 3 (M+ + H).

Example 59 NHR = 3,5- Bis (trifluormethyl) benzylamine LRMS m/z 703. 2 (M+ + H).

Example 60 NHR = Isopropylamine LRMS m/z 619.2 (M+ + H).

Example 61 NHR = 3- (Aminomethyl) pyridine LRMS m/z 568.2 (M+ + H).

Example 62 NHR = 3-Phenyl-1-propylamine LRMS m/z 595.2 (M+ + H).

Example 63 NHR = Ethylamine LRMS m/z 505. 2 (M+ + H).

Example 64 N- {4- [amino (imino) methyl] benzyl}-2- [6- (3-amino-5- isobutoxyphenyl)-3- (isopropylamino)-2-oxopyrazin-1 (2H) - yl] acetamide [6- (3-Hydroxy-5-nitrophenyl)-3- (isopropylamino)-2- oxopyrazin-l (2H)-yl] acetic acid Ex-64a) BBr3 (5 g, 20 mmol) in 18 mL of CHsCIs was cooled in an ice bath. The product from Ex-53a (1.7 g, 4.7 mmol) in 15 mL of CH2C12, followed by a 20 mL CH2Cl2 rinse, was added. The reaction was stirred at room temperature for 6 h. Additional BBr3 (2 mL of a 1 M solution in CH2C12, 2 mmol) was added and the reaction was stirred overnight.

The reaction was quenched with MeOH and concentrated. The residue was taken up in EtOAc and aqueous saturated NaHC03. The layers were separated. The organic phase was extracted with aqueous saturated NaHC03 2 x 100 mL, then 1.2 M aqueous NaOH 4 x 50 mL. The combined aqueous extracts were acidified to pH-2 with 2 N HC1, then extracted with EtOAc 4 x 150 mL. The combined organics were washed with brine, dried over MgS04, and concentrated to give 0. 85 g of a brown solid (53%) : LRMS m/z 349.0 (M+ + H) ; HPLC purity (retention time): 75% (2.1 min). Additional product was recovered from the aqueous phase: The aqueous phase was concentrated to-100 mL. The solid that precipitated was removed by filtration. The filtrate was extracted with THF 5 x 100 mL. The combined organics were washed with brine, dried over MgS04, and concentrated to give 0. 63 g (39%, 92% total yield) of a brown solid: LRMS m/z 349.1 (M+ + H) ; HPLC purity (retention time): 100% (1.6 min).

Isobutyl [6- (3-isobutoxy-5-nitrophenyl)-3- (isopropylamino)-2-oxopyrazin-1 (2H)-yl] acetate Ex-64b) The product from Ex-64a (0.29 g, 0.84 mmol) was dissolved in 7.5 mL of DMSO. K2CO3 (0. 71 g, 5.1 mmol) was added and the reaction was. stirred at 90 °C for 2 h. The reaction was cooled to room temperature and l-bromo-2- methylpropane (0. 23 mL, 2.1 mmol) was added. The reaction was stirred at 90 °C for 1.5 h, then cooled to room temperature. The crude reaction mixture was used directly in the next step. (LRMS m/z 461.2 (M+ + H) ; HPLC purity (retention time): 55% (3.5 min) ) [6- (3-Isobutoxy-5-nitrophenyl)-3- (isopropylamino)-2- oxopyrazin-1 (2H)-yl] acetic acid Ex-64c) The crude reaction solution from Ex-64b (-0. 35 g, - 0. 8 mmol) mmol) was added to LiOH. H20 (194 mg, 4.6 mmol) in 4 mL of H20. The reaction was stirred at room temperature for 45 mins. LC/MS analysis showed unreacted starting material. Another 70 mg (1.7 mmol) of LiOH. HaO in 0. 5 mL of H20 was added.

The crude reaction was washed with EtOAc 3 x 60 mL.

The aqueous phase was acidified with 2 N HC1 and extracted with EtOAc 3 x 40 mL. The combined organics were washed with brine, dried over MgS04 and concentrated to give 20 mg of product.

LC/MS analysis of the EtOAc washes of the crude reaction showed starting material and desired product (-1 : 1). Therefore, the EtOAc washes of the crude reaction were resubmitted to the reaction conditions: The residue was dissolved in 5 mL of THF. Aqueous LiOH. H20 (240 mg, 5.7 mmol, in 5 mL of H20) was added and the reaction was stirred at room temperature. The reaction was stirred for 1 h. LC/MS analysis showed presence of starting material. Another 200 mg (4.8 mmol) of LiOH. H2O in 2.5 mL of H2O was added. The reaction was stirred for 1.5 h. LC/MS showed only a minor amount of starting material remaining.

The THF was removed under reduced pressure. The aqueous residue was extracted with EtOAc 3x. The combined organics were washed with brine, dried over MgSO4, and concentrated to give 0.16 g (47%) of a brown film: LRMS m/z 405.1 (M+ + H); HPLC purity (retention time): >90% (2.5 min).

Benzyl (1Z)-amino{4-[({[6-(3-isobutoxy-5-nitrophenyl)-3- (isopropylamino)-2-oxopyrazin-1 (2H) - yl] acetyl} amin. o) methyl] phenyl} methylidenecarbamate Ex-64d) 0.14 g (0.35 mmol) of the product from Ex-64c ; 6.6 mg (0. 05 mmol) HOBt ; 107 mg (0. 3 mmol) benzyl [4- (aminomethyl) phenyl] (imino) methylcarbamate dihydrochloride; 0.23 mL (2. 0 mmol) NMM; 0.52 g (0.55 mmol) PS-carbodiimide, 5 mL CH2C12, and 1.5 mL DMF.

Agitated for 1.5 h, then added 0. 61 g (1.7 mmol) PS- diethylenetriamine and 0. 60 g (1.7 mmol) Wang aldehyde scavenging resins for 1 h 10 m to give 0. 15 g of crude, desired product: LRMS m/z 670.2 (M+ + H); HPLC purity (retention time): >80% (2.5 min).

Ex-64) 0.15 g of crude product from Ex-64d; 85 mg (0. 04 mmol) of 10% Pd/C (50% water-wet); and 6 mL of MeOH.

Stirred for 24 h.

The mixture was filtered and concentrated. The crude residue was purified by reverse-phase HPLC with a gradient of 10/90%-50/50% acetonitrile/water (+ 0. 1% TFA) to give 53 mg of a pale yellow solid: LRMS m/z 506.2 (M+ + H); HPLC purity (retention time): >95% (1.8 min); HRMS (M + H): Calc'd for C27H35N703 : 506.2874 ; Found: 506. 2918 ; 1H NMR (400 MHz, CD30D) 5 1. 01 (d, 6H, 6.7 Hz), 1.39 (d, 6H, 6.4Hz), 2.05 (m, 1H), 3.76 (d, 2H, 6.4 Hz), 4.07 (m, 1H), 4.48 (s, 2H), 4.58 (s, 2H), 6.67 (s, 1H), 6.87-6. 93 (m, 3H), 7.47 (d, 2H, J = 8.2 Hz), 7.77 (d, 2H, J = 8.3 Hz).

Example 65 1HNMR : 400 MHz, MeOD : (8) 1.389, 1.373 (d, 6H); 4.018 (septet, J= 6.4 Hz, 1H) ; 4.436 (s, 2H); 4.471 (s, 2H); 6.623 (s, 1H) ; 6.85 to 6.84 (m, 1H) ; 6.866 (s, 1H) ; 7.05 to 7.03 (m, 1H).

9FNMR : 400 MHz, MeOD : (5)-65. 030;-77. 953;-142. 772, - 142.808 (d);-146. 090, -146.128,-146. 149, -146.185 (d of d);-152. 810, -152.869 (d).

Elemental analysis: Found C: 37.07 H: 3.29 N: 9.55 Calc. C: 36.90 H: 3.41 N: 10.04 Example 66 3-Amino-5- (1- [2- ( {4- [amino (imino) methyl] benzyl} amino)-2- oxoethyl]-5- (isopropylamino)-6-oxo-1, 6-dihydropyrazin-2- yl] benzenesulfonic acid tert-Butyl [6-{3-[(tert-butoxycarbonyl)amino]-5- mercaptophenyl}-3- (isopropylamino)-2-oxopyrazin-1 (2H) - yl] acetate Ex-66a) LRMS m/z 491.5 (M+ + H); HPLC purity (retention time): >99% (2.7 min).

3-[(tert-Butoxycarbonyl)amno]-5-[1-(2-tert-butoxy-2- <BR> <BR> oxoethyl)-5- (isopropylamino)-6-oxo-1, 6-dihydropyrazin-2- yl]benzenesulfonic acid Ex-66b) The product from Ex-66a (3. 7"5'i 1', taken up in 30 mL of EtOH (not soluble). The mixture was cooled in an ice bath to 10 °C. NaOH (1.46 g, 36 mmol) in 15 mL of H20 was added. The reaction exothermed to 20 °C and became mostly homogeneous.

The reaction was cooled to 5 °C. H2O2 (4.2 mL of a.

30% aqueous solution, 37 mmol) was added dropwise. The reaction exothermed to 9 °C and a thick sludge formed.

The reaction was warmed to room temperature, stirring resumed, and the remaining H2O2 was added. The reaction exothermed to 32 °C. LC/MS analysis after 1 h 10 mins showed disappearance of starting material.

The reaction mixture was filtered through Celite.

The filtrate was partially concentrated under reduced pressure. CH2C12 (100 mL) was added to the remaining basic, aqueous solution. It was swirled with a solution of 52 mL of brine, 3.1 mL of 12 M HCl (37.2 mmol), and 6 mL of H20 (enough to dissolve the NaCl). The biphasic solution was transferred to a separatory funnel, diluted with 50 mL of CH2C12, shaken, and the layers were allowed to separate. The organic phase was concentrated. The resulting solid was triturated with hexanes, filtered, the filter cake was washed well with Et20, and the solid was dried under high vacuum for 40 mins to give 4.2 g (100% yield) of an orangish-yellow solid: LRMS m/z 539.5 (M+ + H) ; HPLC purity (retention time): 85% (2.1 min).

[6- (3-Amino-5-sulfophenyl)-3- (isopropylamino)-2- oxopyrazin-1 (2H)-yl] acetic acid Ex-66c) The product from Ex-66b (127 mg, 0.3 mmol) was taken up in 3 mL of CH2C12. TFA (1 mL, 13 mmol) was added, followed by triflic acid (55 L, 0. 6 mmol). The reaction was stirred at room temperature for 15 mins.

The volatiles were removed under reduced pressure.

The residue was purified by reverse-phase HPLC with a gradient of 0/100%-10/90% acetonitrile/water (+ 0.1% TFA) to give 74 mg of desired product: LRMS m/z 383. 0 (M+ + H) ; HPLC purity (retention time): 95% (0.17 min).

3-Amino-5-[1-(2-{[4-((Z)- amino o{[ (benzyloxy) carbonyl] imino} methyl) benzyl] amino}-2- oxoethyl)-5- (isopropylamino)-6-oxo-1, 6-dihydropyrazin-2- yl] benzenesulfonic acid Ex-66d) 74 mg (0.15 mmol) of the product from Ex-66c; 2.9 mg (0. 02 mmol) HOBt ; 50.7 mg (0. 14 mmol) benzyl [4- (aminomethyl) phenyl] (imino) methylcarbamate dihydrochloride; 0.10 mL (0.91 mmol) NMM; 0.245 g (0.26 mmol) PS-carbodiimide, 3 mL CH2Cl2, and 1.5 mL DMF.

Agitated for 45 mins, then added 0. z7 g (0.77 mmol) Wang aldehyde scavenging resin for-2 h to give 0.14 g of crude, desired product: LRMS m/z 648.2 (M+ + H); HPLC purity (retention time): 40% (1.6 min). (Impurity is the benzyl [4- (aminomethyl) phenyl] (imino) methylcarbamate.) Ex-66) The crude product from Ex-66d was taken up in CH2C12. Trific acid (40 OL, 0. 45 mmol) was added and the reaction was stirred at room temperature overnight.

LC/MS showed starting material still present. Another 150 OL (1.7 mmol) of triflic acid was added and the reaction was stirred for 3 h.

The reaction was diluted with MeOH and concentrated.

The crude residue was purified by reverse-phase HPLC with a gradient of 5/95%-35/65% acetonitrile/water (+ 0.1% TFA) to give 1.7 mg of an off-white solid: LRMS m/z 514.1 (M+ + H); HPLC purity (retention time) : >95% (1.1 min).

Example 67 HPLC/LRMS: >97%, 508 (M+H) + ; HRMS (ES+) calcd. for C22H25N702SF3 508.1737, found 508.1739.

Example 68 HPLC/LRMS: >95%, 455 (M+H) +; HRMS (ES+) calcd. for C2lH27N802S 455.1972, found 455.1982.

Example 69 2-[6-(5-amino-1,1'-biphenyl-3-yl)-3-(isopropylamino)-2- oxopyrazin-1 (2H)-yl]-N- {4- [amino (imino) methyl] acetamid tert-butyl [6-{3-bromo-5-[(tert- butoxycarbonyl) amino] phenyl}-3-(isopropylamino)-2-<BR> oxopyrazin-1 (2H)-yl] acetate Ex-69a) t-Butyl [6-bromo-3- (isopropylamino)-2- oxopyrazin-l (2H)-yl] acetate (3.6 g, 10.5 mmol), (5.0 g, 12.5 mmol), sodium carbonate (4.4 g, 41.8 mmol), tetrakis (triphenylphospine) palladium (0) (1.2 g, 1.0 mmol), THF (600 mL), DI H20 (20 mL).

Yellow solid afforded 2.6 g (46%).

1H NMR (300 MHz, CD3C1) 6 1. 29 (d, 6H, J = 6.6 Hz), 1. 47 (s, 9H), 1.52 (s, 9H), 4.10-4. 20 (m, 1H), 4.39 (s, 2H), 6.13 (b, NH), 6.79 (s, 1H), 7.12 (s, 1H), 7.20 (s, 1H), 7.79 (s, 1H).

LRMS m/z 538. 2 (M+ + H). tert-butyl [6- {5- [ (tert-butoxycarbon. yl) amino]-l, l'- biphenyl-3-yl}-3-(isopropylamino)-2-oxopyrazin-1 (2H) - yl] acetate Ex-69b) Ex-69a (500 mg, 0.9 mmol), phenyl boronic acid (227 mg, 1.9 mmol), sodium carbonate (308 mg, 2.9 mmol),' tetrakis (triphenylphospine) palladium (0) (104 mg, 0.1 mmol), THF (15 mL), DI H20 (2 mL).

Yellow solid afforded 400 mg (80%).

1H NMR (300 MHz, CD3C1) 5 1.30 (d, 6H, J = 6.3 Hz), 1. 39 (s, 9H), 1.55 (s, 9H), 4.08-4. 24 (m, 1H), 4.46 (s, 2H), 6.89 (s, 1H), 7.27-7. 77 (m, 8H).

LRMS m/z 535. 2 (M+ + H).

[6-(5-amino-1,1'-biphenyl-3-yl)-3-(isopropylamino)-2- oxopyrazin-1 (2H)-yl] acetic acid Ex-69c) Ex-69b (300 mg, 0.6 mmol), trifluoromethane sulfonic acid (0.23 mL, 0.3 mmol), CH2C12 (60 mL).

Brown solid afforded 212 mg (98%). benzyl {4-[({[6-(5-amino-1, 1'-biphenyl-3-yl)-3- (isopropylamino)-2-oxopyrazin-1 (2H) - yl] amino) methyl] phenyl} (imino) methylcarbamate Ex-69d) Ex-69c (212 mg, 0.6 mmol), benzyl [4- (aminomethyl) phenyl] (imino) methylcarbamate dihydrochloride (249 mg, 0. 7 mmol), HOBt (25 mg, 0. 2 mmol), and NMM (0.4 mL, 3.4 mmol), PS-carbodiimide resin (1.0 g, 1.1 mmol), PS-diethylene triamine (0.4 g, 1.1 mmol), Aldehyde wang (0 g, 0 mmol), CH2C12 (5 mL) and DMF (3 mL).

Ex-69) Ex-69d (360 mg, 0.6 mmol), Pd/C (10%, 30 mg), MeOH (50 mL). White solid afforded 320 mg (78%).-H NMR (300 MHz, CD30D) 8 1.41 (d, 6H, J = 6.6 Hz), 4.03-4. 13 (m, 1H), 4.48 (s, 2H), 2.66 (s, 2H), 6.72 (s, lh), 6.89 (s, 1H), 7.15 (s, 1H), 7.27 (s, 1H), 7.38-7. 66 (m, 9H).

HRMS m/z 510. 3 (M+ + H).

Example 70 N- {4-Eamino (imino) methyl] benzyl}-2- [6- [3-amino-5- (isobutylthio) phenyl]-3-(isopropylamino)-2-oxopyrazin- 1 (2H)-yl] acetamide tert-Butyl [6-[3-[(tert-butoxycarbonyl)amino]-5- (isobutylthio) phenyl]-3-(isopropylamino)-2-oxopyrazin- 1 (2H)-yl] acetate Ex-70a) LRMS m/z 547.3 (M+ + H) ; HPLC purity (retention time): 70% (3.5 min).

[6- [3-amino-5- (isobutylthio) phenyl]-3- (isopropylamino)-2- oxopyrazin-1 (2H)-yl] acetic acid Ex-70b) The product from Ex-70a (0.23 g, 0.4 mmol) was dissolved in 4 mL of CH2C12. Triflic acid (74 pL, O. 8 mmol) was added, followed by enough TFA to make the reaction homogeneous (0.6 mL, 7.8 mmol). LC/MS analysis after 15 mins showed some starting material with only the BOG protecting group removed. Another 74 pL (0.8 mmol) of triflic acid was added. The reaction was stirred for 1 h. LC/MS showed completion of the reaction.

The volatiles were removed under reduced pressure.

The oil was dissolved in EtOAc. The organic phase was washed with aqueous saturated NaHC03 lx, then 2.5 M aqueous NaOH 3x. Product is present in both the organic and aqueous phases.

The organic phase was concentrated to give 96 mg of a yellow solid: LRMS m/z 391.1 (M+ + H); HPLC purity (retention time): 90% (1.9 min).

The aqueous phase was neutralized with 2 M HCl, then extracted with EtOAc 3x. The combined organics were dried over MgS04, filtered, and concentrated to give 0.28 g of an orange oil. The oil was purified by reverse- phase HPLC with a gradient of 15/85%-45/55% acetonitrile/water (+ 0. 1% TFA) to give 60 mg of a yellow residue: LRMS m/z 391.1 (M+ + H); HPLC purity (retention time): >99% (1.9 min).

Benzyl (lZ)-amino {4- [ ( { [6- [3-amino-5- (isobutylthio) phenyl]-3-(isopropylamino)-2-oxopyrazin- 1 (2H)- yl] acetyl} amino) methyl] phenyljmethylidenecarbamate Ex-70c) 70 mg (0. 18 mmol) of the product from Ex-70b; 4 mg (0. 03 mmol) HOBt ; 60 mg (0. 17 mmol) benzyl [4- (aminomethyl) phenyl] (imino) methylcarbamate dihydrochloride; 0.12 mL (1.1 mmol) NMM; 0.275 g (0.29 mmol) PS-carbodiimide, 3 mL CH2Cl2, and 1.5 mL DMF.

Agitated for 1 h 10 mins. Sequestering resins were not added. The mixture was filtered, rinsed, and concentrated to give 0. 17 g of crude, desired product: LRMS m/z 656 (M+ + H) ; HPLC purity (retention time): >90% (2.1 min).

Ex-70) 0.17 g of crude product from Ex-70c; 43 mg (0. 02 mmol) of 10% Pd/C (50% water-wet) ; and 1.5 mL of MeOH.

Stirred for 30 h. LC/MS showed starting material still present.

The mixture was filtered and concentrated. The crude was taken up in CH2C12. Triflic acid (80 pL, 0. 9 mmol) was added. The reaction was exothermic. The reaction was stirred for 1 h, then quenched with MeOH and concentrated. The crude residue was purified by reverse- phase HPLC with a gradient of 15/85%-45/55% acetonitrile/water (+ 0.1% TFA) to give 7 mg of a dark yellow solid: LRMS m/z 522.2 (M+ + H) ; HPLC purity (retention time): >90% (1.7 min) ; HRMS (M + H): Calc'd for C27H35N702S : 522.2646 ; Found: 522.2645 ; 1H NMR (400 MHz, CD30D) 61. 02 (d, 6H, 6.6 Hz), 1.39 (d, 6H, 6.4Hz), 1.85 (m, 1H), 2.81 (d, 2H, 6.8 Hz), 4.03 (m, 1H), 4.50 (s, 2H), 4.56 (s, 2H), 6.62 (s, 1H), 6.69 (m, 1H), 6.84 (m, 1H), 6.96 (m, 1H), 7.48 (d, 2H, J = 8.2 Hz), 7.77 (d, 2H, J = 8.2 Hz).

Example 71 The compound of Example 71 was prepared in an analogous manner to that of Example 186.

Example 72 The compound of Example 72 was prepared in an analogous manner to that of Example 186.

Example 73 N- {4- [amino (imino) methyl] benzyl}-2- [6- [3-amino-5- (isobutylsulfinyl) phenyl]-3- (isopropylamino)-2-<BR> oxopyrazin-1 (2H)-yl] acetamide tert-butyl [6- [3- [ (tert-butoxycarbonyl) amino]-5- (isobutylsulfinyl) phenyl]-3-(isopropylamino)-2- oxopyrazin-1 (2H) -yl] acetate Ex-73a) The product from Ex-70a (780 mg, 1.4 mmol,-35% Br analog) was dissolved in 16 mL of MeOH and cooled in an ice bath. Oxone (0.44 g, 1.4 mmol KHSO5) in 16 mL of H20 was added dropwise over 2 mins. The reaction became cloudy. The reaction was stirred for 2 mins. Half of the reaction solution was removed and extracted with CH2C12. (The other half was oxidized to the sulfone. See Ex-74a. ) The organic phase was washed with brine, dried over MgS04, filtered, and concentrated to give 224 mg of a white solid (with 10% sulfone impurity, 40% Br impurity, and 5% starting material) : LRMS m/z 563.3 (M+ + H) ; HPLC purity (retention time): 45% (2.7 min).

[6- [3-amino-5- (isobutylsulfinyl) phenyl]-3- (isopropylamino)-2-oxopyrazin-1 (2H)-yl] acetic acid Ex-73b) The crude product from Ex-73a (0.22 g crude, 0.4 mmol crude) was dissolved in 4 mL of CHsCIs and cooled in an ice bath. Triflic acid (180 pL, 2.0 mmol) was added, followed by enough TFA to make the reaction homogeneous (180 CL, 2.3 mmol). LC/MS analysis after 10 mins showed completion of the reaction.

The volatiles were removed under reduced pressure.

The crude residue was purified by reverse-phase HPLC with a gradient of 15/85%-35/65% acetonitrile/water (+ 0. 1% TFA) to give-42 mg of a yellow residue: LRMS m/z 407.1 (M+ + H); HPLC purity (retention time) : >90% (1.3 min).

Benzyl (1Z) -amino{4-[({[6-[3-amino-5- (isobutylsulfinyl) phenyl]-3- (isopropylamino)-2- oxopyrazin-1 (2H) - <BR> <BR> yl] acetyl} amino) methyl] phenyl} methylidenecarbamate Ex-73c) 81 mg (0.16 mmol) of the product from Ex-73b; 3 mg (0.02 mmol) HOBt ; 54 mg (0. 15 mmol) benzyl [4- (aminomethyl) phenyl] (imino) methylcarbamate dihydrochloride; 0.106 mL (0.96 mmol) NMM; 0.305 g (0.30 mmol) PS-carbodiimide, 3 mL CH2C12, and 1.5 mL DMF.

Agitated for 3 h. Sequestering resins were not added.

The mixture was filtered, rinsed, and concentrated to give 0. 20 g of crude, desired product: LRMS m/z 672.2 (M+ + H) ; HPLC purity (retention time): 75% (2. 0 min).

Ex-73) The crude product from Ex-73c was dissolved in 1.5 mL of CH2C12. Triflic acid (0. 14 mL, 1.6 mmol, in two portions) and anisole (17 pL, 0.16 mmol) were added. No product was detected by LC/MS analysis after 1 h 10 mins.

The volatiles were removed under reduced pressure.

25 mg (0. 012 mmol) of 10% Pd/C (50% water-wet) and 2 mL of MeOH. Stirred for 45 mins. LC/MS showed evidence of reduction of the sulfoxide to the sulfide.

The mixture was filtered and concentrated. The crude residue was purified by reverse-phase HPLC with a gradient of 20/80%-60/40% acetonitrile/water (+ 0. 1% TFA) to give 20 mg of a yellow glassy solid: LRMS m/z 538.2 (M+ + H) ; HPLC purity (retention time): >95% (1.3 min) ; HRMS (M + H): Calc'd for C27H35N703S : 538.2595 ; Found: 538.2615 ; 1H NMR (400 MHz, CD30D) 8 1. 06 (d, 3H, 6.8 Hz), 1.13 (d, 3H, 6.6 Hz), 1.40 (d, 6H, 6.4Hz), 2.14 (m, 1H), 2.62-2. 67 (m, 1H), 2.79-2. 85 (m, 1H), 4.02 (m, 1H), 4.40- 4.68 (m, 4H), 6.64 (s, 1H), 6.88 (m, 2H), 7.11 (m, 1H), 7.42 (d, 2H, J = 8.3 Hz), 7.76 (d, 2H, J = 8.3 Hz), 8.84 (br t, 1H).

Examples 74/75 <BR> <BR> N- 4- [amino (imino) methyl] benzyl}-2- [6- [3-amino-5- (isobutylsulfonyl) phenyl]-3-(isopropylamino)-2- oxopyrazin-1 (2H)-yl] acetamide tert-Butyl [6- [3- [ (tert-butoxycarbonyl) aminol-5- (isobutylsulfonyl) phenyl]-3-(isopropylamino)-2- oxopyrazin-1 (2H)-yl] acetate Ex-74a) The product from Ex-70a (780 mg, 1.4 mmol,-35% Br analog) was dissolved in 16 mL of MeOH and cooled in an ice bath. Oxone (0.44 g, 1.4 mmol KHSO5) in 16 mL of H20 was added dropwise over 2 mins. The reaction became cloudy. The reaction was stirred for 2 mins. Half of the reaction solution was removed. (Used to make the sulfoxide. See Ex-73a. ) The reaction was stirred for another 45 mins. LC/MS analysis showed starting material present. Another 42 mg (0.14 mmol KHSOS) of Oxone was added and the reaction was stirred for 45 mins.

The volatiles were removed under reduced pressure.

The aqueous residue was extracted with CH2C123 x 15 mL.

The combined organic extracts were washed with brine, dried over MgS04, filtered, and concentrated to give-465 mg of a white solid (with 15% sulfoxide, 40% bromo analog, and 10% starting material): LRMS m/z 579.2 (M+ + H); HPLC purity (retention time): 35% (3.0 min).

[6- [3-amino-5- (isobutylsulfonyl) phenyl]-3- (isopropylamino)-2-oxopyrazin-l (2H)-yl] acetic acid Ex-74b) The crude product from Ex-74a (0. 62 g crude, 1.1 mmol crude) was dissolved in 10 mL of CH2C12 and cooled in an ice bath Triflic acid (490 StLr 5 @ 5 mmol) was added, followed by enough TFA to make the reaction homogeneous (980 pL, 13 mmol). LC/MS analysis after 10 mins showed completion of the reaction.

The volatiles were removed under reduced pressure.

The crude residue was purified by reverse-phase HPLC with a gradient of 15/85%-35/65% acetonitrile/water (+ 0.1% TFA) to give 130 mg of a yellow solid: LRMS m/z 423.1 (M+ + H) ; HPLC purity (retention time): >95% (1.5 min).

Benzyl (lZ)-amino {4- [ ( { [6- [3-amino-5- (isobutylsulfonyl) phenyl]-3- (isopropylamino)-2- oxopyrazin-1 (2H) - yl] acetyi} amino) methyl] phenyl) methylidenecarbamate Ex-74c) 121 mg (0.22 mmol) of the product from Ex-74b; 2.8 mg (0.02 mmol) HOBt ; 78.8 mg (0.22 mmol) benzyl [4- (aminomethyl) phenyl] (imino) methylcarbamate dihydrochloride; 0. 15 mL (1.4 mmol) NMM; 0. 43 g (0. 45 mmol) PS-carbodiimide, 3 mL CH2C12, and 1.5 mL DMF.

Agitated for 3 h. Sequestering resins were not added.

The mixture was filtered, rinsed, and concentrated to give 0. 30 g of crude, desired product: LRMS m/z 688.3 (M+ + H) ; HPLC purity (retention time): 85% (2. 0 min).

Ex-74) The crude product from Ex-74c was dissolved in 2.2 mL of CH2C12. Triflic acid (0.19 pL, 2.2 mmol, in two portions) and anisole (24 gel, 0. 22 mmol) were added. No product was detected by LC/MS analysis after 1 h 10 mins.

The volatiles were removed under reduced pressure.

25 mg (0. 012 mmol) of 10% Pd/C (50% water-wet) and 2 mL of MeOH. Stirred for 45 mins.

The mixture was filtered and concentrated. The crude residue was purified by reverse-phase HPLC with a gradient of 20/80%-50/50% acetonitrile/water (+ 0.1% TFA) to give 50 mg of a pale yellow solid: LRMS m/z 554.2 (M+ + H) ; HPLC purity (retention time): >98% (1.4 min) ; HRMS (M + H): Calc'd for C27H35N7O4S : 554.2544 ; Found: 544.2576 ; 1H NMR (400 MHz, CD30D) 81. 04 (d, 6H, J = 6.7 Hz), 1.40 (d, 6H, J = 6.4Hz), 2.15 (m, 1H), 3.07 (m, 2H), 4.04 (m, 1H), 4.48 (s, 2H), 4.57 (s, 2H), 6.67 (s, 1H), 6.95 (m, 1H), 7.13 (m, 1H), 7.27 (m, 1H), 7.45 (d, 2H, J = 8. 4 Hz), 7.76 (d, 2H, J = 8.5 Hz), 8.78 (br t,-lH).

Two salts were prepared for this compound and the data for each is reported in Table 3.

Example 76 N- 4- [amino (imino) methyl] benzyl}-2- [6- [3-amino- 5- (3-phenylpropyl) phenyl-3- (isopropylamino) -2- oxopyrazin-1 (2H)-yl] acetamide tert-butyl [6-{3-[(tert-butoxycarbonyl)amino]-5-[(1E)-3- phenylprop-l-enyl] phenyl}-3-(isopropylamino)-2-<BR> oxopyrazin-1 (2H)-yl] acetate Ex-76a) 1H NMR (300 MHz, CD3Cl) 81. 29 (d, 6H, J = 6. 6' Hz), 1.43 (s, 9H), 1.52 (s, 9H), 3.53 (d, 1H, J = 5.7 Hz), 4.11=4. 21 (m, 1H), 4.41 (d, 2H, J = 9.0 Hz), 6.01 (d, 1H, J = 7.8 Hz), 7.18-7. 37 (m, 5H).

LRMS m/z 535.2 (M+ + H).

[6- 3-amino-5- [ (lE)-3-phenylprop-1-enyl] phenyl}-3- (isopropylamino)-2-oxopyrazin-1 (2H)-yl] acetic acid Ex-76b) 76a (350 mg, 0. 6 mmol), trifluoromethane sulfonic acid (0.24 mL, 2.7 mmol), CH2C12 (60 mL). Purified by reverse phase HPLC 25-70% acetonitrile/DI H20 0. 1% TFA over 10 min.

Product as tan solid (80 mg, 31%). benzyl {4-[({[6-{3-amino-5-[(1E)-3-phenylprop-1- enyl] phenyl}-3- (isopropylamino)-2-oxopyrazin-1 (2H) - yl] acetyl} amino) methyl] phenyl} (imino) methylcarbamate EX-76c) 76b (80 mg, 0.2 mmol), benzyl [4- (aminomethyl) phenyl] (imino) methylcarbamate dihydrochloride (85 mg, 0.2 mmol), HOBt (9 mg, 0.1 mmol), NMM (0.1 mL, 1.1 mmol), PS-carbodiimide resin (320 mg, 0.3 mmol), PS-diethylene triamine (135 mg, 0.4 mmol), Aldehyde wang (0 g, 0 mmol). Afforded brown semi-solid.

Ex-76) 76c (300 mg, 0.4 mmol), Pd/C (10%, 25 mg), methanol (50 mL). Reaction purified by reverse phase HPLC 15-50% acetonitrile/DI H20 0.1% TFA to afford tan solid (64 mg, 29%). 1H NMR (300 MHz, CD30D) 1. 42 (d, 6H, J = 6.3 Hz), 1.90-2. 03 (m, 2H), 2.64-2. 74 (m, 4H), 4.05- 4.14 (m, 1H), 4.40 (s, 2H), 4.56 (s, 2H), 6.70 (s, 1H), 7.17-7. 30 (m, 8H), 7.44-7. 77 (abq, 4H, J= 8.7 Hz).

HRMS m/z 552.3 (M+ + H).

Example 77 Ex-77a) C25H25N707 (M. W. 535. 51).

M+H=536 '=R : 400 MHz, DMSO: (D) 1.186, 1.170 (d, 6H) ; 4.098 (septet, J= 6.4 Hz, 1H) ; 4. 324 (s, 2H) ; 4.449 (s, 2H) ; 6. 320 (s, 1H) ; 6. 790 (s, 1H) ; 7.018, 6.997 (d, 1H) ; 7.117 (s, 1H) ; 7.672, 7.652 (D, 1H) ; 8.302 (t, J=1.6 Hz, 1H) ; 8.507 (t, J= 1. 6 Hz, 1H) ; 8.584 to 8.507 (m, 1H).

Ex-77) 77a (535 mg; 0.001 mole) and Pd-black (50 mg) were dissolved/suspended in MeOH (10 ml). Ammonium formate (504 mg; 0. 008 mole) was added and the mixture was stirred for 4 hr and the mixture filtered and concentrated. The residue was chromatographed using reverse phase, eluting with H20/MeCN. 180 mg of product.

C25H29N705 (M. W. 507.54) : *3.5 TFA * 2.0 H20 : F. W. 942.66.

M+H=508 1HNMR : 400 MHz, MeOD : (8) 1.410, 1.389 (d, 6H) ; 3.869 (s, 3H); 4.060 (septet, J= 6.4 Hz, 1H) ; 4.344 (s, 2H); 4.575 (s, 2H) ; 6.647 (s, 1H) ; 6.857, 6.851 & 6. 829, 6.824 (d of d, 1H) ; 6.912, 6.908 (d, 1H) ; 7.095 (t, J= 2.4 Hz, 1H); 7.470 (t, J= 2.4 Hz, 1H) ; 7.64 to7.571 (m, 2H).

Elemental analysis: Found C: 40.46 H: 3.76 N: 10.45 Calc. C: 40.77 H: 3.90 N: 10.40 Example 78 Ex-78a) C2oH25N508 (M. W. 447. 44).

M+H=448 1HNMR : 400 MHz, DMSO: (5) 1.174, 1. 158 (d of d, 6H) ; 1.461 (s, 9H) ; 4.079 (septet, J= 6.4 Hz, 1H) ; 4.364 (s, 2H) ; 60725 (s, 1H) ; 7.050, 7.030 (d, 1H) ; 7.721 (s, 1H) ; 7.762 (t, J= 2.4 Hz, 1H) ; 8.456 (s, 1H).

Ex-78b) C28H32N8O5 (M. W. 592. 6).

M+H=593 Ex-78) 78b (592 mg; 0.001 mole) and Pd-black (50 mg) were dissolved/suspended in MeOH (10 ml). Ammonium formate (504 mg; 0. 008 mole) was added and the mixture was stirred for 4 hr and the mixture filtered and concentrated. The residue was chromatographed using reverse phase, eluting with H20/MeCN. 400 mg of product.

C28H36N805 (M. W. 564. 63): *3. 5 TFA * 3.0 H20 : F. W. 1014.74.

M+H=565 HNMR : 400 MHz, MeOD : (5) 1.379, 1.363 (d, 6H) ; 1.491 (s, 9H) ; 4.047 (septet, J= 6.4 Hz, 1H) ; 4.358 (s, 2H) ; 4.482 (s, 2H) ; 6.648 (s, 1H) ; 6.774 (t, J= 1.6 Hz, 1H) ; 6.863, 6.860 & 6.842, 6.839 (d of d, 1H) ; 6.904 (s, 1H ; 7.228 (s, 1H) ; 7.400 (s, 1H) ; 7.593, 7.573 (d of d, 1H).

Elemental analysis: Found C: 41.23 H: 4.12 N: 10.72 Calc. C: 41.30 H: 4.51 N: 11.01 Example 79 C28H36N805 (M. W. 464.52) : *4.5 HCl * 2.75 H20 : F. W. 697.37.

M+H=465 1HNMR : 400 MHz, MeOD : (5) 1.410, 1.394 (d, 6H) ; 4.082 (t, J= 6.4 Hz, 1H) ; 4.356 (s, 2H) ; 4.603 (s, 2H) ; 6.701 (s, 1H) ; 6.928, 6.924 & 6.908, 6.904 (d of d, 1H) ; 6.961 (s, 1H) ; 7.173 to 7.163 (m, 1H) ; Elemental analysis: Found C: 41.01 H: 5.45 N: 15.70 Calc. C: 40.65 H: 5.84 N: 16.07 Example 80 N- {4- [amino (imino) methyl]benzyl}-2-[6-{3-amino-5-[(1E)-3- <BR> <BR> phenylprop-1-enyl] phenyl}-3-(isopropylamino)-2-<BR> <BR> oxopyrazin-l (2H)-yl] acetamide Ex-80) 76c (300 mg, 0.4 mmol) was dissolved in methanol (50 mL) and stirred with lithium hydroxide monohydrate (250 mg) at room temperature for 5 h. The solution was neutralized to pH 7 with 2 M HC1 then purified by reverse phase HPLC 15-50% acetonitrile/DI H20 0.1% TFA over 10 min. Afforded yellow solid product (39 mg, 18%).

Example 81 1H NMR (300 MHz, CD30D) 8 0.92-1. 07 (m, 2H), 1.17 (d, 3H, J = 6.9 Hz), 1. 42 (d, 6H, J = 6.3 Hz), 1. 69-1. 83 (m, 5H), 3. 83-3. 94 (m, 1H), 3. 99-4. 13 (m, 1H), 4. 48 (s, 2H), 4. 66 (d, 2H, J = 4.8 Hz), 6.67 (s, 1H), 6.95 (s, 1H), 7.14 (s, 1H), 7.31 (s, 1H), 7.38-7. 78 (abq, 4H, J = 8.4 Hz).

LRMS m/z 587. 2 (M+ + H).

Example 82 1H NMR (300 MHz, CD30D) 8 0.97-1. 08 (m, 3H), 1.17 (d, 3H, J = 6.9 Hz), 1.17-1. 22 (m, 2H), 1.42 (d, 6H, J = 6.3 Hz), 1.69-1. 83 (m, 5H), 3.84-3. 96 (m, 1H), 4.02-4. 14 (m, 1H), 4.47 (s, 2H), 4.66 (d, 2H, J = 4.8 Hz), 6.68 (s, 1H), 6.98 (s, 1H), 7.17 (s, 1H), 7.34 (s, 1H), 7.38-7. 78 (abq, 4H, J = 8.1 Hz).

LRMS m/z 587. 2 (M+ + H).

Example 83 1H NMR (300 MHz, CD30D) 8 0. 96 (d, 3H, J = 6.0 Hz), 0. 99 (d, 3H, J = 6.0 Hz), 1.42 (d, 6H, J = 6.6 Hz), 1.72-1. 81 (m, 2H), 4.02-4. 13 (m, 1H), 4.47 (s, 2H), 4.61-4. 67 (m, 1H), 4.68 (d, 2H, J = 3.9 Hz), 6.69 (s, 1H), 7.22 (s, 1H), 7. 37 (s, 1H), 7. 39-7. 78 (abq, 4H, J = 8.4 Hz).

HRMS m/z 611.3 (M+ + H).

Example 84 HRMS m/z 611.3 (M+ + H).

Example 85 H NMR (300 MHz, CD30D) 8 0.96 (d, 3H, J = 6.0 Hz), 0.99 (d, 3H, J = 6.0 Hz), 1.42 (d, 6H, J = 6.6 Hz), 1.72-1. 81 (m, 2H), 4. 02-4. 13 (m, 1H), 4. 47 (s, 2H), 4.61-4. 67 (m, 1H), 4.68 (d, 2H, J = 3.9 Hz), 6.69 (s, 1H), 7.22 (s, 1H), 7. 37 (s, 1H), 7. 39-7. 78 (abq, 4H, J = 8.4 Hz).

HRMS m/z 591.3 (M+ + H).

Example 86 1H NMR (300 MHz, CD30D) 8 1.41 (d, 6H, J = 6.6 Hz), 3. 75 (s, 3H), 4.00-4. 11 (m, 1H), 4.44 (s, 2H), 4.66 (s, 2H), 5. 68 (s, 1H), 6.67 (s, 1H), 6.92 (s, 2H), 7.15 (s, 2H), 7.31 (s, 2H), 7.36-7. 47 (m, 5H), 7. 45-7.75 (abq 4H, J = 8.4 Hz).

LRMS m/z 625.2 (M+ + H).

Sulfonamide Library IR i HsN H CH2CI2 HN H N\ 5eq. NMM N 1. 5eq. R-CI N O -- N O N I NOi N II NOi Nay H O H O Scaffold R 1. 7eq. P-CD THF/MeOH HN 1. Oeq. HOBt 5eq NaOHaq H 1 0eq. NMM DMF Tris-amine N 0 0 P-CHO IR Han/\ N 0 han H 0 H2N Ph I/HN OH O OH Ph^O N NH Ph^OJ N NH Ph"0 N NH 1. 1eq. MeOH Pd/C H2 T R R HN. u ? N H2d/C NHz N 0 0 TFA CH2CI2 N'y N N H 0'ion H 0 H NH2 NHZ nu NH HN NH2 General Library Protocol Shaken on an orbital shaker was leq. of scaffold (0.20g, 0.464mmoles) with 1. 5eq. of 4-fluorobenzenesulfonyl chloride (0.135g) and 5eq. of N-Methyl Morpholine (0. 25mL) in dichloromethane (25mL). After 6hours of shaking the reaction was concentrated under a nitrogen stream and dried under high vacuum. The residue was shaken with methanol (3mL), tetrahydron furan (3mL), and 2. 5N sodium hydroxide (lmL). Once hydrolysis was complete the reaction was blown dry under a nitrogen stream. The resulting basic residue was chromatographied on Gilson HPLC-RP to reduce salt load and dried under nitrogen stream. The resulting carboxylate residue was activated in N, N-dimethylformamide (25mL) with N-methyl morpholine (lOeq., lmL), PS-Carbodiimide (1. 7eq) from Argonaut Technologies Inc. , and 1-hydroxybenzotriazole (l. Oeq, 120mg). After 15minutes the benzamidine (l. leq. , 360mg) was added and shaken for 4 hours. Added excess polymer bound Tris-amine and aldehyde resins, and then shaken for an additional hour. The reaction was then filtered and the resins rinsed with dichloromethane. The filtrate was concentrated invacuo. The residue was taken up in methanol (50mL) and purged with nitrogen. Excess palladium, 10 wt. % (dry basis), on activated carbon was added, tube capped with a septum, and a hydrogen balloon added. Once hydrogenolysis was complete the reaction was filtered through Celite, the filtrate concentrated invacuo, and dried under high vacuum. The residue was taken up in dichloromethane (25mL) and trifluoroacetic acid (5mL). Once the t-butyl ester was cleaved the reaction was concentrated invacuo. The residue was then chromatographed on Gilson HPLC-RP with 0.1% TFA (AN/H20) to yield the desired product as the TFA salts.

Example 87 The compound of Example 87 was prepared in an analogous manner to that of Example 186.

Example 88 Using 4- (trifluoromethoxy) benzenesulfonyl chloride and following the general library protocol listed above the desired product was obtained in 11% yield as an off- white solid. HPLC/LRMS: >97%, 673 (M+H) +; HRMS (ES+) calcd. for C30H32N805SF3 673.2163, found 673.2194.

Example 89 Using 2- (trifluoromethyl) benzenesulfonyl chloride and following the general library protocol listed above the desired product was obtained in 14% yield as an off- white solid. HPLC/LRMS: >95%, 657 (M+H) +; HRMS (ES+) calcd. for C30H32N804SF3 657.2214, found 657.2231.

Example 90 Using 2-naphthalenesulfonyl chloride and following the general library protocol listed above the desired product was obtained in 8.3% yield as an off-white solid.

HPLC/LRMS: >98%, 639 (M+H) +; HRMS (ES+) calcd. for C33H35N804S 639.2497, found 639.2530.

Example 91 Using 2-thiophenesulfonyl chloride and following the general library protocol listed above the desired product was obtained in 2. 6% yield as an off-white solid.

HPLC/LRMS: >95%, 595 (M+H) +; HRMS (ES+) calcd. for C27H31N804S2 595.1904, found 595.1894.

Example 92 Using 4-methoxybenzenesulfonyl chloride and following the general library protocol listed above the desired product was obtained in 31% yield as an off-white solid. HPLC/LRMS: >98%, 619 (M+H) +; HRMS (ES+) calcd. for C30H35N808S 619. 2446, found 619.2479.

Example 93 Using 4-fluorobenzenesulfonyl chloride and following the general library protocol listed above the desired product was obtained in 28% yield as an off-white solid.

HPLC/LRMS: >97, 607 (M+H) + ; 19F NMR (282MHz, DMF-d7) 6- 107.57 ; 1H NMR (300MHz, DMF-d7) # 10.18 (3H, br m), 9.43 (2H, br s), 8.88 (1H, br m), 8.00-7. 94 (6H, m), 7.54 (2H, m), 7.43 (2H, m), 6.76 (2H, m), 6.62 (1H, s), 6.49 (1H, s), 4.57-4. 53 (4H, m), 4.22 (1H, m), 1.34 (6H, d); HRMS (ES+) calcd. for C29H32N804SF 607.2246, 607.2282 found Example 94 Using 2,4-difluorobenzenesulfonyl chloride and following the general library protocol listed above the desired product was obtained in 7. 8% yield as an off- white solid. HPLC/LRMS: >95%, 625 (M+H) +; HRMS (ES+) calcd. for C2gH3lN804SF2 625.2152, found 625.2169.

Example 95 Using trans-p-styrenesulfonyl chloride and following the general library protocol listed above the desired product was obtained in 11% yield as an off-white solid.

HPLC/LRMS: >98%, 617 (M+H) +; HRMS (ES+) calcd. for C31H37N804S 617. 2653, found 617.2675.

Example 96 Using benzenesulfonyl chloride and following the general library protocol listed above the desired product was obtained in 28% yield as an off-white solid.

HPLC/LRMS: >95%, 589 (M+H) +; HRMS (ES+) calcd. for C29H33N804S 589.2340, found 589.2325.

Example 97 LCMS (RP, 15-90% acetonitrile in 0. 1% ammonium acetate over 14 min): retention time: 5.90 min; (M+H) + = 536, Negative Ion mode (M-H)-= 534.

Reductive amination library Example 98 By following the method of Example 110 and substituting benzaldehyde for phenylacetaldehyde, Example 98 was prepared: 1H NMR (400 MHz, DMF-d7) 8 10.24 (s, 2H), 9.72 (br s, 5H), 9.41 (s, 2H), 8.80-8. 79 (m, 1H), 7.92 (d, J = 8.5 Hz, 2H), 7.50 (d, J = 8.3 Hz, 2H), 7.40-7. 38 (m, 2H), 7.34-7. 30 (m, 2H), 7.26-7. 23 (m, 1H), 6.78 (s, 1H), 6.65 (s, 1H), 6.50-6. 47 (m, 2H), 4.62 (s, 2H), 4.50 (d, J = 5.8 Hz, 2H), 4.32 (s, 2H), 4.22-4. 20 (m, 1H), 1.31 (d, J = 6.4 Hz, 6H) ; @@C NMR (100 MHz, DMF-d7) 8 167.38, 167.31, 152.5, 150.3, 148.4, 146.4, 140.3, 134.2, 130.3, 128.87, 128.70, 128. 07, 128.01, 127.67, 127.39, 109.2, 104.4, 49.01, 47.5, 44.1, 42.8, 21.8 ; HRMS (EI) calcd for C3oH35N802 539.2877, found 539.2870.

Reverse amide library R I H2N H CH2CI2 HO N_0\ 5eq. NMM n N 1. 5eq. R-CI N 0 0 N 0 0 N<O °/o NO/ H 0 H 0 O O Scaffold R 1. 7eq. P-CD THF/MeOH . HN 1. Oeq. HOBt 5eq NaOHaq 10eq. NMM DMF Tris-amine NYO °/P-CHO VR H HN H N IK N'N p H N O zizi OI I/H OH Ph'O'jN NH Ph N NH2 1. 1eq. MeOH Pd/C H2 t f R ? HN R y"S- n/HN v' y-N HN H R N 0 HN N HN NH2 N 0 0 TFA CH2CI2 H_ O \N II N\N W H 0 H NH2 N H HN NH2 General Library Protocol Shaken on an orbital shaker was leq. of scaffold (0.20g, 0.464mmoles) with 1. 5eq. of 4-fluorobenzenesulfonyl chloride (0.135g) and 5eq. of N-Methyl Morpholine (0. 25mL) in dichloromethane (25mL). After 6hours of shaking the reaction was concentrated under a nitrogen stream and dried under high vacuum. The residue was shaken with methanol (3mL), tetrahydron furan (3mL), and 2.5N sodium hydroxide (lmL). Once hydrolysis was complete the reaction was blown dry under a nitrogen stream. The resulting basic residue was chromatographied on Gilson HPLC-RP to reduce salt load and dried under nitrogen stream. The resulting carboxylate residue was activated in N, N-dimethylformamide (25mL) with N-methyl morpholine (lOeq., lmL), PS-Carbodiimide (1. 7eq) from Argonaut Technologies Inc. , and 1-hydroxybenzotriazole (l. Oeq, 120mg). After 15minutes the benzamidine (l. leq. , 360mg) was added and shaken for 4 hours. Added excess polymer bound Tris-amine and aldehyde resins, and then shaken for an additional hour. The reaction was then filtered and the resins rinsed with dichloromethane. The filtrate was concentrated invacuo. The residue was taken up in methanol (50mL) and purged with nitrogen. Excess palladium, 10 wt. % (dry basis), on activated carbon was added, tube capped with a septum, and a hydrogen balloon added. Once hydrogenolysis was complete the reaction was filtered through Celite, the filtrate concentrated invacuo, and dried under high vacuum. The residue was taken up in dichloromethane (25mL) and trifluoroacetic acid (5mL). Once the t-butyl ester was cleaved the reaction was concentrated invacuo. The residue was then chromatographed on Gilson HPLC-RP with 0.1% TFA (AN/H20) to yield the desired product as the TFA salts.

Example 99 Using phenylacetyl chloride and following the reverse amide general library protocol the the desired product was obtain. HPLC/LRMS: >98%, 567 (M+H) +; HRMS (ES+) calcd. for C31H35N803 567.2827, found 567.2849.

Example 100 Using cyclopentanecarbonyl chloride and following the reverse amide general library protocol the the desired product was obtained. HPLC/LRMS: >98%, 545 (M+H) +; HRMS (ES+) calcd. for C29H37N803 545.2983, found 545.2995.

Example 101 By following the method of Example 110 and substituting 3-phenylbutyraldehyde for phenylacetaldehyde, Example 101 was prepared: H NMR (400 MHz, DMF-d7) 8 10.24 (br s, 7H), 9.43 (br s, 2H), 8.80-8. 78 (m, 1H), 8.10 (br s, 1H), 7.93 (d, J = 8.3 Hz, 2H), 7.48 (d, J = 8.2 Hz, 2H), 7.32- 7.25 (m, 4H), 7.20-7. 16 (m, 1H), 6.82 (s, 1H), 6.68 (s, 1H), 6.55 (s, 1H), 6.48 (s, 1H), 4.63 (s, 2H), 4.48 (d, J = 5.9 Hz, 2H), 4.24-4. 23 (m, 1H), 3.07-2. 85 (m, 3H), 1.94-1. 88 (m, 2H), 1. 33 (d, J = 6.5 Hz, 6H), 1. 24 (d, J = 6.9 Hz, 3H) ; 13C NMR (100 MHz, DMF-d7) 8 167.36, 167.26, 152.6, 149.7, 148.3, 147.5, 146.3, 134.3, 130.1, 128.98, 128.71, 128.06, 127.65, 127.47, 126.6, 118.5, 115.71, 115.60, 110.0, 105.4, 49.0, 44.2, 42.95, 42. 79,37. 82, 37.25, 22.4, 21.7 ; HRMS (EI) calcd for C33H4lN8°2 581.3347, found 581.3370.

Example 102 By following the method of Example 110 and substituting isovaleraldehyde for phenylacetaldehyde, Example 102 was prepared: H NMR (400 MHz, DMF-d7) 8 9.74 (br s, 7H), 9.09-9. 06 (m, 1H), 8.03 (d, J = 8.6 Hz, 2H), 7.35 (d, J = 8.2 Hz, 2H), 7.27 (s, 1H), 6.94-6. 92 (m, 2H), 6.68 (s, 1H), 4. 76 (s, 2H), 4.64-4. 59 (m, 1H), 4. 44 (d, J = 5. 2 Hz, 2H), 3.14-3. 11 (m, 2H), 1.71-1. 56 (m, 3H), 1. 40 (d, J = 6.3 Hz, 6H), 0. 85 (d, J = 6.3 Hz, 6H); 13C NMR (100 MHz, DMF-d7) 5 166.89, 166.54, 153.2, 146.21, 146.03, 133.1, 129.7, 128.9, 127.9, 126.8, 109.1, 46.6, 42.7, 36.7, 35.6, 26.2, 22.5, 21.4 ; HRMS (EI) calcd for C28H39Ng02 519.3190, found 519.3191.

Example 103 By following the method of Example 110 and substituting 3-thiophenecarboxaldhyde for phenylacetaldehyde, Example 103 was prepared : H NMR (400 MHz, DMF-d7) 6 10. 63 (br s, 5H), 10.18 (s, 2H), 9.41 (s, 2H), 8.83-8. 80 (m, 1H), 8.25 (br s, 1H), 7. 92 (d, J = 8.3 Hz, 2H), 7.51-7. 49 (m, 3H), 7.41-7. 40 (m, 1H), 7.14 (dd, J = 1.2, 5.0 Hz, 1H), 6.82 (s, 1H), 6.77-6. 76 (m, 1H), 6.60 (s, 1H), 6.56 (s, 1H), 4.63 (s, 2H), 4.51 (d, J = 5.8 Hz, 2H), 4.33 (s, 2H), 4.24-4. 23 (m, 1H), 1.33 (d, J = 6.5 Hz, 6H) ; 13C NMR (100 MHz, DMF-d7) 5 167.34, 167. 25,152. 6,150. 2,148. 1, 146.3, 140.9, 134.1, 130.2, 128.71, 128.13, 128.08, 127.7, 126.6, 122.5, 110.14, 109.9, 49.1, 44.4, 43.1, 42.8, 21.7 ; HRMS (EI) calcd for C28H33N802S 545.2442, found 545.2444.

Example 104 Using 2-methylvaleryl chloride and following the reverse amide general library protocol the the desired product was obtained. HPLC/LRMS: >98%, 547 (M+H) +; HRMS (ES+) calcd. for C2gH39NgO3 547.3140, found 547.3124.

Example 105 Using 3-methoxyphenylacetyl chloride and following the reverse amide general library protocol the the desired product was obtained. HPLC/LRMS: >98%, 597 (M+H) +; HRMS (ES+) calcd. for C32H37N804 597.2932, found 597.2942.

Example 106 Using hydrocinnamoyl chloride and following the reverse amide general library protocol the the desired product was obtained. HPLC/LRMS: >98%, 581 (M+H) +; HRMS (ES+) calcd. for C32H37N803 581.2983, found 581.2990.

Example 107 Using 3-cyclopentylpropionyl chloride and following the reverse amide general library protocol the desired product was obtained. HPLC/LRMS: >98%, 573 (M+H) +; HRMS (ES+) calcd. for C3lH4lN803 573.3296, found 573.3322.

Example 108 Using 4-propylbenzoyl chloride and following the reverse amide general library protocol the desired product was obtained. HPLC/LRMS : >98%, 595 (M+H) + ; 1H NMR (DMF-d7, 300MHz) # 10. 20 (3H, br m), 9. 35 (2H, br s), 8. 78 (1H, br m), 8.21 (1H, br m), 7.99 (2H, m), 7.91 (2H, m), 7.61 (1H, s), 7.49 (2H, m), 7.36 (3H, m), 6.89 (1H, s), 6.68 (lH, s), 4.73 (2H, m), 4.53 (2H, m), 4.28 (1H, m), 2.67 (2H, m), 1.67 (2H, m), 1.37 (6H, m), 0.94 (3H, m); HRMS (ES+) calcd. for C33H3gN803 959.3140, found 595.3147.

Example 109 Using benzoyl chloride and following the general library protocol listed above the reverse amide general library protocol the desired product was obtained.

HPLC/LRMS : >97%, 553 (M+H) +; HRMS (ES+) calcd. for C30H33NBO3 553.2676, found 553.2641.

Example 110 N- {4- [amino (imino) methyl] benzyl}-2- [6- {3-amino-5- [ (2- phenylethyl) amino] phenyl}- 3- (isopropylamino)-2-oxopyrazin-1 (2H)-yl] acetamide trifluoroacetate Ex-110a) 6-bromo-l-methoxycarbonylmethyl-3- (N- isopropylamino) pyrazinone was prepared: H NMR (300 MHz, CDC13) 6 7.04 (s, 1H), 5.96 (d, J =. 5 « zs'H ;) 4 ; ; ; t sl, 2H), 4.16-4. 00 (m, 1H), 3. 80 (s, 3H), 1. 25 (d, J = 6.5 Hz, 6H); C NMR (75 MHz, CDC13) 8 167.1, 152.3, 148.9, 124.4, 104.2, 52.8, 48.7, 42.6, 22.2 ; HRMS (EI) calcd for C10H15BrN3O3 304.0297, found 304.0340.

Ex-110b) A mixture of 6-bromo-1-methoxycarbonylmethyl-3- (N-isopropylamino) pyrazinone (9.31 g, 30.61 mmol) and 3- [(tert-butoxylcarbonyl) amino] -5-nitrophenylboronic acid (10.41 g, 36.91 mmol) in 200 mL THF (0. 15 M) was allowed to stir for 5 minutes at room temperature with argon flushing. The solution was then added 37 mL of 2.0 M solution of sodium carbonate (73.87 mmol) followed by tertakis (triphenylphosphine) palladium (0) (1.8111 g, 5 mol%). The resulting mixture was then heated to reflux and after approximately 4 hours, tertakis (triphenylphosphine) palladium (0) (1.8111 g, 5 mol%) was added in a second portion. The solution was allowed to reflux overnight (ca 18 hours). The reaction mixture was allowed to cool to room temperature and was diluted with ethylacetate (1 L). The organic solution was washed with saturated sodium bicarbonate (1 x 300 mL), brine (1 x 300 mL), dried (MgSO4), filtered and concentrated. Purification of the crude product by MPLC (16.7 % ethyl ether to 50% ethyl ether/25% ethyl acetate/hexanes) afforded pure methyl [6- (3- [ (tert- butoxycarbonyl) amino]-5-nitrophenyl}-3- (isopropylamino) - 2-oxopyrazin-1 (2H)-yl] acetate in 86% yield: H NMR (400 MHz, CDC13) 5 8.32-8. 31 (m, 1H), 7.84-7. 83 (m, 1H), 7.78 (s, 1H), 7.19 (s, 1H), 6.85 (s, 1H), 6.13 (d, J = 7.8 Hz , 1H), 4.51 (s, 2H), 4.23-4. 13 (m, 1H), 3.78 (s, 3H), 1. 53 (s, 9H), 1. 29 (d, J = 6.5 Hz, 6H) ; 13C NMR (100 MHz, CDC13) 8 167.8, 152.1, 151. 7, 149.7, 148.8, 140.3, 134.4, 125.5, 124.6, 123.5, 118.1, 113.3, 81.9, 52.8, 47.2, 42.6, 28.1, 22.3 ; HRMS (EI) calcd for C2lH28N507 462.1989, found 462.1984.

Ex-llOc) A solution of pure methyl [6- {3- [ (tert- butoxycarbonyl) amino]-5-nitrophenyl}-3- (isopropylamino)- 2-oxopyrazin-1 (2H)-yl] acetate (10.6022 g, 22.97 mmol) in 230.0 mL ethyl acetate and ethanol (1: 1,0. 1 M) was added 0. 7825 10% Pd-C (wet) in one portion. The resulting suspension was allowed to stir under an atmosphere of hydrogen gas (balloon) over night (ca. 18 hours).

Filtration through a pad of Celite 545 followed by concentration afforded pure methyl [6-{3-amino-5-[(tert- butoxycarbonyl) amino] phenyl}-3-(isopropylamino)-2- oxopyrazin-l (2H) -yl] acetate (EX-lra3) in 96% yield as an off-white solid: 1H NMR (400 MHz, CDC13) 56. 95 (s, 1H), 6.80 (s, 1H), 6.77 (s, 1H), 6.56 (s, 1H), 6.28 (s, 1H), 5.99 (d, J = 7.8 Hz, 1H), 4.52 (s, 2H), 4.19-4. 10 (m, 1H), 3.85 (s, 3H), 3. 85 (br s, 2H), 3.74 (s, 3H), 1.50 (s, 9H), 1.26 (d, J = 6.4 Hz, 6H) ; 13C NMR (100 MHz, CDCl3) 8 168.1, 152.5, 151.8, 149.2, 147.6, 139.8, 133.7, 127.8, 122.1, 110. 6, 109.6, 105.1, 80.5, 52.5, 47.1, 42.3, 28.2, 22.4 ; HRMS (EI) calcd for C21H3oN5o5 432. 2247, found 432.2237.

Ex-llOd) A solution of methyl [6-{3-amino-5-[(tert- butoxycarbonyl) amino] phenyl}-3-(isopropylamino)-2- oxopyrazin-l (2H)-yl] acetate (1.1721 g, 2.716 mmol) and phenylacetaldehyde (0. 650 mL, 5.556 mmol) and 1.0 mL acetic acid in 30. 0 mL THF (0. 1 M) was added sodium triacetoxyborohydride (1.7433 g, 8.225 mmol) in-one portion at room temperature. The resulting suspension was allowed to stir overnight. The reaction mixture was quenched with saturated sodium bicarbonate (50 mL). The aqueous solution was extracted with ethyl acetate (3 x 25 mL). The combined organic solutions were washed with with saturated sodium bicarbonate (1 x 25 mL), brine (2 x 25 mL), dried (MgS04), filtered and concentrated.

Purification by MPLC (20% ethyl acetate to 40% ethyl acetate/hexanes) afforded pure methyl [6- {3- [ (tert- butoxycarbonyl) amino]-5-[(2-phenylethyl) amino] phenyl}-3- (isopropylamino)-2-oxopyrazin-1 (2H)-yl] acetate in 92% yield: 1H NMR (400 MHz, CDC13) 8 7.32-7. 27 (m, 2H), 7.24- 7.19 (m, 3H), 6.88 (br s, 1H), 6.82 (s, 1H), 6.67 (s, 1H), 6.51-6. 50 (m, 1H), 6.21-6. 20 (m, 1H), 5.99 (d, J = 7.9 Hz, 1H), 4.51 (s, 2H), 4.19-4. 10 (m, 1H), 3.88 (br s, 1H), 3.70 (s, 3H), 3.37-3. 33 (m, 2H), 2.90-2. 86 (m, 2H), 1.49 (s, 9H), 1.26 (d, J = 6.4 Hz, 6H) ; 13C NMR (100 MHz, CDC13) 8 168.1, 152.5, 151.9, 149.2, 148.9, 139.8, 138.3, 133.7, 128.66, 128.56, 126.4, 108.65, 108.31, 103.1, 80.5, 52.4, 47.2, 44.7, 42.4, 35.3, 28.2, 22.4 ; HRMS (EI) calcd for C2gH38NsO5 536.2867, found 536.2859.

Ex-110-e) A solution of methyl [6- {3- [ (tert- butoxycarbonyl) amino]-5-[(2-phenylethyl) amino] phenyl}-3- (isopropylamino)-2-oxopyrazin-1 (2H)-yl] acetate (1.1183 g, 2.087 mmol) in 25.0 mL THF/methanol (3: 1,0. 1 M) was added 3.00 mL of 2.5 M sodium hydroxide (7.50 mmol) at room temperature. After stirring for approximately 3 hours, the solvent was removed under reduced pressure.

The resulting residue was diluted with brine (25.0 mL) and cooled in an ice bath (ca. 0°C). The solution was then acidified (pH approximately 4 as determined by indicating litmus paper). The aqueous solution was extracted with ethyl acetate (3 x 25 mL). The combined organic solutions were washed with brine (2 x 25 mL), dried (MgS04), filtered and concentrated to give pure [6- {3-[(tert-butoxycarbonyl) amino]-5-[(2- phenylethyl) amino] phenyl}-3-(isopropylamino)-2- oxopyrazin-1 (2H)-yl] acetic acid as a yellow solid in 90%. yield: 1H NMR (400 MHz, DMF-d7) 8 9.25 (s, 1H), 7.34-7. 28 (m, 4H), 7.24-7. 19 (m, 1H), 7.12 (s, 1H), 7.02 (br s, 1H), 6.85 (s, 1H), 6.75 (s, 1H), 6.37-6. 36 (m, 1H), 4.58 (s, 2H), 4.28-4. 19 (m, 1H), 3.34-3. 30 (m, 2H), 2.93-2. 89 (m, 2H), 1.46 (s, 9H), 1.28 (d, J = 6.5 Hz, 6H) ; 13C NMR (100 MHz, DMF-d7) 8 169.5, 153.7, 152.2, 150.2, 149.4, 141.8, 140.7, 134.1, 130.1, 129.4, 128.92, 128.59, 126.6, 108.21, 107.95, 103.1, 79.5, 47.6, 45.8, 43.1, 28.3, 22.2 ; HRMS (EI) calcd for C28H36N5Os 522.2711, found 522.2754.

Ex-llOf) A solution of [6- {3- [ (tert- butoxycarbonyl) amino]-5-[(2-phenylethyl) amino] phenyl}-3- (isopropylamino)-2-oxopyrazin-1 (2H)-yl] acetic acid (0.8875 g, 1.701 mmol) in 17.0 mL dry dichloromethane/DMF (3: 1,0. 1 M) was added 1-hydroxybenzotriazole (0.3061 g, 2.265 mmol), N-methylmorpholine (2.00 mL, 18.19 mmol), and carbodiimde resin (2.46 g, 2.583 mmol). The resulting suspension was allowed to shake for 10 minutes and was then added 4- (N- benzyloxycarbonylamidino) benzylamine hydrogen chloride salt (0.6574 g, 2.0557 mmol) in one portion. The resulting suspension was allowed to shake for 3 hours.

The reaction mixture was then added aldehyde resin (2.0 equivalents) and the reaction was shook an additional one hour. The reaction was filtered and rinsed with dichloromethane (3 x 10 mL) and DMF (1 x 10 mL). The solvent was removea unaer reaucea pressure. Purification. by MPLC (50% ethyl acetate to 80% ethyl acetate/hexanes) afforded pure benzyl {4-[({[6-{3-[(tert- butoxycarbonyl) amino]-5-[(2-phenylethyl) amino] phenyl}-3- (isopropylamino)-2-oxopyrazin-1 (2H) - yl] acetyl} amino) methyl] phenyl} (imino) methylcarbamate in 75% yield: H NMR (400 MHz, DMF-d7) 5 9.43 (s, 1H), 8.78- 8.75 (m, 1H), 8.26-8. 15 (m, 3H), 7.71-7. 46 (m, 10H), 7.42-7. 38 (m, 1H), 7.32 (s, 1H), 7.06 (s, 1H), 6.94 (s, 1H), 6.78 (d, J = 8.1 Hz, 1H), 6.63 (s, 1H), 6.07 (br s, 0.5H), 5.39 (s, 2H), 4.80 (s, 2H), 4.62 (d, J = 5.6 Hz, 2H), 4.41-4. 29 (m, 1H), 3.52-3. 47 (m, 2H), 3.13-3. 08 (m, 2H), 1.66 (s, 9H), 1.45 (d, J = 6.4 Hz, 6H); C NMR (100 MHz, DMF-d7) 8 167.95, 167.61, 164.9, 162.9, 153.7, 152.3, 150.16, 150.05, 144.4, 141.6, 140.7, 138.2, 134.6, 133.7, 130.4, 129.47, 129.00, 128.93, 128.59, 128.47, 128.39, 127.74, 127.63, 126.7, 124.9, 121.6, 119.7, 110.2, 108.38, 108.05, 107.1, 103.0, 79.5, 66.9, 48.9, 45.9, 42.97, 42.61, 35.8, 28.4, 22.4 ; HRMS (EI) calcd for C44H51Ng06 787.3926, found 787.3921.

Ex-110) A solution of benzyl {4-[({[6-{3-[(tert- butoxycarbonyl) amino]-5-[(2-phenylethyl) amino] phenyl}-3- (isopropylamino)-2-oxopyrazin-1 (2H) - yl] acetyl} amino) methyl] phenyl} (imino) methylcarbamate (0.6532 g, 0.8300 mmol) in 8.0 mL methanol (0.1 M) was added 10% Pd-C (wet) (0.1121 g) in one portion. The resulting suspension was purged with hydrogen gas, and then the reaction mixture was allowed to stir under an atmosphere of hydrogen (balloon). After approximately 3 hours, the reation was filtered through a pad of Celite 545 and the solvent was removed under reduced pressure.

The residue was added dry chloroform (4.0 mL, 0.2 M) followed bytrifluoroacetic acid (1. 60 mL, 20.77 mmol).

After approximately 2 hours, the solvent was removed under reduced pressure. Purification by reverse phase HPLC (5% acetonitrile to 50% acetonitrile/water/0.1 % trifluoroacetic acid) afforded pure N-f4- [amino (imino) methyl] benzyl}-2-[6-{3-amino-5-[(2- phenylethyl) amino] phenyl}- 3-(isopropylamino)-2-oxopyrazin-1 (2H)-yl] acetamide trifluoroacetate in 40% yield: 1H NMR (400 MHz, DMF-d7) 6 10.25 (br s, 7H), 9.42 (s, 2H), 8.81-8. 78 (m, 1H), 7.92 (d, J = 8.3 Hz, 3H), 7.47 (d, J = 8.3 Hz, 3H), 7.31-7. 28 (m, 4H), 7.24-7. 22 (m, 1H), 6.83 (s, 1H), 6.68 (s, 1H), 6.52-6. 50 (m, 2H), 4.65 (s, 2H), 4.47 (d, J = 5.9 Hz, 2H), 4.25-4. 20 (m, 1H), 3.35-3. 11 (m, 2H), 2.92-2. 89 (m, 2H), 1.32 (d, J = 6.5 Hz, 6H) ; 13C NMR (100 MHz, DMF-d7) 8 167.41, 167.40, 152.6, 150.1, 148.5, 146.3, 140.4, 134.4, 130.3, 129.4, 128.92, 128.73, 128.10, 127.7, 118.5, 115.6, 126.7, 109.39, 109.17, 104.7, 49.1, 46.0, 44.1, 52.8, 35.4, 21.8 ; HRMS (EI) calcd for C31H37N8o2 553. 3034, found 553.3064.

Example 111 By following the method of Example 110 and substituting hydrocinnamaldehyde for phenylacetaldehyde, Example 111 was prepared :-H NMR (400 MHz, DMF-d7) b 10.72 (br s, 5H), 10.25 (br s, 2H), 9.43 (s, 2H), 8.82-8. 80 (m, 1H), 8.12 (br s, 1H), 7.93 (d, J = 8.3 Hz, 2H), 7.48 (d, J = 8.2 Hz, 2H), 7.30-7. 16 (m, 5H), 6.85 (s, 1H), 6.74 (s, 1H), 6.57-6. 53 (m, 2H), 4.65 (s, 2H), 4.49 (d, J = 5.8 Hz, 2H), 4.25-4. 23 (m, 1H), 3.15-3. 12 (m, 2H), 2.73-2. 70- (m, 2H), 1.97-1. 89 (m, 2H), 1.33 (d, J = 6.4 Hz, 6H) ; C NMR (100 MHz, DMF-d7) 8 167.34, 167.27, 152.6, 149.8, 148.3, 146.3, 142.5, 134.3, 130.1, 128.89, 128.86, 128.68, 128.05, 127.6, 126.3, 115.7, 110.0, 105.5, 49.0, 44.23, 44.08, 42.8, 33.4, 30.8, 21.7 ; HRMS (EI) calcd for C32H39N802 567.3190, found 567.3212.

Example 112 Using isovaleryl chloride and following the reverse amide general library protocol the desired product was obtained. HPLC/LRMS: >98%, 533 (M+H) +; HRMS (ES+) calcd. for C28H37N803 533.2960, found 533.2989.

Example 113 Using phenyl isocyanate and following the reverse amide library protocol the desired product was obtained.

HPLC/LRMS: >98%, 568 (M+H) + ; 1H NMR (DMF-d7, 300MHz) # 10.02 (1H, br s), 9.65 (1H, br s), 9.60 (1H, br s), 9.42 (1H, br s), 8.77 (1H, br m), 7.94 (2H, m), 7.64 (2H, m), 7.48 (5H, m), 7.30 (2H, m), 7.17 (1H, m) 6.99 (1H, m), 6.90 (1H, m), 6.64 (1H, s), 4.70 (2H, s), 4.55 (2H, m), 4. 28 (1H, m), 1. 38 (6H, d); HRMS (ES+) calcd. for C30H34NgO3 568.2784, found 568.2784.

Example 114 Using benzoyl isocyanate and following the reverse amide library protocol the desired product was obtained.

HPLC/LRMS: >98%, 582 (M+H) +; 1H NMR (DMF-d7, 300MHz) 8 10.14 (2H, br s), 9.43 (2H, br s), 9.15 (1H, br m), 8.76 (1H, br m), 8.21 (1H, br m), 7.94 (2H, m), 7.46 (3H, m), 7.36 (4H, m), 7.26 (1H, m), 7. 18 (1H, m), 7.03 (1H, m), 6.84 (1H, m), 6.60 (1H, m), 4.69 (2H, s), 4.51 (2H, m), 4.43 (2H, m), 4.26 (1H, br m), 1.36 (6H, d); HRMS (ES+) calcd. for C31H36NgO3 582.2941, found 582.2975.

Example 115 The compound of Example 115 was prepared in an analogous manner to that of Example 186.

Example 116 EX-116) To a solution of N-[(3-amino-4-fluoro-1,2- benzisoxazol-6-yl) methyl]-2- [6- [3-amino-5- (trifluoromet. hyl) phenyl]-3- (isopropylamino)-2-oxopyrazin- 1 (2H)-yl] acetamide (230 mg, 0.43 mmol) in 95 % ethanol (60 ml) and conc. HC1 (6 ml) was added 10% Pd/C catalyst (150 mg) under argon flow. This mixture was stirred under 55 psi of hydrogen at room temperature for 4 hours.

The catalyst was removed by filtration through Celite.

The filtrate was concentrated and the residue was purified by RP HPLC (15-85 gradient, acetonitrile in 0.1 % TFA) to give 170 mg of Ex-116 as an amorphous powder.

HRMS (M+H) + 536.2015 found for C24H25F4N703 ; 536. 2028 calc'd.

H-NMR, 400 MHz, DMSO-d6 8 9.30 (s, 2H), 9.08 (s, 2H), 8.70 (bt, 1H), 6.90 (s, 1H), 6.75 (s, 1H), 6.70 (bs, 2H), 4.36 (s, 2H), 4.25 (d, J = 6.0 Hz, 2HO, 4.07 (m, 1H), 1.20 (d, J = 7.3 Hz, 6H).

Example 117 EX-117) The carboxylic acid, [6-{3-[(tert- butoxycarbonyl) amino]-5-nitrophenyl}-3- (isopropylamino)- 2-oxopyrazin-1 (2H)-yl] acetic acid (852 mg, 1.91 mmol), 6- (aminomethyl-4-fluoro-1, 2-benzisoxazol-3-amine (320 mg, 2.1 mmol) and HOBt-H20 (2.7 g, 20 mmol) were placed in a flask. DMF (60 ml) and CH2C12 (40 ml) were added. To this stirred solution was added polymeric DCC resin (8.28 g, loading 1. 38 mmol/g, 11.5 mmol) and triethylamine (1. 39 ml) and the resulting mixture stirred over night. The resin was removed by filtration and the filtrate concentrated. The crude residue was purified by flash chromatography (Merck 230-400 mesh Si02, Hexane: Ethyl acetate; 2: 1) to give 750 mg of the product as a white solid. This material (700 mg, 1.15 mmol) was dissolved in methanol (15 ml) and sparged with nitrogen. To this solution was added 10% Pd/C (200 mg) followed by 4N HCl in dioxane (15 ml). This mixture was stirred under 60 psi of hydrogen at room temperature for 4 hours. The catalyst was removed by filtration through Celite. The filtrate was concentrated and the residue was purified by prep HPLC (10-90% gradient, acetonitrile in 0.1 % TFA) to give 115 mg of Ex-117 as amorphous solid.

HRMS (M+H) + 483.2264 found for C23H27FN803 ; 483.2263 calc'd.

H-NMR : 400 MHz, DMSO-d6 b 9.28 (s, 2H), 9.15 (s, 2H), 8.84 (bt, 1H), 6.74 (s, 1H), 6.61 (s, 1H), 6.56 (s, 2H), 6.49 (s, 2H), 4. 32 (s, 2H), 4.15 (d, J = 5. 77 Hz, 2H), 1.21 (d, J = 6.31 Hz, 6H).

Example 118 The compound of Example 118 was prepared using the procedures outlined in Examples 16/17 and is merely a different salt thereof.

Example 119 The compound of Example 119 was prepared using the procedures outlined in Example 26 and is merely a different salt thereof.

Example 120 The compound of Example 120 was prepared using the procedures outlined in Example 44 and is merely a different salt thereof.

Example 121 The compound of Example 121 was prepared using the procedures outlined in Example 49 and is merely a different salt thereof.

Example 122 Using isobutyryl chloride and following the reverse amide general library protocol the desired product was obtained. HPLC/LRMS: >98%, 519 (M+H) +; HRMS (EI) calcd for C27H35Ng03 519. 2827, found 519.2806.

Example 123 Ex-122) Prepared as previously described for Ex-117.

LCMS (RP, 5-90% acetonitrile in 0. 1% TFA over 14 min): retention time: 3.41 min; (M+H) + = 498.

Example 124 isopropyl 3-amino-5-[1-[2-({4- [amino (imino) methyl] benzyl} amino)-2-oxoethyl]-5- <BR> <BR> (isopropylamino)-6-oxo-1, 6-dihydropyrazin-2-yl] benzoate HRMS calcd for C27H33N704 (M+H): 520.2667. Found: 520.2667.

Anal. Calcd for C27H33N7O4+0. 7H20+2.4TFA : C: 47.39 ; H: 4.60 ; N: 12.16.

Found: C: 47.40 ; H: 4.59 ; N: 12.14.

1H NMR (DMSO-d6, 300 MHz) # 1. 25 (d, 6H), 1. 30 (d, 6H), 4.12 (m, 3H), 5.11 (m, 2H), 6.73 (s, 1H), 6.80 (s, 1H), 7.12 (s, 1H), 7.28 (s, 1H), 7.43 (d, 2H), 7.76 (d, 2H), 8.71 (t, 1H), 9.05 (s, 2H), 9.28 (s, 2H).

Example 125 3-amino-5-[1-[2-({4-[amino (imino) methyl-3- hydroxybenzyl} amino)-2-oxoethyl]-5-(isopropylamino)-6- oxo-1, 6-dihydropyrazin-2-yl]-N- [ (1S)-1- methylpropyl]benzamide HRMS calcd for C28H36N804 (M+H): 549.2932. Found: 549.2921.

Anal. Calcd for C28H36N804+2. 25TFA+0.75H20 : C: 47.67 ; H: 4.89 ; N: 13.68.

Found: C: 47.70 ; H: 4.87 ; N: 13.66.

'H NMR (DMSO-d6, 300 MHz) 8 0.85 (t, 3H), 1.11 (d, 3H), 1.22 (d, 6H), 1.48 (m, 2H), 3.87 (m, 2H), 4.10 (m, 3H), 4.22 (m, 3H), 4.38 (s, 2H), 6.69 (m, 2H), 6.76 (d, 1H), 6.89 (s, 1H), 6.99 (s, 1H), 7.10 (s, 1H), 7.44 (d, 1H), 8.02 (d, 1H), 8.62 (t, 1H), 8.79 (bs, 2H), 8.95 (bs, 2H).

Example 126 The compound of Example 126 was prepared in an analogous manner to that of Example 186.

Example 127 The compound of Example 127 was prepared in an analogous manner to that of Example 186.

Examples 128/129 Using 2-methylvaleryl chloride and following the reverse amide general library protocol the desired product was obtained. HPLC/LRMS: >98%, 547 (M+H) +; HRMS (EI) calcd for C29H39Ng03 547.3140, found 547.3109 Example 130 Using butyryl chloride and following the reverse amide general library protocol the desired product was obtained. HPLC/LRMS: >98%, 519 (M+H) +; HRMS (EI) calcd for C27H35Ng03 519.2827, found 519.2802.

Example 131 Using 2-methylbutyryl chloride and following the reverse amide general library protocol the desired product was obtained. HPLC/LRMS : >98%, 533 (M+H) +; HRMS (EI) calcd for C28H37N803 533.2983, found 533.2965.

Example 132 Using trimethyl acetyl chloride and following the reverse amide general library protocol the desired product was obtained. HPLC/LRMS: >98%, 533 (M+H) +; HRMS (EI) calcd for C28H37N803 533.2983, found 533.2968.

Example 133 Using tert-butyl acetyl chloride chloride and following the reverse amide general library protocol the desired product was obtained. HPLC/LRMS: >98%, 547 (M+H) +; HRMS (EI) calcd for C29H39NgO3 547.3140, found 547.3098.

Example 134 Using 2-ethylbutyryl chloride and following the reverse amide general library protocol the desired product was obtained. HPLC/LRMS: >98%, 547 (M+H) +; HRMS (EI) calcd for C2gH3gNg03 547.3140, found 547.3147 Example 135 Using 4-methyl pentanoyl chloride and following the reverse amide general library protocol the desired product was obtained. HPLC/LRMS: >98%, 547 (M+H) +; HRMS (EI) calcd for C2gH39Ng03 547.3140, found 547.3117 Example 136 Using 2,2-di-n-propylacetyl chloride and following the reverse amide general library protocol the desired product was obtained. HPLC/LRMS: >98%, 575 (M+H) +; HRMS (EI) calcd for C3lH43N803 575.3453, found 575.3494.

Example 137 Using 2-ethylhexanoyl chloride and following the reverse amide general library protocol the desired product was obtained. HPLC/LRMS: >98%, 575 (M+H) +; HRMS (EI) calcd for C31H43N803 575.3453, found 575.3446.

Example 138 Using 2-methylheptanoyl chloride and following the reverse amide general library protocol the desired product was obtained. HPLC/LRMS: >98%, 575 (M+H) +; HRMS (EI) calcd for C3lH43N803 575. 3453, found 575.3453.

Example 139 Using 3,5, 5-trimethylhexanoyl chloride and following the reverse amide general library protocol the desired product was obtained. HPLC/LRMS: >98%, 589 (M+H) +; HRMS (EI) calcd for C32H45N803 589.3609, found 589.3606.

Example 140 Using Lrans-2-phenyl-cyclopropane carbonyl chloride and following the reverse amide general library protocol the desired product was obtained. HPLC/LRMS: >98%, 593 (M+H) +; HRMS (EI) calcd for C33H37N803 593.2983, found 593. 3020.

Example 141 Using cyclopentylacetyl chloride and following the reverse amide general library protocol the desired product was obtained. HPLC/LRMS: >98%, 559 (M+H) +; HRMS (EI) calcd for C3oH39N803 559.3140, found 559.3123.

Example 142 Using 4-dimethylaminobenzoyl chloride and following the reverse amide general library protocol the desired product was obtained. HPLC/LRMS : >98%, 559 (M+H) +; HRMS (EI) calcd for C32H38NgO3 559.3140, found 559.3123.

Example 143 Using 2-phenylbutyryl chloride and following the reverse amide general library protocol the desired product was obtained. HPLC/LRMS: >98%, 595 (M+H) +; HRMS (EI) calcd for C33H3gNgO3 595.3140, found 595.3156.

Example 144 Using cyclopropanecarbonyl chloride and following the reverse amide general library protocol the desired product was obtained. HPLC/LRMS: >98%, 517 (M+H) +; HRMS (EI) calcd for C27H33NgO 517.2670, found 517.2690.

Example 145 By following the method of Example 110 and substituting butyraldehyde for phenylacetaldehyde, Example 145 was prepared: HPLC/LRMS: >98%, 505 (M+H) +; HRMS (ES+) calcd. for C27H37N802 505.3034, found 505.3045.

Example 146 By following the method of Example 110 and substituting N-Boc-4-piperidinylcarboxaldehyde for phenylacetaldehyde, Example 146 was prepared: HPLC/LRMS: >97%, 546 (M+H) +; HRMS (ES+) calcd. for Cz9H4pNgO2 546.3299, found 546.3268.

Example 147 By following the method of Example 110 and substituting N-Boc-4-piperidinylcarboxaldehyde for phenylacetaldehyde, Example 147 was prepared: HPLC/LRMS: >98%, 546 (M+H) +; HRMS (ES+) calcd. for C2gH40N9O2 546.3299, found 546.3255.

Example 148 By following the method of Example 110 and substituting cyclopentanone for phenylacetaldehyde, Example 148 was prepared: HPLC/LRMS: >98%, 517 (M+H) +; HRMS (ES+) calcd. for C28H37N802 517.3034, found 517.3038.

Example 149 By following the method of Example 110 and substituting butyraldehyde (2.0 equivalents) for phenylacetaldehyde, Example 149 was prepared: HPLC/LRMS: >97%, 561 (M+H) +; HRMS (ES+) calcd. for C31H45M802 561.3660, found 561.3653.

Acid coupling library 2. Oeq. P-CD 1. Oeq. HOBt 10eq. NMM R O 1. Oeq. R-C02H H2N DMF/DCM HN Tris-amine O P-CHO O Nl o ° > NAl/O ° I I II I II , y N-A)'YN,, Jo,, H II H II O 1. 1 eq. Scaffold R 0 1. 7eq. P-CD THF/MeOH 1. Oeq. HOBt HN N 0eg 10eq. NMM 5eq NaOHaq DMF Tris-amine N 0 0 P-CHO HN JL ji'U H-< HN. u \ N N N N H 0 H2N - NHz 0 OH NH2 n J o O Ph 0 N NH2 Ph 0 N NH2 1. 1eq. MeOH Pd/C H2 R i Rio HN H OtS mNH2 nu2 NlY O TFA/CH2C12 W/ N zozo H N O N v'N H 0 H I/NH2 NH HN NH2 General Library Protocol Modification : Follows the same General Library Protocol outlined previously except the first step is a peptide coupling with a commercially available carboxylic acid.

Example 150 Using 1- (tert-butoxycarbonyl)-4-piperidinecarboxylic acid and following the acid coupling library protocol the desired product was obtained. HPLC/LRMS: >97%, 561 (M+H) +; HRMS (ES+) calcd. for C2gH38Ng03 560. 3092, found 560.3114.

Example 151 Using 1- (tert-butoxycarbonyl)-3-piperidinecarboxylic acid and following the acid coupling library protocol the desired product was obtained. HPLC/LRMS : >98%, 560 (M+H) +; HRMS (ES+) calcd. for C29H38N9O3 560.3092, found 560. 3111.

Example 152 By following the method of Example 110 and substituting trimethylacetaldehyde for phenylacetaldehyde, Example 152 was prepared: HPLC/LRMS: >97%, 519 (M+H) +; HRMS (ES+) calcd. for C28H39N802 519.3190, found 519.3206.

Example 153 By following the method of Example 110 and substituting 3,3-dimethylbutyraldehyde for phenylacetaldehyde, Exampl 153 was prepared: HPLC/LRMS: >75%, 533 (M+H) +; HRMS (ES+) calcd. for C29H41N802 533.3347, found 533.3368.

Example 154 <BR> <BR> <BR> <BR> <BR> <BR> N- 4- [amino (imino) methyl]-3-fluorobenzyl}-2- [6- [3-amino-<BR> <BR> <BR> <BR> <BR> 5-(trifluoromethyl) phenyl]-3-(isopropylamino)-2- oxopyrazin-1 (2H)-yl] acetamide Example 155 LCMS (RP, 15-90% gradient acetonitrile in 0. 1% ammonium acetate over 6 min): retention time = 6.05 ; (M+H) + = 536 ; negative ion mode (M-H)-= 534.

Example 156 LCMS (RP, 15-50% acetonitrile in 0. 1% TFA over 14 min) retention time = 4.05 ; (M+H) + = 567 Example 157 Using 4-pyridinebutanoic acid hydrochloride and following the acid coupling library protocol the desired product was obtained. HPLC/LRMS: >95%, 596 (M+H) +; HRMS (ES+) calcd. for C32H38NgO3 596.3092, found 596.3075.

Example 158 LCMS (RP, 15-90% acetonitrile gradient in ammonium acetate over 14 min): retention time = 5.35 min; (M+H) + = 567 ; negative ion mode (M-H)- = 565 Examples 159/160 3-amino-5- [1- [2- ( {4- [amino (imino) methyl]benzyl}amino)-2- oxoethyl]-5- (isopropylamino)-6-oxo-1, 6-dihydropyrazin-2- yl]-N- (4-fluorobenzyl) benzamide 1H NMR (400 MHz, CD30D) : 8 7.78 (d, 2 H), 7.33-7. 30 (m, 4 H), 7.23 (t, 1 H), 7.04 (t, 1 H), 6.99 (t, 2 H), 6.84 (t, 1 H), 6.65 (s, 1 H), 4.62 (s, 2 H), 4.48 (d, 2 H), 4.40 (d, 2 H), 4.05-4. 02 (m, 1 H), 1.34 (d, 6 H); Analysis: C31H33FN803 + 2.45 TFA + 1.15 H2O calcd: C, 48.73 ; H, 4.3 ; N, 12.66 ; found: C, 48.73 ; H, 4.28 ; N, 12.64.

Two salts were prepared for this compound and data for each is reported in Table 3.

Example 161 3-amino-5- [1- [2- ( {4- [amino (imino) methyl-3- hydroxybenzyl} amino)-2-oxoethyl]-5- (isopropylamino) -6- oxo-1, 6-dihydropyrazin-2-yl]-N-benzylbenzamide 1H NMR (400 MHz, CD30D) 7.53 (d, 2 H), 7.31-7. 21 (m, 5 H), 7.16 (t, 1 H), 6.92 (t, 1 H), 6. 87 (s, 1 H), 6. 76- 6.73 (m, 1 H), 6. 64 (s, 1 H), 4. 59 (s, 2 H), 4. 53 (s, 2 H), 4.29 (s, 2 H), 4.05-4. 02 (m, 1 H), 1.37 (d, 6 H); MS- ESI (M+H) = 583 ; Analysis : C31H34N8O4 + 3. 0 TFA + 0.6 H20 calcd: C, 47.5 ; H, 4.11 ; N, 11.97 ; found: C, 47.52 ; H, 4.12 ; N, 11.84.

Example 162 3-amino-5- [l- ({4-amino (imino) methyl-3- hydroxybenzyl} amino)-2-oxoethyl]-5-(isopropylamino)-6- oxo-1, 6-dihydropyrazin-2-yl] -N- (4-fluorobenzyl) benzamide 1H NMR (400 MHz, CD30D) : 8 7.53 (d, 1 H), 7.34-7. 30 (m, 2 H), 7. 26 (t, 1 H), 7.11 (t, 1 H), 7.0 (t, 2 H), 6. 88-6. 86 (m, 2 H), 6. 76-6. 73 (m, 1 H), 6. 64 (s, 1 H), 4. 59 (s, 2 H), 4.49 (s, 2 H), 4.30 (s, 2 H), 4.06-4. 02 (m, 1 H), 1. 36 (d, 6 H) ;"F NMR (371 MHz, CD30D)-77. 05 (s, 8.7),-188. 16 (sep, 1 F) ; MS-ESI (M+H) = 601 ; Analysis: C3lH33FN804 + 2. 25 TFA + 0.65 H20 calcd: C, 49.07 ; H, 4.23 ; N, 12.89 ; found: C, 49.1 ; H, 4.29 ; N, 12.8.

Example 163 1H NMR ppm (deuteromethanol): 1.26 (d, 6H), 3.63 (septet, 1H), 4.44 (d, 2H), 4.65 (d, 2H), 6.27 (dd, 1H), 6.78 (dd, 1H), 7. 62 (m, 9H); HPLC purity (retention time): >99% (2. 39 min); HRMS calcd for C24H29N7O2 (M+ + H) 448.2456, found 448.2447.

Example 164 HRMS: (M+H) + 603. 2616 found for C28H33F3N804 ; 603.2650 calc'd.

1H-NMR : 300 MHz, DMSO-d6 6 9.63 (bs, 2H), 9.58 (bs, 2H), 9. 30 (bm, 1H), 8. 88 (t, J = 5.6 Hz, 1H), 8. 42 (d, J = 8.4 Hz, 1H), 7. 66 (s, 1H), 7.57 (s, 1H), 7.23 (s, 1H), 6.71 (s, 1H), 4.38 (bs, 2H), 4.27-4. 34 (m, 3H), 3.88 (septet, J = 6.9 Hz, 1H, 1. 49 (m, 2H), 1. 26 (d, J = 6.9 Hz, 6H), 1.12 (d, J = 6.9 Hz, 3H), 0. 85 (t, J = 6.9 Hz, 3H).

19F NMR: 282 MHz, DMSO-d6 5-138. 45 (d, J = 13.0 Hz, 1F), - 144. 72 (dd, J = 13.0 Hz, J = 24.0 Hz, 1F),-151. 24 (d, J = 24.0 Hz, 1F).

Example 166 Prepared analogously to Example 110.

Example 167 3-amino-5- [1- [2- ( {4- [amino (imino) methyl-2- <BR> <BR> hydroxybenzyl} amino)-2-oxoethyl]-5- (isopropylamino)-6- oxo-1, 6-dihydropyrazin-2-yl]-N-[(1S)-1- methylpropyl] benzamide Benzyl (1Z)-amino{4-[({[6-[3-amino-5-({[(1S)-1- <BR> <BR> <BR> <BR> methylpropyl] amino} carbonyl) phenyl]-3-(isopropylamino)-2- oxopyrazin-1 (2H)-yl] acetyl} amino) methyl]-3- methoxyphenyl} methylidenecarbamate Ex-167a) LRMS m/z 697.3 (M+ + H); HPLC purity (retention time): 90% (1.9 min).

Ex-167) The crude product from Ex-167a (0.94 g crude, 1.3 mmol) was dissolved in 4 mL of CH2C12. BBr3 (14 mL total of a 2M solution in CH2C12, 28 mmol) was added portionwise until the reaction was complete (3 portions over 8 h).

The solid was filtered, then washed with CH2Cl2and Et20.

The solid was purified by reverse phase HPLC with a gradient of 15/85-45/55% acetonitrile/water (+ 0.1% TFA) over 12 mins. to give 0.1 g of an off-white solid: LRMS m/z 549.2 (M+ + H) ; HPLC purity (retention time): 98% (1.3 min) ; HRMS (M + H) : Calc'd for C28H36N8O4 : 349.2932; Found: 549. 2898. 1H NMR (400 MHz, CD30D) b0. 92 (t, 3H, J = 7.3 Hz), 1.19 (d, 3H, J = 6.5 Hz), 1.40 (d, 6H, J = 6.2 Hz), 1.56 (m, 2H), 3.97 (m, 1H), 4.05 (m, 1H), 4.38 (s, 2H), 4.64 (s, 2H), 6.65 (s, 1H), 6.96 (s, 1H), 7.16 (m, 4H), 7.30 (s, 1H), 8.62 (br t, 1H).

Example 168 Prepared analogously to Examples 53 and 117.

Alkyl Scheme 1. Oeq. Bromo PHA400721 o2N 1. 5eq Boronate N Br 02N-, qMe 4eq. Na2CO3 0. 1eq. Pd (PPh3) 4 Me THF N \ O H 0 JYN, 0 - ° TFA/DCM O N 2. Oeq. P-CD 02N l. Oeq HOBt 10eq. NMM Me 1. 1eq. Benzamidine Me N, 0 0 , p N N\ II H 0 H 0 0 H p O O WO) 4N1 NH2 Pd/C H2 H2 HCI-MeOH H2N k Han' N ill 0 N I I N -- eH H 0 N AHNX AN'H J HN NH2 Example 170 HPLC/LRMS: >97%, 448 (M+H) + ; lH NMR (DMF-d7, 400MHz) 8 9. 91 (2H, s), 9.74 (2H, s), 9.25 (1H, br s), 9.02 (1H, m), 8. 01 (2H, m), 7.44 (1H, s), 7.37 (3H, m), 7.14 (1H, s), 6.68 (1H, s), 4.80 (2H, m), 4.61 (1H, m), 4.37 (2H, m), 2.27 (3H, s), 1.37 (6H, d) ; HRMS (ES+) calcd. for C24H3oN702 448.2456, found 448.2434.

Example 171 Prepared analogously to Example 186.

Example 172 Prepared analogously to Example 186.

Example 173 LCMS (RP, 15-90% acetonitrile in 0.1% ammonium acetate over 6 min): retention time 3.04 min; (M+H) + = 567, Negative Ion mode (M-H)-= 565.

Modified amide library 3- [l- (2-tert-butoxy-2-oxoethyl)-5- (isopropylamino)-6-oxo- 1, 6-dihydropyrazin-2-yl]-5-nitrobenzoic acid 1H NMR (300 MHz, CD30D) 8 1. 37 (d, 6H, J = 6.3 Hz), 1. 45 (s, 9H), 4.21-4. 36 (m, 1H), 4.41 (s, 2H), 7.00 (s, 1H), 8.45 (s, 1H), 8.49 (s, 1H), 8.97 (s, 1H).

Amine 1 4-methoxy benzylamine Amine 2 3-methoxy benzylamine Amine 3 Beta analine methylester hydrochloride Amine 4 Methyl-4- (aminomethyl)-benzoate hydrochloride Intermediate A (3.9 g, 9.0 mmol), primary amines 1-8 (see above list, 9. 9 mmol), HOBt (0. 6 g, 4.5 mmol), NMM (5.9 mL, 54.0 mmol), PS-carbodiimide (11.1 g, 13.5 mmol), PS- diethylene triamine (9.6 g, 27. 0 mmol), Aldehyde wang (9.5 g, 27.0 mmol), CH2C12 (90 mLO, DMF (50 mL).

Intermediate B (9.0 mmol), TFA (30 mL), CH2C12 (100 ml).

Intermediate C (4.5 mmol), benzyl [4- (aminomethyl) phenyl] (imino) methylcarbamate dihydrochloride (1.7 g, 4.9 mmol), HOBt (0.3 g, 2.5 mmol), NMM (6.5 mL, 59.3 mmol), PS-carbodiimide resin (6.1 g, 7. 4 mmol), PS-diethylene triamine (5.3 g, 14.8 mmol), Aldehyde wang (5.2, 14.8 mmol). Intermediate D (4.5 mmol), Pd/C (10%, 0.8 g), methanol (100 mL).

Example 165 NHR = Methyl-4- (aminomethyl)-benzoate hydrochloride 'H NMR (300 MHz, CD30D) 8 1.42 (d, 6H, J = 6.6 Hz), 2.62- 2.70 (m, 2H), 3.60-3. 65 (m, 2H), 3.68 (s, 3H), 4.07-4. 14 (m, 1H), 4. 46 (s, 2H), 4. 67 (s, 2H), 6.71 (s, 1H), 7. 20 (s, 1H), 7.52 (s, 1H), 7.41 (s, 1H), 7.38-7. 81 (abq, 4H, J = 8.1 Hz).

LRMS m/z 563.2 (M+ + H).

Example 169 NHR = (S)- (+)-sec-butylamine H NMR (300 MHz, CD30D) 8 1.44 (d, 6H, J = 6. 6 Hz), 3.92 (s, 3H), 4.05-4. 14 (m, 1H), 4. 45 (s, 2H), 4.63 (s, 2H), 4.72 (s, 2H), 6. 70 (s, 1H), 7.04 (s, 1H), 7. 26 (s, 1H), 7.31-7. 46 (m, 5H), 7.71-7. 98 (abq, 4H, J = 8. 4 Hz).

LRMS m/z (M+ + H).

Example 174 NHR = 4-methoxy benzylamine H NMR (400 MHz, CD30D) 6 1.38 (d, 6H, J = 6. 6 Hz), 3.73 (s, 3H), 4.01-4. 05 (m, 1H), 4.38 (s, 2H), 4.44 (s, 2H), 4.63 (s, 2H), 6.63 (s, 1H), 6.82-7. 28 (m, 7H), 7.31-7. 69 (abq, 4H, J = 8.4 Hz).

LRMS m/z 597. 3 (M+ + H).

Example 175 Prepared analogously to Example 55.

Example 176 Prepared analogously to Example 186.

Example 177 NHR = 3-methoxy benzylamine H NMR (400 MHz, CD30D) 8 1.26 (d, 6H, J = 6.4 Hz), 3.75 (s, 3H), 4.11-4. 22 (m, 1H), 4.45 (d, 2H, J = 6.0 Hz), 4.52 (d, 2H, J = 6.0), 4.63 (s, 2H), 6.76 (s, 1H), 6.80- 7.35 (m, 7H), 7.41-7. 88 (abq, 4H, J = 8.2 Hz).

LRMS m/z 597. 3 (M+ + H).

Example 178 Prepared analogously to Example 4.

Phenol Scheme leq. Borate 1eq. Bromo-core 1. 5eq. Na2CO3 02N 0. 1 eq. Pd (PPh3) 4 /"\ NB 0 02N I oPh 1-propanol ph ILI NI u A N N O H II O O TFA/DCM O2N 2. Oeq. P-CD O2N 1. Oeq HOBt 10eq. NMM o'-Ph I. leq. Benzamidine Ph N N I N,, 0 N 0 ° OUI' 0 N NH2 Pd/C H2 MeOH MeOH OH /3 H N O \ HN NHZ Example 179 Ex-179a) HPLC/LRMS : >97%, 493 (M+H) + ; 1H NMR (CDC13, 400MHz) 8 7.85-7. 81 (2H, m), 7.39-7. 28 (6H, m), 6.87 (1H, s), 6.34 (1H, m), 5.12 (2H, s), 4.34 (2H, s), 2.80 (1H, m), 1.42 (9H, s), 0. 86 (2H, m), 0.61 (2H, m) ;"C NMR (CDC13, 100MHz) 8 166.56, 159.59, 151.96, 151.84, 135.40, 135.11, 129.05, 128.83, 1 27.80, 126.80, 123.54, 122.84, 117.06, 110.09, 83.46, 71.12, 48.1 4,28. 13,23. 75,7. 17 ; HRMS (ES+) calcd. for C26H29N4O6 493.2082, found 493.2052.

Ex-179) 179a (1.07grams) was stirred in DCM (50mL) and TFA (lOmL) for 18hrs. The reaction was concentrated invacuo and taken up repeatedly with heptane to reduce TFA load. Carboxylate residue was taken up in DMF and activated with P-CD (2. Oeq), HOBt (l. Oeq), and lOeqNMM) on orbital shaker. The benzamidine (SC81368, l. leq) was added and shaking continued for 4hrs mixture'was""" filtered and the resin cake rinsed with DCM. The filtrate was concentrated in-vacuo and the crude partitioned between chloroform and saturated sodium bicarbonate solution. The aqueous was extract twice more with equal amounts of chloroform. The combined organic- layers were concentrated to dryness under reduced vacuum.

After drying on high vacuum pump, the residue was taken up in methanol, and minimal 3N HCl-MeOH. Hydrogenolysis and reduction was completed on Parr Hydrogenator at 50psi. The concentrated crude was triturated with diethyl ether and filtered. The cake was dried in vacuum 'desicator. The desired product was collected by further purification on Gilson HPLC-RP with 0. 1% TFA (AN/H20) to yield an off-white solid (516mg). HPLC/LRMS: >99%, 448 (M+H) +; 1H NMR (DMF-d7, 400MHz) 8 10.21 (2H, br s), 9.41 (2H, br s), 8.76 (1H, m), 7.91 (2H, m), 7.47 (2H, m), 6.87 (1H, s), 6.52 (1H, s), 6.36 (1H, s), 6.30 (1H, s), 4.62 (2H, s), 4.49 (2H, d), 2.94 (1H, m), 0.94 (2H, m), 0.87 (2H, m); HRMS (ES+) calcd. for C23H26N703 448.2092, found 448.2055.

Example 180 HRMS (M+H)'484. 2070 found for C23H26FN704 ; 484.2103 calc'd.

Example 181 2- [6- (3-amino-5-hydroxyphenyl)-3- (isopropylamino)-2- oxopyrazin-1- (2H)-yl]-N-{4- [amino (imino) methyl-3- hydroxybenzyl} acetamide 6- (aminomethyl)-1, 2-benzisoxazol-3-amine Ex-181a) To a 250mL RBF was added di (tert-butyl) (3- amino-1, 2-benzisoxazol-6-yl) methylimidodicarbonate (2.5g, 6.8mmol) in 4 N HC1 in dioxane. The reaction stirred for 1 hour then checked by M. S. and L. C.. The starting material was observed to be gone and a new product that corresponded to the mass of the product was observed.

The excess HCl and dioxane was removed in vacuo toafford Ex-4a as a white solid that was used without further purification.

M. S. 163.4 (MH+164.5) tert-butyl 3- [I- (2- {E (3-amino-1, 2-benzisoxazol-6- yl) methyl]amino}-2-oxoethyl)-5-(isopropylamino)-6-oxo- 1, 6-dihydropyrazin-2-yl]-5-hydroxyphenylcarbamate Ex-181b) To the 250mL RBF with Ex-4a (2. 0g, 6. 8mmol) was added the DMF (40mL) and potassium t- butoxide (6.5g, 6. 8mmol). The reaction stirred for 20 minutes. To the reaction was added the acid (1. 5g, 3. 6mmol) and TBTU (1. 3g, 4. 0mmol). The reaction stirred at room temperature overnight. The reaction was poured into water and the ppt. ws filtered and washed with additional water. The solid was dissolved in methylene chloride and dried over MgS04 then concentrated in vacuo to afford Ex-181b (0. 85g) in 19% yield.

M. S. 663. 72 (MH+664.1) NMR (400MHZ, CDC13) : 1H 1. 23 ppm (6H, d), 1. 49 ppm (9H, s), 1.99 ppm (lH, d), 4.1 ppm (2H, q), 4.46 ppm (2H, s), 4.58 ppm (2H, s), 6.48 ppm (1H, t), 6.70 ppm (1H, s), 6.75 ppm (1H, s), 6.98 ppm (1H, t), 7.10 ppm (1H, d), 7.36 ppm (1H, t), 7.41 ppm (1H, d), 7.84 ppm (1H, d). tert-butyl 3- 2-({4-[amino (imino) methyl-3- <BR> <BR> <BR> hydroxybenzyl} znino)-2-oxoethyl]-5-(isopropylamino)-6-<BR> <BR> <BR> <BR> oxo-1, 6-dihydropyrazin-2-yl]-5-hydroxyphenylcarbamate Ex-181c) To a lOOmL flask was added palladium black in MeOH (25mL) under a blanket of nitrogen. To the slurry was added Ex-4b (1. 43g, 2. 54mmol) and ammonium fomate (2. 0g, 31.7 mmol). The reaction stirred at room temperature for 2 hours. The palladium was filtered off through ceilite and then the reaction was concentrated in vacuo. The resulting solid was tritrated with toluene then dried under a high vacuum. The resulting tan solid (1. 40g) was used without further purification.

M. S. 565.62 (MH+566.3) Ex-181) To a 50 mL RBF was added Ex-4c (0. 23g, 0. 41mmol) in 20% TFA/methylene chloride (lOmL). The reaction stirred for 1 hour. The reaction was then concentrated in vacuo. The resulting yellow-tan solid was tritrated with diethyl ether then filtered and dried on a high vacuum to afford the title compound (0.18g) in 95% yield.

Isolated as 2.6TFA andl H20 Found C : 54. 08 H: 5.55 N: 16.35 vil..," Calc. C: 42.30 H: 4.16 N: 10. 18 Example 182 3-amino-5- [l- ({4-amino (imino) methyl-2- methoxybenzyl} amino)-2-oxoethyl]-5- (isopropylamino)-6- oxo-1, 6-dihydropyrazin-2-yl]-N-[(1R)-1- methylpropyl] benzamide 4- (bromomethyl)-3-methoxybenzenecarboximidamide Ex-182a) NH4Br (6.9 g, 70 mmol) was taken up in 70 mL of chlorobenzene. The mixture was cooled in an ice bath and flushed well with N2. AlMe3 (30 mL of a 2 M solution in heptane, 60 mmol) was added dropwise. The heterogeneous reaction was warmed to room temperature, then slowly heated to 55 °C. Most of the NH4Br dissolved. The methyl 4-bromomethyl-3-methoxybenzoate was added (3.14 g, 12 mmol), followed by 15 mL of chlorobenzene. The reaction was heated to 80 °C under positive N2 pressure overnight.

The reaction was cooled in an ice bath and slowly quenched with-20 mL of MeOH. The mixture was stirred at room temperature-2 h, then filtered through Celite.

The filtrate was concentrated to remove the MeOH. The solid that crashed out of the remaining chlorobenzene was filtered, washed well with Et20, and dried under high vacuum for 1 h to give 3.2 g of a pale yellow solid: LRMS m/z 243,245 (M+ + H); HPLC purity (retention time): >90% (1.1 min).

Benzyl (lZ)-amino [4-(bromomethyl)-3-<BR> methoxyphenyl] methylidenecarbamate Ex-182b) The product from Ex-182a (2.9 g, 12 mmol) was taken up in 50 mL of THF. Et3N (5 mL, 36 mmol) was added.

Water (1.5 mL) was added until the solid partially dissolved. The mixture was cooled in an ice bath.

Benzyl chloroformate (2.6 mL, 18.2 mmol) in 4 mL of THF (plus a 2 mL rinse) was added dropwise, keeping the temperature below 6 °C. The ice bath was removed. LC/MS analysis after 30 mins showed complete reaction.

The reaction mixture was filtered through Celite.

The filtrate was concentrated to a yellow oil. The oil was taken up in 50 mL of EtOAc, washed with water 1 x 25 mL, brine 1 x 25 mL, dried over MgS04, and concentrated.

The oil solidified after standing overnight under N2. The solid was dried under high vacuum for 3 hours to give 2.7 g (60%) of a pale yellow solid: LRMS m/z 377,379 (M+ + H) ; HPLC purity (retention time): 80% (1.9 min).

Benzyl (lZ)-amino [4-(aminomethyl)-3- methoxyphenyl] methylidenecarbamate Ex-182c) The crude product from Ex-182b (2.6 g crude, 6.9 mmol crude) was added to-30 mL of NH3 condensed in a pressure flask at-78 °C. The pressure flask was tightly capped and warmed to room temperature. The heterogeneous reaction became homogeneous. LC/MS analysis after 1.5 hours showed complete reaction.

The mixture was filtered through Celite and concentrated to give 2.1 g (95% crude yield) of a yellow oil: LRMS m/z 314.1, 610.2 (dimer) (M + H); HPLC purity (retention time): 70% (1.2 min), 10% (1.9 min, dimer). Benzyl (1Z)-amino{4-[({[3-(isopropylamino)-6-[3-({[(1R)- l-methylpropyl] amin. o} carbonyl)-5-nitrophenyl]-2- oxopyrazin-1 (2H)-yl] acetyl} amino) methyl]-3- methoxyphenyl} methylidenecarbamate Ex-ld) LRMS m/z 727.3 (M+ + H) ; HPLC purity (retention time): 60% (2.3 min).

Ex-182) The crude product from Ex-182d (0.25 g crude, 0. 34 mmol) was dissolved in 2 mL of MeOH. Pd/C (10% Pd/C, 50% water-wet) (48 mg, 0. 02 mmol) in 2 mL of N2- flushed MeOH was added. The reaction was evacuated and flushed with N2 several times. Repeated with H2, then stirred under a H2 balloon for 2 h. The mixture was filtered through Celite and the filtrate was concentrated.

The dark yellow oil was purified by reverse phase HPLC with a gradient of 15/85%-50/50% acetonitrile/water (+ 0.1% TFA) over 12 mins. Product eluted at 4 mins, 23% acetonitrile, giving 46 mg (24%) of a white solid: LRMS m/z 563.3 (M+ + H); HPLC purity (retention time): 98% (1.4 min) ; HRMS (M + H): Calc'd for C2gH38N804 : 563.3089 ; Found: 563.3084 ; 1H NMR (300 MHz, CD30D) 80. 91 (t, 3H, J = 7.35 Hz), 1.17 (d, 3H, J = 6. 6Hz), 1.39 (d, 6H, J = 6.45 Hz), 1.55 (m, 2H), 3.92 (s, 3H), 3.94-4. 09 (m, 2H), 4.38 (s, 2H), 4.64 (s, 2H), 6.64 (s, 1H), 6.89 (s, 1H), 7.08 (s, 1H), 7.18-7. 35 (m, 5H), 8.60 (br t,-1H).

Examples 183/184 HPLC/LRMS: >95%, 531 (M+H) +; HRMS (ES+) calcd. for C28H35N803 531.2827, found 531.2796.

Two salts were prepared for this compound and the data for each is recorded in Table 3.

Example 185 3-[1-[2-({4-[amino (imino) methyl-2, 3, 6-trifluoro-5- hydroxybenzyl} o)-2-oxoethyl]-5-(isopropylamino)-6- oxo-1, 6-dihydropyrazin-2-yl]-N-[(lR)-1-methylpropyl]-5- aminobenzamide dihydrochloride HRMS: (M+H) + 603. 2684 found for C28H33F3N804 ; 603.2650 calc'd.

1H-NMR : 400 MHz, DMSO-d6 5 9.57 (bs, 2H), 9.52 (bs, 2H), 9.19 (bm, 1H), 8.84 (t, J = 5.5 Hz, 1H), 8. 36 (d, J = 8.2 Hz, 1H), 7. 57 (s, 1H), 7. 48 (s, 1H), 7.19 (s, 1H), 6. 67 (s, 1H), 4.38 (bs, 2H), 4.24-4. 34 (m, 3H), 3.84 (septet, J = 6.8 Hz, 1H), 1.46 (m, 2H), 1.22 (d, J = 6.8 Hz, 6H), 1.08 (d, J = 6.8 Hz, 3H), 0. 812 (t, J = 6.8 Hz, 3H).

Example 186 4-fluoro-3-methoxybenzylamine Ex-186a) To 4-fluoro-3-methoxybenzonitrile (2.55 g, 16.9 mmol) in 75 ml of ethanol was added 0. 85 g of 10% palladium on carbon and 7.5 ml of hydrogen chloride (conc.). The mixture was shaken on the Parr apparatus under 20 Psi of hydrogen for 5.5 hours. The mixture was filtered and concentrated in vacuo to give 3.19 g (99% yield) of a light pink solid. m/z (M+H) +156 5- (aminomethyl)-2-fluorophenol Ex-186b) The product from 186a (3.07 g, 16.1 mmol) in 9 ml of hydrogen chloride (conc.) was heated at 125°C for 8 hours in a sealed tube. The solution was treated with 75 ml of ethanol and concentrated in vacuo to give 2.88 g (quantitative yield) of a tan solid. m/z (M+H) +142 Ex-186c) m/z (M+H) +765 Ex-186) To the product from 186c (0.87 g, 1.14 mmol) and 0. 28 g of 10% palladium on carbon under nitrogen was added 10 ml of methanol (anhyd. ) and then ammonium formate (0. 323 g, 5.12 mmol). The mixture was heated at reflux for 2 hours. The mixture was filtered and concentrated in vacuo and purified by reverse phase chromatography with 10-35% CH3CN/H20 to give 0. 46 g (46% yield) of an off-white solid. m/z (M+H) +601 Analysis: C3iH33Ng04 + 2.45 TFA + 1.55 H20 calcd: C, 47.49 ; H, 4.28 ; N, 12.34 ; found: C, 47.45 ; H, 4.22 ; N, 12.42.

HRMS calcd: 601.2682 ; Found: 601.2670 1H NMR (400MHz, DMSO): 1.22 (6H, d), 4. 09 (1H, m), 4.33 (4H, m), 4.43 (2H, s), 6.71 (3H, m), 6.89 (1H, m), 7.03 (2H, m), 7.16 (1H, s), 7.37 (2H, d), 7.38 (1H, br s), 7.73 (2H, d), 8.68 (1H, t), 8.84 (1H, t), 9.08 (2H, s), 9.25 (2H, s).

Example 187 Ex-187a) m/z (M+H) +698 Ex-187) To the product from Ex-187a (1.11 g, 1.60 mmol) and 0. 40 g of 10% palladium on carbon under nitrogen was added 14 ml of methanol (anhyd. ) and then ammonium formate (0.462 g, 7.34 mmol). The mixture was heated at reflux for 2 hours. The mixture was filtered and concentrated in vacuo to give 0. 80 g of a yellow solid (94% yield). A 100 mg portion of this solid was purified by reverse phase chromatography with 10-45% CH3CN/H20 to give 60 mg of a white solid. m/z (M+H) +534 Analysis: C28H35N7O4 + 1. 90 TFA + 1. 15 Ha0 calcd: C, 49.54 ; H, 5.15 ; N, 12.72 ; found: C, 49.53 ; H, 5.15 ; N, 12.69.

HRMS calcd: 534.2801 ; Found: 534.2823 H NMR (400MHz, DMSO): 0. 91 (3H, t), 1. 22 (6H, d), 1. 40 (2H, sextet), 1. 64 (2H, quintet), 4.09 (1H, m), 4.21 (2H, m), 4.38 (4H, br s), 6.69 (1H, s), 6.78 (1H, s), 7.11 (1H, s), 7.27 (1H, s), 7.30 (1H, br s), 7.39 (2H, d), 7.73 (2H, d), 8.68 (lui, br s), 9.12 (2H, br s), 9.27 (2H, br s).

Example 188 Prepared analogously to Example 55.

Example 189 Prepared analogously to Example 55.

Example 190 HPLC/LRMS: >97%, 561 (M+H) +; HRMS (ES+) calcd. for C30H41N803 561.3296, found 561.3288.

Example 191 HPLC/LRMS : >98%, 547 (M+H) +; HRMS (ES+) calcd. for C29H39N8O3 547.3140, found 547.3158.

Example 192 HPLC/LRMS: >98%, 533 (M+H) +; HRMS (ES+) calcd. for C28H37N803 533.2983, found 533.2961.

Example 193 The product from Ex-196 (0.090 g, 0.00013 mol) was suspended in anhydrous CH2Cl2 (5 mL) and cooled to-80°C.

BBr3 (1M soln in CH2Cl2, 0.25 mL) was added and the solution was heated to reflux for 2 hours. After 2 hrs additional BBr3 (0.25 mL) was added. After refluxing for a total of 4.5 hrs the solution was cooled to 0°C and 5 mL of methanol was added. The solution was concentrated and the residue was coevaporated with methanol (4 x 5mL). The crude product was purified by prep HPLC (RP, 15% isocratic, acetonitrile in 0. 1% TFA). The purified TFA salt was coevaporated with 1 N HCl and lyophilized from water to yield Ex-193 (0.0217 g, 26. 2%) as a yellow solid.

HRMS: (M+H) + 565.2881 found for C28H36N805 ; 565.2809 calc'd.

H-NMR, 400 mHz, CD30D 8 7.61 (d, 2H, J=8. 0 Hz), 7.34 (s 1H), 6.69 (s, 3H), 4.54 (s, 2H), 4.35 (s, 2H), 4.07-3. 97 (m, 2H), 1.67-1. 55 (m, 2H), 1.40 (d, 6H, J=6.4 Hz), 1.24 (d, 3H, J=6.6 Hz), 0.96 (t, 3H, J=7.4 Hz).

Example 194 HPLC/LRMS: >97%, 519 (M+H) +; HRMS (ES+) calcd. for C27H35N803 519.2827, found 519.2815.

Example 195 Ex-195 was prepared analogously to Ex-193.

HRMS: (M+H) + 579.3038 found for C29H38N8o5i 579.2965 calc'd.

1H-NMR, 400 mHz, CD30D 5 7.56 (s, 1H), 7.52 (s, 1H), 7.27 (s, 1H), 6.85 (s, 2H), 6.67 (s, 1H), 4.53 (s, 2H), 4.37 (s, 1H), 4.05-4. 00 (m, 2H), 3.88 (s, 3H), 1.63-1. 59 (m, 2H), 1.40 (d, 6H, J=5.6 Hz), 1.23 (d, 3H, J=6.7 Hz), 0.96 (t, 3H, J=7.4 Hz).

Example 196 3,5-dimethoxy-4-methylbenzamide Ex-196a) 3,5-dimethoxy-4-methylbenzoic acid (50 g, 0. 255 mol) was dissolved in DMF (500 mL) to this solution was added DIEA (100 mL, 0. 573 mol) and HBTU (100 g, 0. 263 mol). The reaction was stirred at room temperature overnight. Additional HBTU (19 g, 0. 05 mol) was added and the reaction stirred for an additional 30 min. The solution was cooled to ODC and NH40H (20 mL) was added dropwise over 6 min. The solvent was removed and the residue treated with CH2C12 (500 mL) and water (300 mL).

The precipitate that formed was collected by filtration.

The CH2C12 layer from the filtrate was concentrated and extracted with water. The precipitate and solid from the CH2C12 layer were combined to give Ex-196a (37.4 g, 75. 2%) as a white solid.

H-NMR, 300 mHz, DMSO-d6 0 7.94 (s, 1H), 7.28 (s, 1H), 7.12 (s, 2H), 3.78 (s, 6H), 1.99 (s, 3H).

3, 5-dimethoxy-4-methylbenzonitrile Ex-196b) 3,5-dimethoxy-4-methylbenzamide, Ex-196a (30 g, 0. 154 mol) was suspended in 550 mL of toluene. To this solution was added thionyl chloride (14.8 mL, 0. 20 mol) and a catalytic amount of DMF (2 mL). The resulting solution was heated to 75°C for 4 hours. After cooling to room temperature the solution was concentrated in vacuo.

The residue was recrystallized from acetonitrile to give 21.6 g (79.4%) of Ex-196b as off-white crystals.

H-NMR, 300 mHz, CDC13 8 6. 72 (s, 2H), 3.78 (s, 6H), 2.05 (s, 3H) 4- (bromomethyl)-3, 5-dimethoxybenzonitrile Ex-196c) 3,5-dimethoxy-4-methylbenzonitrile, Ex-196b (41.9 g, 0. 24 mol) was dissolved in CC14 (1000 mL) followed by addition of N-bromosuccinimide (50.5 g, 0. 28 mol) and benzoyl peroxide (9.2 g, 0. 038 mol). The reaction mixture was refluxed for two hours. The reaction was cooled, filtered and concentrated. The residue was coevaporated two times with methanol. The crude product was recrystallized from acetonitrile/ether to give 41.9 g (69.4 %) of an off-white solid. H-NMR, 300 mHz, CDC13 8 6. 77 (s, 2H), 4. 57 (s, 2H), 3. 89 (s, 6H). di (tert-butyl) 4-cyano-2,6- dimethoxybenzylimidodicarbonate Ex-196d) Sodium hydride (3.84 g, 0.15 mol) was dissolved in anhydrous DMF (1000 mL). To this solution was added di-tert-butyl iminodicarboxylate (34.7 g, 0. 16 mol).

After stirring at room temperature for 45 min 4- (bromomethyl) -3,5-dimethoxybenzonitrile, Ex-196c (40 g, 0.16 mol) was added as a solution in DMF (100 mL). The solution was stirred for 2.5 days. The reaction mixture was cooled with an ice bath and diluted with water (500 mL). The entire mixture was extracted with ethyl acetate (3 x 650 mL). The ethyl acetate layers were combined, dried over MgS04, filtered and concentrated. The dark yellow oil obtained was recrystallized from hexane/ether to give 42.9 g (68.4%) of an off-white solid.

HRMS: (M+Na) + 415. 1840 found for C2oH28N2NaOg ; 415. 1845 calc'd.

H-NMR, 300 mHz, CDC13 5 6. 75 (s, 2H), 4.86 (s, 2H), 3.77 (s, 6H), 1. 39 (s, 18H). di (tert-butyl) 4amino (hydroxyimino) methyl-2, 6- dimethoxybenzylimidodicarbonate Ex-196e) Hydroxylamine hydrochloride (10.6 g, 0.15 mol) was dissolved in methanol (400 mL) followed by addition of diisopropylethylamine (26.7 mL 0. 15 mol). To this solution was added di (tert-butyl) 4-cyano-2,6- dimethoxybenzylimidodicarbonate, Ex-196d (15 g, 0.038 mol). The solution was stirred at room temperature overnight. The reaction had not proceeded to completeness, therefore, additional hydroxylamine hydrochloride (0. 019 mol) and diisopropylethylamine (0. 076 mol) were added. The solution was stirred for an additional hour. The solvent was evaporated and the residue was partitioned between ethyl acetate (200 mL) and water (50 mL). The ethyl acetate was washed with saturated aqueous sodium chloride (60 mL), dried over MgS04, filtered and concentrated to give 15.5 g of Ex-196e (94.7%) of an off-white solid.

1H-NMR, 300 mHz, CDC13 5 6.77 (s, 2H), 4.88 (s, 2H), 3.79 (s, 6H), 1.40 (s, 18H). di (tert-butyl) 4-amino (imino) methyl-2, 6- dimethoxybenzylimidodicarbonate Ex-196f) Di (tert-butyl) 4 [amino (hydroxyimino) methyl] -2, 6- dimethoxybenzylimidodicarbonate, Ex-196e (14.5 g, 0.034 mol) was dissolved in acetic acid (200 mL) followed by addition of acetic anhydride (4.5 g, 0. 044 mol) and 10% Pd/C (1.5 g). The mixture was placed at 50 psi of H2 pressure overnight. The reaction mixture was filtered through celite and concentrated to give 12.9 g (92. 7%) of Ex-196f as an off-white powder.

HRMS: (M+H) + 410.2286 found for C2oH3lN306 ; 410.2213 calc'd.

1H-NMR, 300 mHz, DMSO-d6 5 7.04 (s, 2H), 4.71 (s, 2H), 3.79 (s, 6H), 1.35 (s, 18H).

HCI 4-aminomethyl-3,5-dimethoxybenzamidine hydrochloride Ex-196g) Di (tert-butyl) 4- [amino (imino) methyl-2, 6- dimethoxybenzylimidodicarbonate, Ex-196f (5. 0 g, 0. 012 mol) was dissolved in 4 N HCl/dioxane (20 mL). The solution was stirred for 2 hours at room temperature.

The reaction mixture was filtered and the solid was washed with ether and dried to give 3. 0 g (88.3%) of Ex- 196g as an off-white powder.

HRMS: (M+H) + 210.1216 found for CloHlsN302 ; 210.1164 calc'd.

H-NMR, 400 mHz, DMSO-d6 5 9.70 (s, 1H), 9.36 (s, 1H), 8.23 (NH2), 7.25 (s, 2H), 3.90 (s, 2H), 3.35 (s, 6H).

Ex-196) The carboxylic acid, [3- (isopropylamino)-6- [3- <BR> <BR> <BR> ( [ (lS)-1-methylpropyl] amino} carbonyl)-5-nitrophenyl]-2- oxopyrazin-1 (2H)-yl] acetic acid (0.500 g, 0.0012 mol) was dissolved in anhydrous DMF (15 mL). To this solution was added diisopropylethylamine (0.24 mL, 0.0014 mol) followed by HBTU (0.527 g, 0.0014 mol). The resulting solution was stirred for one hour followed by addition of the benzyl amine, 4-aminomethyl-3,5- dimethoxybenzenecarboximidamide dihydrochloride, Ex-196g (0.397 g, 0.0014 mol). The solution was stirred for 4 hrs at room temperature. The solvent was evaporated and the crude product was dissolved in methanol (40 mL).

Nitrogen was bubbled through the solution. A solution of 4 N HC1 in dioxane (2 mL) was added followed by 10% Pd/C (0.30 g). The solution was placed at 40 psi of hydrogen pressure for 5 hours. The reaction mixture was filtered through celite and the celite was washed with methanol.

The filtrate was concentrated and the crude residue was purified by prep HPLC (RP, 5-50% gradient, acetonitrile in 0.1% TFA). The purified TFA salt was coevaporated with 1 N HC1 and lyophilized from water to give 0.45 g (56. 3%) of Ex-196 as a yellow solid.

HRMS: (M+H) + 593.3194 found for C30H40N805 ; 593.3122 calc'd.

1H-NMR, 400 mHz, CD30D 8 9.26 (br s, NH), 8.84 (br s, NH), 7.98 (br s, 2H), 7.69 (s, 1H), 7.03 (s, 2H), 6.74 (s, 1H), 4.52 (s 2H), 4.38 (s, 2H), 4.12-4. 06 (m, 1H), 4.06- 3.99 (m, 1H), 3.89 (s, 6H), 1.69-1. 57 (m, 2H), 1.41 (d, 6H, J=6.4 Hz), 1.25 (d, 3H, J=6.7 Hz), 0.96 (t, 3H, J=7.4 Hz).

Example 197 Ex-197 was prepared analogously to Ex-196, except the R- isomer of the carboxylic acid, [3- (isopropylamino)-6- [3- <BR> <BR> <BR> ({[(1R)-l-methylpropyl] aminocarbonyl)-5-nitrophenyl]-2- oxopyrazin-l (2H)-yl] acetic acid, was used. The purified TFA salt was coevaporated with 1N HCl to give Ex-197 (0.412 g, 53.6%) as a pale yellow solid.

HRMS: (M+H) + 593. 3181 found for C30H40N8O5; 593. 3122 calc'd.

H-NMR, 400 mHz, CD30D b 9.25 (br s), 8.82 (br s, 1H), 7.95 (br s, 2H), 7.66 (br s, 1H), 7.04 (s, 2H), 6.73 (s, 1H), 4.52 (s, 2H), 4.30 (s, 2H), 4.10-4. 00 (m, 1H), 3.89 (s, 6H), 1.64-1. 62 (m, 2H), 1.41 (d, 6H, J=6. 4Hz), 1.25 (d, 3H, J=6.6Hz), 0.97 (t, 3H, J=7.4 Hz).

Example 198 Ex-198 was prepared analogously to Ex-195, except that the product from Ex-195 was used as the starting material. The purified TFA salt was coevaporated with 1N HCl and lyophilized from water to give Ex-198 (0. 028 g, 27. 5%) as a pale yellow solid.

HRMS: (M+H) + 579.3038 found for C29H38N805 ; 579.2965 calc'd.

1H-NMR, 400 mHz, CD30D 8 7.75 (s, 2H), 7.48 (s, 1H), 6.86 (s, 2H), 6.71 (s, 1H), 4.54 (s, 2H), 4.36 (s, 2H), 4.08- 4.01 (m, 1H), 3.88 (s, 3H), 1.65-1. 60 (m, 1H), 1.41 (d, 6H, J=6.4 Hz), 1.24 (d, 3H, J=6.7 Hz), 0.96 (t, 3H, J=7.4 Hz).

Example 199 Ex-199 was prepared analogously to Ex-193 except the product from Ex-193 was used as the starting material.

The purified TFA salt was co-evaporated with 1N HCl and lyophilized from water to give Ex-199 (0.144 g, 95.7%) as a pale yellow solid.

HRMS: (M+H) + 565.2853 found for C28H36N805 ; 565.2809 calc'd.

H-NMR, 400 mHz, CD30D 8 7. 76 (br s, 2H), 7. 53 (s, 1H), 6.71 (s, 1H), 6.68 (d, 1H, J=7. 6 Hz), 4.55 (s, 2H), 4.34 (s, 2H), 4.08-4. 01 (m, 1H), 1.65-1. 60 (m, 2H), 1.41 (d, 6H, J=6.4 Hz), 1.24 (d, 3H, J=6.8 Hz), 0.97 (t, 3H, J=7.4 Hz).

Example 200 Ex-200a) m/z (M+H) +788 Ex-200) To the product from Ex-200a (1.38 g, 1.75 mmol) and 0. 43 g of 10% palladium on carbon under nitrogen was added 15 ml of methanol (anhyd. ) and then ammonium formate (0.497 g, 7.89 mmol). The mixture was heated at reflux for 2 hours. The mixture was filtered and concentrated in vacuo to give 1.10 g of a yellow foam (quantitative yield). A 120 mg portion of this solid was purified by reverse phase chromatography with 5-35% CH3CN/H20 to give 60 mg of a white solid. m/z (M+H) +624 Analysis : C3lH4lN707 + 2.25 TFA + 1.15 H20 calcd: C, 47.33 ; H, 5.10 ; N, 10.88 ; found: C, 47.31 ; H, 5. 03; N, 10. 94.

HRMS calcd: 624. 3140 ; Found: 624.3143 1H NMR (400MHz ; DMSO): 1. 22 (6H, d), 3.20 (3H, S), 3.38 (2H, m), 3. 47-3.57 (6H, m), 3. 70 (2H, m), 4. 10 (1H, m), 4. 30- 4.39 (6H, m), 6. 69 (1H, s), 6.78 (1H, t), 7.11 (1H, t), 7.27 (1H, t), 7.40 (2H, d), 7.73 (2H, d), 8.67 (1H, t), 9.04 (2H, s), 9.26 (2H, s).

Example 201 Ex-201a) m/z (M+H) +920 Ex-201) To the product from Ex-201a (1.59 g, 1.73 mmol) and ammonium formate (0. 490 g, 7.78 mmol) in 15 ml of methanol (anhyd. ) under nitrogen was added 0. 43 g of 10% palladium on carbon. The mixture was heated at reflux for 2 hours. The mixture was filtered and concentrated in vacuo. The residue was purified by reverse phase chromatography with 5-35% CH3CN/H2O to give 270 mg (15% yield) of a foam. m/z (M+H) +756 Analysis: C37H53N7O10 + 2.60 TFA + 1.25 H2O calcd: C, 47.16 ; H, 5.45 ; N, 9.12 ; found: C, 47.18 ; H, 5.53 ; N, 9.01.

HRMS calcd: 756.3927 ; Found: 756.3935 1H NMR (400MHz, DMSO): 1.22 (6H, d), 3.22 (3H, s), 3.39- 3.58 (20H, m), 3.71 (2H, m), 4.09 (1H, m), 4.32-4. 39 (6H, m), 6.70 (1H, s), 6.79 (1H, t), 7.11 (1H, t), 7.28 (1H, t), 7.40 (2H, d), 7.73 (2H, d), 8.68 (1H, t), 9.09 (2H, s), 9. 26 (2H, s).

Example 202 HPLC/LRMS: >98%, 561 (M+H) +; HRMS (ES+) calcd. for C30H41N803 561.3296, found 561.3285.

Example 203 HPLC/LRMS: >98%, 547 (M+H) +; HRMS (ES+) calcd. for C29H39N8O3 547.3140, found 547.3131.

Example 204 3-amino-5- [1- [2- ({4-[amino(imino)methyl]benzyl}amino)-2- oxoethyl]-5- (cyclopropylamino)-6-oxo-1, 6-dihydropyrazin- 2-yl] benzoic acid 1H NMR (400 MHz, CD30D) : 8 7.73 (d, 2 H), 7.47 (t, 1 H), 7.39 (d, 2 H), 7.31 (t, 1 H), 6.91 (t, 1 H), 6.68 (s, 1 H), 4. 59 (s, 2 H), 4. 44 (d, 2 H), 2. 80-2. 76 (m, 1 H), 1.09-1. 04 (m, 2 H), 0. 88-0.84 (m, 2 H) ; MS-ESI (M+H) = 476; Analysis: C24H25N704 + 2.45 TFA + 1.05 Hz0 calcd: C, 44.85 ; H, 3.84 ; N, 12.67 ; found: C, 44.85 ; H, 3.84 ; N, 12.65.

Example 205 Salt of Example 204.

Example 206 Salt of Example 204.

Example 207 Ethyl 3-amino-5- (1- [2- ({4- [amino (imino) methyl] benzyl} amino)-2-oxoethyl]-5- (cyclopropylamino)-6-oxo-1, 6-dihydropyrazin-2-yl] benzoate HRMS calcd for C26H29N704 (M+H): 504.2354. Found: 504.2318.

Anal. Calcd for C26H29N704 +2.4TFA : C: 46.77 ; H: 4.13 ; N: 12.81.

Found: C: 46.92 ; H: 4.32 ; N: 12.56.

1H NMR (DMSO-d6, 300 MHz) 8 0.66 (m, 2H), 0.75 (m, 2H), 1.27 (t, 3H), 2.75 (m, 1H), 4.25 (q, 2H), 4.36 (m, 4H), 6. 74 (s, 1H), 6.77 (s, 1H), 7.11 (s, 1H), 7.27 (s, 1H), 7.38 (d, 2H), 7.71 (d, 2H), 8.67 (t, 1H), 9.02 (s, 2H), 9.25 (s, 2H).

Example 208 HPLC/LRMS: >97%, 549 (M+H) +; HRMS (ES+) calcd. for C28H37N8O4 549.2932, found 549.2912.

Example 209 Prepared analogously to Example 64. Prepared analogously to Example 64.

Example 211 Prepared analogously to Example 64.

Prepared analogously to Example 64.

Example 213 Prepared analogously to Example 64.

Example 214 Prepared analogously to Example 64.

Example 215 Prepared analogously to Example 64.

Example 216 Prepared analogously to Example 64.

Example 217 Prepared analogously to Example 64.

Example 218 Prepared analogously to Example 64.

Example 219 Prepared analogously to Example 64.

Example 220 Prepared analogously to Example 64.

Example 221 Prepared analogously to Example 64.

Example 222 Prepared analogously to Example 64.

Example 223 Prepared analogously to Example 64.

Example 224 Prepared analogously to Example 64.

Example 225 Prepared analogously to Example. 64.

Example 226 Prepared analogously to Example 64.

Example 227 N- {4- [amino (imino) methyl] benzyl}-2- [6- [3-amino-5- (lH- tetraazol-5-yl) phenyl]-3-(isopropylamino)-2-oxopyrazin- 1 (2H)-yl] acetamide tert-butyl [6- [3- (aminocarbonyl)-5-nitrophenyl]-3- (isopropylamino)-2-oxopyrazin-1 (2H)-yl] acetate Ex-227a) 1H NMR (300 MHz, CDC13) : 8 8.75 (t, 1 H), 8.40 (t, 1 H), 8.23 (t, 1 H), 8.02 (s, 1 H), 6.85 (bs, 2 H), 6.15 (d, 1 H), 4.36 (s, 2 H), 4.18-4. 11 (m, 1 H), 1.45 (s, 9 H), 1.29 (d, 6 H) ; MS-ESI (M+H) = 432. tert-butyl [6- (3-cyano-5-nitrophenyl)-3- (isopropylamino)- 2-oxopyrazin-1 (2H)-yl] acetate Ex-227b) To a solution of 227a (1.87 g, 4.3 mmol) in dichloromethane (20 mL) at 0 °C was added TEA (0. 6 mL, 9.5 mmol) and TFAA (0. 7 mL, 4.8 mmol). After stirring at room temperature for 1 hr the reaction mixture was poured into water and dichloromethane. The layers were separated and organic layer washed with sodium carbonate and brine. The solvent was removed in vacuo to give an oil. The oil was taken up in MeOH: H20 (20 mL: 2 mL). To the solution was added Na2CO3 (0. 79 g, 7.5 mmol) at 0 OC.

The reaction was stirred at room temperature for 5 hrs and then acidified with 1N HC1 and extracted with ethyl acetate. The organic extracts were combined and washed with brine and dried (Na2SO4). The solvent was removed in vacuo to give an orange oil (1.39 g, 98%). MS-ESI (M+H) 414. tert-butyl [3- (isopropylamino)-6- [3-nitro-5- (lH- tetraazol-5-yl) phenyl]-2-oxopyrazin-1 (2H)-yl] acetate Ex-227c) To a solution of Ex-227b (1.39 g, 3.4 mmol) in dioxane (15 mL) at room temperature was added Me3SnN3. (2. 0 g, 10.2 mmol). The reaction mixture was heated to reflux for 4 hrs and then cooled to room temperature. The mixture was diluted with water and ethyl acetate. The layers were separated and the organic layer washed with 10% KF and brine. The extract was dried (Na2SO4) and the solvent removed in vacuo to give a brown oil, which after RP-HPLC (CH3CN: H20) gave the desired product (380 mg). 1H NMR (400 MHz, CD30D) : 5 9.01 (t, 1 H), 8. 52 (t, 1 H), 8.44 (t, 1 H), 6.88 (s, 1 H), 4.49 (s, 2 H), 4.12-4. 07 (m, 1 H), 1.37 (s, 9 H) ; MS-ESI (M+H) = 457.

[3- (isopropylamino)-6- [3-nitro-5- (lH-tetraazol-5- yl) phenyl]-2-oxopyrazin-1 (2H)-yl] acetic acid Ex-227d) To a round bottom flask containing Ex-227c (0. 38 g, 0. 83 mmol) 25 mL of 4N HC1 in dioxane was added.

The reaction mixture was heated to 50 °C for 4 hrs and then cooled to room temperature. The reaction mixture was placed in the refrigerator (-5 °C) to effect precipitation of the product. The mixture was filtered and dried on high vacuum to give the desired product as a yellow solid (0.31 g, 86%). 1H NMR (400 MHz, CD3OD) : # 8.86 (t, 1 H), 8.44 (t, 1 H), 8.36 (t, 1 H), 8.10 (bs, 1 H), 6.91 (s, 1 H), 5. 61-4. 81 (bs, 3 H), 4.45 (s, 2 H), 4.15-4. 10 (m, 1 H), 1.21 (d, 6 H); MS-ESI (M+H) = 401.

N-[4-(1-aminovinyl)benzyl]-2-[3-(isopropylamino)-6-[3- nitro-5- (1H-tetraazol-5-yl) phenyl]-2-oxopyrazin-1 (2H) - yl] acetamide Ex-227e) To a solution of Ex-227d (0. 31 g, 0. 77 mmol) in DMF (10 mL) at 0 °C was added DIEA (0.59 mL, 3.38 mmol) and TBTU (0. 37 g, 1.15 mmol). After 15 min, SC-81368 (0.37 g, 1.15 mmol) was added and the reaction stirred overnight at room temperature. The reaction was poured into water and ethyl acetate. The layers were separated and the organic layer washed with brine and dried (Na2SO4). The solvent was removed in vacuo to give a brown oil (0. 51 g, 100%). MS-ESI (M+H) = 666.

Ex-227) To a solution of Ex-227e (0. 51 g, 0. 76 mmol) in methanol (15 mL) was added 10% Pd/C (0. 15 g) and NH4CO2H (0. 14 g, 2.3 mmol). The reaction mixture was heated to reflux for 2 hrs and then cooled to room temperature.

The mixture was filtered through Celite and rinsed with methanol. The solvent was removed in vacuo to give a yellow oil, which was purified by RP-HPLC (CH3CN : H20) to give the desired product (139 mg). 1H NMR (400 MHz, CD30D) : 8 7.64 (d, 2 H), 7.43 (s, 1 H), 7.35 (d, 2 H), 7. 24 (s, 1 H), 6. 87 (1 H), 6. 68 (s, 1 H), 4. 46 (s, 2 H), 4.43 (d, 2 H), 4.07-4. 03 (m, 1 H), 1.37 (d, 6 H); MS-ESI (M+H) = 502 ; Analysis: C24H27N1102 + 2. 5 TFA + 1.2 H20 calcd: C, 43.09 ; H, 3.97 ; N, 19.06 ; O, 16.23 ; found: C, 43.17 ; H, 4.2 ; N, 18.96 ; 0, 16.26.

Example 228 Prepared analogously to Example 74.

Example 229 Prepared analogously to Example 74.

Example 230 Prepared analogously to Example 74.

Example 231 Prepared analogously to Example 74.

Example 232 Prepared analogously to Example 74.

Example 233 Prepared analogously to Example 74.

Example 234 Prepared analogously to Example 74.

Example 235 Prepared analogously to Example 74.

Example 236 Prepared analogously to Example 74.

Example 237 Prepared analogously to Example 74.

Example 238 Prepared analogously to Example 55 Example 239 Prepared analogously to Example 55 Example. 240 Prepared analogously to Example 182 Example 241 m/z (M+H) +532 Analysis: C28H33N704 + 2.35 TFA + 0.90 H2O calcd: C, 48.15 ; H, 4.59 ; N, 12.02 ; found: C, 48.18 ; H, 4.63 ; N, 11.97.

HRMS calcd: 532.2667 ; Found: 532. 2683 1H NMR (400MHz, DMSO): 0.64 (2H, m), 0.73 (2H, m), 0.91 (3H, t), 1.40 (2H, sextet), 1.64 (2H, quintet), 2.75 (1H, m), 4.21 (2H, t), 4.36 (2H, d), 4.38 (2H, s), 6.73 (1H, s), 6.77 (1H, t), 7.11 (1H, s), 7.27 (1H, t), 7.38 (2H, d), 7. 61 (1H, d), 7.72 (2H, d), 8.67 (1H, t), 9. 08 (2H, s), 9.26 (2H, s).

Example 242 Ex-242a) The product from Ex-193 (0.300 g, 0.00047 mol) was dissolved in acetonitrile (5 mL). To this solution was added (Boc) 20 (0.206 g, 0.00094 mol), triethylamine (0,. 132 mL, 0. 00094 mol), and a catalytic amount of DMAP (0. 1%). The solution was stirred at room temperature overnight. An additional amount of (Boc)2O (0.00037 mol) and triethylamine (0.040 mL, 0.00028 mol) was added and the reaction was stirred for an additional 1.5 hrs. The solvent was evaporated and the crude product purified flash chromatography (Merck 230-400 mesh, Si02, 4% methanol/CH2Cl2). Ex-242a was obtained (0.240 g, 57.4%) as pale yellow crystals.

HRMS: (M+H) + 865.4454 found for C43H6oN8011 ; 865. 4382 calc'd.

Ex-242) The product from Ex-242a (0.036 g, 0.000042 mol) was dissolved in anhydrous DMF (0.30 mL). To this solution was added a slurry of NaH in anhydrous DMF (0.20 mL) (0.0018 g, 0.000071 mol). After 30 min of stirring at room temperature, benzyl bromide (0.0093 mL, 0.000077 mol) was added. After 2 hrs the DMF was evaporated and the residue was treated with 4N HC1 in dioxane (15 mL) and stirred overnight. The reaction mixture was concentrated and the crude product was purified by prep HPLC (RP, gradient 5-50% acetonitrile in 0.1% TFA). The purified TFA salt was coevaporated with 1N HC1 and lyophilized from water to give 0.009 g (29.4%) of Ex-242 as a pale yellow solid.

HRMS: (M+H) + 655.3351 found for C35H42N8Os ; 655.3278 calc'd.

H-NMR, 300 mHz, CD30D 6 7.45-7. 28 (m, 5H), 7.19 (br s, 1H), 7.09 (br s, 1H), 6.93 (d, 1H), 6.87 (br s, 2h), 6.61 (s, 1H), 5.17 (s, 2H), 4.52 (s, 2H), 4.45 (s, 2H), 4.05- 3.94 (m, 2h), 1.61-1. 51 (m, 2h), 1.38 (d, 6H, J=6.4 Hz), 1.19 (d, 3H, J=6.6 Hz), 0.93 (t, 3H, J=7.4 Hz).

Example 243 Prepared analogously to Example 185.

Example 244 Ex-244a) Ex-244a was prepared analogously to example Ex- 242a except that Ex-199 was used as the starting material.

HRMS: (M+H) + 865.4454 found for C43H60N8O11; 865.4382 calc'd.

Ex-244) The product from Ex-244a (0.031 g, 0.000035 mol) was dissolved in anhydrous DMF (0. 30 mL). A DMF solution containing NaH (0. 001 g, 0. 000039 mol) was added. After 20 min t-butylbromoacetate (0. 013 mL) was added and the reaction mixture was then stirred at room temperature overnight. The DMF was evaporated and the crude residue was treated with 4N HC1 in dioxane (15 mL) overnight.

The solvent was evaporated and the crude product was purified by prep HPLC (RP, gradient 5-50% acetonitrile in 0.1% TFA). Ex-244 was obtained as the TFA salt (0.010 g, 33%).

HRMS: (M+H) + 623.2936 found for C30H38N807 ; 623.2863 calc'd.

1H-NMR, 400 mHz, CD30D 8 7.12 (t, 1H), 7. 02 (t, 1H), 6.88 (d, 1H, J=1.65 Hz), 6.80 (d, 2H, J=1. 65 Hz), 6.6 (s, 1H), 4.80 (s, 2H), 4.53 (s, 2H), 4.46 (s, 2H), 3.99-3. 95 (m, lh), 4.06-4. 00 (m, 1H), 1.61-1. 51 (m, 2H), 1.37 (d, 6H, J=6.4 Hz), 1.20 (d, 3H, J=6.7 Hz), 0.95 (t, 3H, 7.4 Hz).

Example 245 Prepared analogously to Example 181.

Example 246 Ex-246a) 1HNMR (300 MHz, DMSO-d6) 6 3.30 (s, 3H), 3.62- 3.68 (m, 2H), 4.36-4. 42 (m, 2H), 7.56 (s, 1H), 7.69 (s, 1H), 7.88 (s, 1H). LCMS (ES+) m/z 240.

Ex-246b) Into a solution of (3-amino-5-carboxylphenyl) boronic acid (1.0 g, 5.5 mmol) in n-butanol (15 ml) was bubbled hydrogen chloride gas for 5 minutes. The reaction was sealed and heated at 85 °C for two hours.

The reaction was diluted with diethyl ether and the resulting crystals collected by vacuum filtration to give 1.2 g of a colorless solid (ca. 40 mole% n-butanol).

LCMS (ES+) m/z 238.

Ex-246c) LCMS (ES+) m/z 459.

Ex-246d) LCMS (ES+) m/z 403.

Ex-246e) To a stirred solution of Ex-246c (200 mg, 0.46 mmol), Ex-246d (204 mg, 0.64 mmol), and N- methylmorpholine (0. 3 ml, 2.73 mmol) in N, N- dimethylacetamide (4 ml) cooled in an ice bath was added TBTU (161 mg, 0.5 mmol). Stirring was continued at ambient temperature for 1.5 hours. Purification by reverse phase HPLC (10-55% acetonitrile/water) followed by lyophilization yielded 169 mg (38% yield) of an off- white solid. 1HNMR (300 MHz, DMSO-d6) 5 0.62-0. 79 (m, 4H), 2.70-2. 80 (m, 1H), 3.58-3. 63 (m, 2H), 4.40-4. 50 (m, 6H), 5.33 (s, 2H), 6.74 (s, 1H), 6.77 (s, 1H), 7.10 (s, 1H), 7.27 (s, 1H), 7.39 (d, J = 8.4 Hz, 2H), 7.39-7. 50 (m, 5H), 7.73 (d, J = 8.4 Hz, 2H), 8.67 (t, J = 6.0 Hz, 1H), 10.41 (br s, 1H). HRMS (ES) calcd for C35H38N707 (M+H): 668. 2827. Found: 668. 2805. Anal. Calcd for C35H37N707 + 2.45 TFA + 0.75 H2O : C, 49.88 ; H, 4.29 ; N, 10.20. Found: C, 49.90 ; H, 4.32 ; N, 10.18.

Ex-246) A solution of Ex-246e (25 mg) in ethanol (25 ml) was shaken with 10% palladium on carbon under hydrogen at 40 psi. The reaction was filtered and purification by reverse phase HPLC (5-50% acetonitrile/water) followed by lyophilization yielded 8 mg of an off-white solid. 1HNMR (300 MHz, DMSO-d6) # 0. 60- 0.78 (m, 4H), 2.70-2. 80 (m, 1H), 3.28 (s, 3H), 3.59-3. 65 (m, 2H), 4.29-4. 39 (m, 6H), 6.73 (s, 1H), 6.77 (s, 1H), 7.10 (s, 1H), 7.25-7. 29 (m, 1H), 7.39 (d, J = 8.4 Hz, 2H), 7.71 (d, J = 8.4 Hz, 2H), 8.54 (t, J = 5.7 Hz, 1H), 8.90 (br s, 1H), 9.24 (br s, 2H). HRMS (ES) calcd for C27H32N7Os (M+H) : 534. 2459. Found: 534.2417.

Example 247 2- (dimethylamino) ethyl 3-amin. o-5- [l- [2- ( {4- amino (imino) methyl] benzyl} amino)-2-oxoethyl]-5- (cyclopropylamino)-6-oxo-1, 6-dihydropyrazin-2-yl] benzoate HRMS calcd for C28H34N804 (M+H): 547.2776. Found: 547.2791.

H NMR (DMSO-d6, 300 MHz) 8 0.65 (m, 2H), 0.75 (m, 2H), 2.86 (bs, 7H), 4.38 (m, 5H), 4.53 (m, 3H), 6.74 (s, 1H), 6.82 (s, 1H), 7. 19 (s, 1H), 7.30 (s, 1H), 7.42 (d, 2H), 7. 73 (d, 2H), 7. 96 (m, 1H), 8. 73 (t, 1H), 9.12 (bs, 2H), 9. 26 (bs, 2H), 9. 77 (bs, 1H).

Example 248 HPLC/LRMS: >97%, 550 (M+H) +; HRMS (ES+) calcd. for C28H37N8O4 549.2932, found 549.2912.

Example 249 Prepared analogously to Example 172.

Example 250 Prepared analogously to Example 55.

Example 251 Ex-251a) To a solution of di (tert-butyl)-4- [amino (imino) methyl] benzylimidodicarbonate (1.07 g, 2.71 mmol) in 48 ml of tetrahydrofuran and 5.3 ml of water at 0°C was added sodium carbonate (1.44 g, 13.6 mmol) and 9- fluorenylmethyl chloroformate (1.54 g, 5.97 mmol). The reaction mixture was stirred overnight while warming to room temperature. The mixture was treated with brine and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, filtered and evaporated in vacuo to give a white solid. The solid was purified by silica gel chromatography with 10-50% EA/Hex to give 0.63 g (41 % yield) of a white solid. m/z (M+H) +572, Ex-251b) The product from Ex-251a (0.626 g, 1.10 mmol) was dissolved in 1.5 ml of dioxane and treated with 4M hydrogen chloride in dioxane (4 ml, 16 mmol) and stirred overnight. The mixture was diluted with 20 ml of ethyl ether and the resulting precipitate was collected by vacuum filtration to give 0.475 g (quantitative yield) of a white solid. m/z (M+H) +372 Ex-251c) m/z (M+H) +491 Ex-251d) To the product from Ex-251c (0.216 g, 0.745 mmol) was added 4M hydrogen chloride in dioxane (7 ml, 28 mmol). The solution was heated at 65°C for 2 hours. The mixture was diluted with ethyl ether and the resulting precipitate was collected by vacuum filtration and dried over phosphorous pentoxide under high vacuum to give 0. 194 g (94% yield) of a yellow solid. m/z (M+H) +435 Ex-251e) To the product from Ex-251d (0.190 g, 0.404 mmol) and the product from Ex-251b (197 mg, 0.485 mmol) in 2.5 ml of N, N-dimethylformamide at 0 OC was added N, N- diisopropylethylamine (0. 28 ml, 1.62 mmol) and then benzotriazol-1-yl tetramethyluronium tetrafluoroborate (0. 156 g, 0. 485 mmol). The solution was stirred for 2 hours at room temperature and then added to a solution of brine. The precipitate was collected by vacuum filtration and dried over phosphorous pentoxide under high vacuum to give 288 mg (91% yield) of an off-white solid m/z (M+H) +788 Ex-251) To the product from Ex-251e (0.282 g, 0.358 mmol) in 4 ml of dichlormethane was added diethylamine (0.4 ml, 3.87 mmol) and the solution was stirred for 2 hours. Another portion of diethylamine (0. 8 ml, 7.74) was added and the solution was stirred an additional 1.5 hours. The solvent was removed in vacuo and the residue was dissolved in methyl sulfoxide, acetonitrile and acidified with trifluoroacetic acid. The solution was purified by reverse phase chromatography to give 120 mg (43% yield) of a yellow solid m/z (M+H) +566 Analysis: C31H3lN704 + 1.60 TFA + 2.35 H2O calcd: C, 51.97 ; H, 4.76 ; N, 12.40 ; found: C, 51.92 ; H, 4.69 ; N, 12.46.

HRMS calcd: 566.2510 ; Found: 566.2471 1H NMR (400MHz, DMSO): 0.66 (2H, br s), 0.75 (2H, m), 2.71 (1H, m), 4.22 (2H, d), 4.31 (2H, s), 5.23 (2H, s), 6.69 (1H, s), 6.74 (1H, s), 7.10 (1H, s), 7.28-7. 39 (8H, m), 7.67 (2H, d), 8.66 (1H, t), 9.08 (2H, s), 9.26 (2H, s).

Example 252 1H NMR (400 MHz, DMF-d7) S 10.02 (s, 2H), 9.42 (br s, 6H), 8. 70 (t, J = 6. 0 Hz, 1H), 8.14 (d, J = 8.3 Hz, 1H), 7.90 (d, J = 8. 3 Hz, 2H), 7.44 (d, J = 8.3 Hz, 3H), 7.26 (s, 1H), 7.01 (s, 1H), 6.76 (s, 1H), 6.37 (br s, 1H), 4.64 (s, 2H), 4.49 (d, J = 5.9 Hz, 2H), 4.04-3. 94 (m, 1H), 1.63-1. 43 (m, 11H), 1.16 (d, J = 6.7 Hz, 3H), 0.88 (t, J = 7. 4 Hz, 3H) ; 13C NMR (100 MHz, DMF-d7) # 167.50, 167.41, 166.7, 152.5, 149.8, 147.4, 146.4, 137.4, 134.1, 129.5, 128.77, 128.02, 127.6, 51.7, 48.6, 47.5, 42.7, 29. 7, 28.3, 20.4, 10.9 ; HRMS (ES) calcd for C29H39N803 547.3140, found 547.3147.

Example 253 Prepared analogously to Example 172.

Example 254 Prepared analogously to Example 181.

Example 255 The product from Ex-244a (0.030 g, 0.000035 mol) was dissolved in anhydrous DMF (0.300 mL). To this solution was added NaH (0.0010 g in 0.5 mL DMF). After 30 min a solution of pyridyl bromide (0.0087 g, 0.000035 mol) neutralized with DIEA was added (0.0062 mL) in DMF (0.20 mL). The solution was stirred at room temperature overnight. The DMF was evaporated and the crude product was treated with 4N HC1 in dioxane overnight. The solvent was evaporated and the crude product was purified by prep HPLC (RP, gradient 5-35% acetonitrile in 0. 1% TFA). The purified TFA salt was coevaporated with 1N HC1 and lyophilized from water to give 2.6 mg (10.2%) of the product Ex-255 as a pale yellow solid.

HRMS: (M+H) + 656.3303 found for C34H4lNgO5 ; 656. 3231.

1H-NMR, 400 mHz, CD30D 8 8.88 (s, 1H), 8.78 (d, 1H, J=5.6 Hz), 8.66 (d, 1H, J=8.0 Hz), 8.08 (t, 1H, J=6.9 Hz), 7.16 (s, 1H), 7.08 (s, 1HO, 6.79 (s, lh), 6.78-6. 68 (m, 2H), 6.58 (s, 1H), 4.63 (s, 2H), 4.49 (s, 2H), 4.39 (s, 2H), 4.04-3. 95 (m, 2H), 1.60-1. 56 (m, 2H), 1.39 (d, 6H, J=6.4 Hz), 1.20 (d, 3H, J=6.6 Hz), 0.93 (t, 3H, J=7.4 Hz).

Example 256 Ex-256a) tert-butyl [3- (tert-butylamino)-6- [3- (f [ (lR)-l- methylpropyl] amino} carbonyl)-5- nitrophenyl]-2-oxopyrazin-1 (2H)-yl] acetate 1H NMR (400 MHz, CDC13) 8. 67-8.66 (m, 1H), 8.35-8. 34 (m, 1H), 8.17-8. 16 (m, 1H), 6.82 (s, 1H), 6.55 (br d, J = 8.3 Hz, 1H), 6.23 (s, 1H), 4.34 (s, 2H), 4.19-4. 09 (m, 1H), 1.66-1. 56 (m, 2H), 1.47-1. 44 (m, 18H), 1.26 (d, J = 6.6 Hz, 3H), 0.98 (t, J = 7.4 Hz, 3H) ; 13C NMR (100 MHz, CDC13) 6 166. 5,163. 6,151. 8,149. 8,148. 3,137. 1,134. 8, 133.6, 126.2, 124.6, 123.8, 122.1, 83.2, 51.5, 48.2, 47.8, 29.5, 28.1, 27.8, 20.2, 10.4 ; HRMS (ES) calcd for C25H36NsO6 502.2660, found 502.2636.

Ex-256b) A solution of EX-256a (5.61 g, 11.19 mmol) in a solution 112.0 mL of ethyl acetate and ethanol (1: 1,0. 1 M) was added 326.6 mg 10% Pd-C (wet) in one portion. The resulting suspension was flushed with hydrogen and then allowed to stir under an atmosphere of hydrogen (balloon) over night (approximately 18 hours). The reaction mixture is filtered through a pad of Celite 545 and the filtrate is concentrated under reduced pressure.

Purification of the crude product by trituration with ethyl ether to afforded pure tert-butyl [6- [3-amino-5- ({[(1R)-1-methylpropyl]amino} carbonyl) phenyl]-3- (tert- butylamino)-2-oxopyrazin-1 (2H)-yl] acetate in 80% yield : 1H NMR (400 MHz, DMF-d7) 8 8. 03-8.01 (br m, 1H), 7.2-7. 28 (m, 1H), 7.03 (s, 1H), 6. 76-6.75 (m, 2H), 6.24 (s, 1H), 5.52 (s, 2H), 4. 44. (s, 2H), 4.05-3. 95 (m, 1H), 1.65-1. 48 (m, 11H), 1.39 (s, 9H), 1.17 (d, J = 6.6 Hz, 3H), 0. 90 (t, J = 7.4 Hz, 3H) ; 13C NMR (100 MHz, DMF-d7) # 167.4, 166.9, 152.3, 150.04, 149.93, 137.7, 133.7, 129.3, 121.6, 117. 8 116.4, 114.3, 82.5, 51.6, 48.1, 47.4, 29.8, 28.46, 27.99, 20.5, 11.1 ; HRMS (ES) calcd for C25H38N504 472.2918, found 472.2923.

Ex-256c) A solution of EX-256b (4.0056 g, 8.494 mmol) in chloroform (85.0 mL, 0.15 M) was added trifluoroacetic acid (16.00 mL, 207.7 mmol) in one portion at room temperature. The solution was allowed to stir over night (approximately 18 hours). The reaction was concentrated to an oil and then diluted with aqueous hydrochloric acid (25.0 mL, 1N) and the solvent was removed under reduced pressure. This process was repeated two more times to afford pure [6-[3-amino-5-({[(1R)-1- methylpropyl]amino}carbonyl)phenyl]-3-(tert-butylamino)- 2-oxopyrazin-1 (2H)-yl] acetic acid dihydrochloride in 69% yield : 1H NMR (400 MHz, DMF-d7) 6 10.96 (br s, 5H), 8.57 (d, J = 8.1 Hz, 1H), 8.16 (s, 1H), 7.95 (s, 1H), 7.75 (s, 1H), 6.91 (s, 1H), 4.58 (s, 2H), 4.05-3. 94 (m, 1H), 1. 67- 1.48 (m, 11H), 1.18 (d, J = 6.6 Hz, 3H), 0.88 (t, J = 7.4 Hz, 3H) ; 13C NMR (100 MHz, DMF-d7) 6 168.9, 165.0, 152.7, 147.6, 138.0, 135.6, 133.3, 128.2, 127.2, 126.6, 123.4, 53.3, 48.2, 47. 7, 29.6, 27.9, 20.3, 10.9 ; HRMS (ES) calcd for C21H30N5O4 416. 2292, found 416.2320.

Ex-256d) benzyl (lZ)-amino {4- [ ( { [6- [3-amino-5- ( { [ (lR)-l- methylpropyl]amino}carbonyl)phenyl]-3-(tert-butylamino)- 2-oxopyrazin-1 (2H) - yl] acetyl} amino) methyl] phenyl} methylidenecarbamate 1H NMR (400 MHz, DMF-d7) 8 9.50 (br s, 1H), 9. 12 (br s, 1H), 8. 56 (t, J = 5.8 Hz, 1H), 8. 07-8. 01 (m, 4H), 7. 48- 7.31 (m, 7H),. 7.13 (s, 1H), 6.85 (s, 1H), 6.75 (s, 1H), 6.25 (s, 1H), 5.53 (s, 2H), 5.21 (s, 2H), 4.60 (s, 2H), 4.46 (d, J = 5.8 Hz, 2H), 4.06-3. 96 (m, 1H), 1.64-1. 44 (m, 11H), 1.17 (d, J = 6.7 Hz, 3H), 0. 89 (t, J = 7.5 Hz" 3H) ; 13C NMR (100 MHz, DMF-d7) 8 168.0, 167.45, 166.95, 165.2, 152.5, 150.0, 149.9, 144.3, 138.3, 137.4, 134.1, 133.9, 129.81, 129.01, 128.58, 128.51, 128.37, 127.7, 121.6, 117.9, 116.6, 114.2, 66.9, 51.5, 48.8, 47.4, 43.0, 29.8, 28.5, 20.5, 11.0 ; HRMS (ES) calcd for C37H45N805 681.3507, found 681.3498.

Ex-256) A solution of EX-256d (2.2515 g, 3.307 mmol) in methanol/HCl (34.0 mL, 3: 1 methanol: 4 M HCl in methanol, 0. 1M) was added 378.8g 10% Pd-C (wet) in one portion.

The resulting suspension was flushed with hydrogen and then allowed to stir under an atmosphere of hydrogen (balloon) for approximately 4 hours. The reaction mixture is filtered through a pad of Celite 545 and the filtrate is concentrated under reduced pressure.

Purification by reverse phase HPLC (5% acetonitrile to 50% acetonitrile/water/0.1% trifluoroacetic acid) afford pure 3-amino-5-[1-[2-({4- [amino (imino) methyl] benzyl} amino)-2-oxoethyl]-5- (tert- butylamino)-6-oxo-1, 6-dihydropyrazin-2-yl]-N-[(lR)-1- methylpropyl] benzamide bis (trifluoroacetate) in 81% yield : 1H NMR (400 MHz, DMF- d7) # 9.98-9.81 (br m, 8H), 9.44 (s, 2H), 8.720 (t, J = 5. 9 Hz, 1H), 8.17 (d, J = 8.2 Hz, 1H), 7.90 (d, J = 8.3 Hz, 2H), 7.51-7. 50 (m, 1H), 7.43 (d, J = 8.3 Hz, 2H), 7.31 (s, 1H), 7.07-7. 06 (m, 1H), 6.77 (s, 1H), 6.41 (br s, 1H), 4.66 (s, 2H), 4.48 (d, J = 5.9 Hz, 2H), 4.04-3. 94 (m, 1H), 1.63-1. 44 (m, 11H), 1.16 (d, J = 6.6 Hz, 3H), 0.88 (t, J = 7.4 Hz, 3H) ;"C NMR (100 MHz, DMF-d7) 6 167.46, 167.39, 166.6, 152.5, 149.7, 146.48, 146.43, 137.4, 134. 1,'129. 3,128. 77,128. 01,127. 5,121. 0, 119. 88, 119. 11, 118.1, 116.2, 115.2, 112.3, 51.7, 48.6, 47.5, 42.7, 29.7, 28.3, 20.4, 10.9 ; HRMS (ES) calcd for C2gH39N803 547.3140, found 547.3127.

Example 257 HPLC/LRMS: >98%, 505 (M+H) +; HRMS cacld for C26H33N8O3 505.2670, found 505.2661.

Example 258 1H NMR (400 MHz, DMF-d6) # 10.20 (br m, 7H), 9.44-9. 36 (m, 3H), 8.81-8. 78 (m, 1H), 8.14 (d, J = 8.2 Hz, 1H), 7.91 (d, J = 8.3 Hz, 2H), 7.44-7. 42 (m, 3H), 7.20 (s, 1H), 6.94-6. 92 (m, 2H), 4. 66 (s, 2H), 4. 49 (d, J = 5.8 Hz, 2H), 4. 05-3. 94 (m, 1H), 2.99-2. 95 (m, 1H), 1.64-1. 47 (m, 2H), 1.17 (d, J = 6.6 Hz, 3H), 1. 00-0. 87 (m, 7H) ; 13C NMR (100 MHz, DMF-d7) 8 167.5, 166.87, 166.71, 160.3, 159. 9, 152.7, 150.3, 149.0, 146.2, 137.6, 132.7, 131.1, 128.79, 128.07, 127. 7, 118.3, 117.4, 115.3, 48.7, 47. 5, 42.8, 29.7, 24.9, 20.4, 10.9, 7.2 ; HRMS (ES) calcd for C28H35N8o3 531.2827, found 531.2794.

Example 259.

Step A:

To a slurry of 500 mmol of the ammonium salt of 2- nitroacetamide in 400 grams of water is added 600 mmol of ethyl 2, 4-dioxo-4- (3- (t-butoxycarbonylamino)-5- trifluoromethylphenyl) butanoate (prepared by standard methods from diethyl oxalate and 1-acetyl-3- (t- butoxycarbonylamino) -5-trifluoromethylbenzene). A solution of piperidinium acetate (prepared by adding 72 mL of piperidine to 42 mL of acetic acid in 200 mL of water) is then added. The resulting reaction mixture is stirred at 40 °C for about 24 hours. The reaction product 259a is then separated, dried and used in the next step.

Step B:

A solution of the pyridone 259a from Step A (400 mmol) in 500 mL of methylene chloride is treated with 500 mmol of solid trimethyloxonium tetrafluoroborate and the mixture stirred at 40 °C until the reaction is complete as monitored by liquid chromatography. The reaction mixture is concentrated about 70% and chromatographed on silica gel to afford the methoxy pyridine 259b.

Step C:

To a solution of the pyridine 259b from Step B (350 mmol) in 1000 mL of methylene chloride at-70 °C is added with 700 mmol of DIBAL (1 molar in hexane) using a

dropping funnel. The resulting solution is stirred for 1 hour and then warmed to room temperature over an additional hour. The reaction mixture is quenched by the careful addition of saturated sodium potassium tartrate.

After stirring for 30 additional minutes, the solid is filtered and washed with 500 mL methylene chloride. The filtrate is washed twice with 500 mL of saturated sodium potassium tartrate and then 500 mL of brine. The solution is concentrated and then chromatographed to afford the desired alcohol 259c.

Step D: To a solution of phosgene (350 mmol) in 1000 mL of methylene chloride at-70 °C is added 700 mmol of DMSO in 100 mL methylene chloride using a dropping funnel. Then, the resulting solution is treated with the pyridone alcohol 259c from Step C (300 mmol) in 500 mL of methylene chloride, stirred for an additional 15-30 minutes, treated with 225 mL of triethylamine, and then warmed to room temperature over an additional 1. 5 hours. The reaction mixture is quenched by the addition of 1000 mL water and the two phases separated. The aqueous is extracted twice with 1000 mL of methylene chloride and the combined

organic extracts is washed with 500 mL of brine. The methylene chloride solution is dried over MgSO4, concentrated, and then chromatographed to afford the desired aldehyde 259d.

Step E:

To a solution of diethyl 2- (3-methyl-2-oxo- butyl) phosphonate (250 mmol ; obtainable through a standard Arbuzov reaction between l-bromo-3-methyl-2-butanone and triethyl phosphite) in 1000 mL of THF at 0 °C is added 250 mmol of NaH. Then, the resulting solution is stirred until hydrogen evolution ceased and then treated with the pyridine aldehyde 259d from Step D (250 mmol) in 800 mL of THF. The solution is heated at 50 °C for 180 minutes, cooled, and evaporated. The residue is redissolved in 2000 mL of ethyl acetate and quenched to a pH of 7 with saturated ammonium chloride. The organic phase is washed with brine, dried over MgSO4, concentrated, and then chromatographed to afford the desired nitro ketone 259e.

Step F:

To a solution of nitro ketone 259e from Step E (225 mmol) in 1000 mL of ethyl acetate is added 20 grams of 10% Pd/C. Hydrogen gas is added until uptake of hydrogen stopped. The reaction mixture is filtered through Celite and the filtrate evaporated. The residue is then chromatographed to afford the desired bicyclic methoxy pyridine 259f.

Step G: To a solution of methoxy pyridine 259f from Step F (200 mmol) in 1000 mL of dichloroethane at ambient temperature is added 400 mmol of boron tribromide in 400

mL methylene chloride. After stirring for about two hours, the reaction mixture is quenched to a pH of 8 with saturated sodium bicarbonate. The mixture was diluted with 2000 mL of ethyl acetate and 200 mL of THF. The aqueous phase is discarded and the organic solution washed with 200 mL water followed by 200 mL of brine. The reaction mixture evaporated to afford the desired bicyclic pyridone 259g.

Step H:

The bicyclic pyridone 259g from Step G (150 mmol) is alkylated with tert-butyl bromoacetate using procedures previously disclosed to afford the desired bicyclic pyridone acetate 259h.

Step I:

The bicyclic pyridone acetate 259h from Step H (100 mmol) is deprotected with trifluoroacetic acid as described in Example lg to afford the desired bicyclic pyridone acetic acid 259i.

A solution of compound bicyclic pyridone acetic acid 259i (50 mmol) in DMF (250 mL) is treated with N- hydroxybenzotriazole (60 mmol) and EDC hydrochloride (60 mmol). The mixture is stirred at room temperature for 30 min and treated with 4- (N-Cbz-amidinobenzylamine (50 mmol). The resulting mixture is allowed to stir overnight. Typical aqueous workup is followed by chromatographic purification to afford pure Example 259 product.

Example 260

Compound of Example 259 (10 mmol) and 10% Pd on activated carbon (0.100 g) are mixed with 100 mL methanol.

The mixture is stirred for 2 hours under an atmosphere of hydrogen that is introduced through a rubber balloon.

After filtering off the catalyst and removing the methanol, the remaining residue is obtained as Example 260.

Example 261 Step A:

To a slurry of 500 mmol of the ammonium salt of 2- nitroacetamide in 400 grams of water is added 600 mmol of ethyl 3-oxo-3- (3- (t-butoxycarbonylamino)-5- trifluoromethylphenyl) propanoate (prepared by standard methods from diethyl carbonate and 1-acetyl-3- (t- butoxycarbonylamino) -5-trifluoromethylbenzene). A solution of piperidinium acetate (prepared by adding 36 mL of piperidine to 21 mL of acetic acid in 100 mL of water) is then added. The resulting reaction mixture is stirred at 40 °C for about 24 hours. The reaction product 261a is then separated, dried and used in the next step.

Step B:

A solution of the pyridone 261a from Step A (400

mmol) in 2000 mL of acetonitrile is treated with 1.6 moles of phosphorusoxychloride and 1.5 moles N-benzyl-N, N, N- triethylammonium chloride. The mixture is stirred at 40 °C and then heated at reflux until the reaction is complete as monitored by liquid chromatography. The reaction mixture is concentrated to remove solvent, and the residue is slurried with water (1000 mL). The product is separated to afford the chloro pyridone 261b.

Step C:

The chloro pyridone 261b from Step B (350 mmol) is alkylated with tert-butyl bromoacetate using the procedure of Example 1d to afford the desired bicyclic pyridone acetate 261c.

Step D:

To a solution of bicyclic pyridone acetate 261c from Step C (300 mmol) in 1500 mL of ethanol is added 2,2- dimethoxy-3-methylbutanamine (300 mmol) and 600 mmol of triethylamine. The solution is stirred at 70 °C for 16 hours or until the reaction is complete. The reaction mixture is cooled and evaporated to remove all of the ethanol. The residue is partitioned between ethyl acetate and water, and the organic phase is washed with brine, dried over MgSO4, concentrated, and then chromatographed to afford the desired nitro ketal 261d.

Step'E :

The nitro ketal 261d from Step D (250 mmol) is hydrolyzed and the tert-butyl ester removed by stirring with trifluoroacetic acid (50 mL), water (200 mL) and THF (500 mL) until completion as monitored by chromatography.

The reaction mixture is concentrated at ambient temperature to give the trifluroacetic acid salt of unpurified nitro ketone 261e and used as is in the next step.

Step F: To the nitro ketone 261e from Step E (225 mmol) in 1000 mL of ethyl acetate is added 20 grams of 10% Pd/C.

Hydrogen gas is added until uptake of hydrogen stopped.

The reaction mixture is filtered through Celite and the filtrate evaporated. The residue is then chromatographed to afford the desired bicyclic pyridone acetic acid 19f.

A solution of compound bicyclic pyridone acetic acid 261f (50 mmol) in DMF (250 mL) is treated with N- hydroxybenzotriazole (60 mmol) and EDC hydrochloride (60 mmol). The mixture is stirred at room temperature for 30 min and treated with 4- (N-Cbz-amidinobenzylamine (50 mmol). The resulting mixture is allowed to stir overnight. Typical aqueous workup is followed by chromatographic purification to afford pure Example 261 product.

Example 262

Compound of Example 261 (10 mmol) and 10% Pd on activated carbon (0.100 g) are mixed with 100 mL methanol.

The mixture is stirred for 2 hours under an atmosphere of hydrogen that is introduced through a rubber balloon.

After filtering off the catalyst and removing the methanol, the remaining residue is obtained as Example 262.

Using these methods and ordinary skill in the art numerous novel compounds of the present invention have been or can be prepared.

BIOLOGICAL DATA Effect of Compounds of the Invention in Combination with Aspirin for the Treatment of Thrombus in Mammals Deep Vein Thrombosis Model This model measures the accumulation of thrombus on

a set of four threads (4-0 surgical silk) that are introduced into the vena cava of a non-human primate. The device used to introduce the threads consists of a copper wire (12 cm) contained in a sheath of polyethylene tubing (9 cm). Four 4-0 surgical silk threads (3 cm) are tied to . the end of the wire and retracted into the tubing. When the device is inserted into the iliac vein, the wire is advanced introducing the threads into the vena cava between the bifurcation and the left renal vein.

Non-human primates (Macaca fascicularis) are lightly anesthetized with ketamine to facilitate placement of an endotracheal tube and a femoral venous catheter. Animals are put into and maintained in a deep plane of anesthesia using pentobarbital via the femoral vein cannula. A jugular vein is cannulated for infusion of drug and a carotid artery is cannulated for blood sampling and for monitoring hemodynamic parameters.

The abdominal cavity is opened and an ultrasonic flow probe placed on the left iliac vein. The right iliac vein (RIV) is dissected free of surrounding tissue for a length of approximately 4 cm. The RIV is ligated approximately 4 cm distal to the bifurcation of the abdominal vena cava and a second ligature is placed, loosely, approximately 2 cm distal to the bifurcation. An incision is made in the RIV between the two ligatures, the device described above introduced into the iliac vein and the threads advanced into the vena cava. Every study consists of three thrombus measurements: Control-Saline infusion. Threads are introduced and left in for 30 min, removed and thrombus weighed.

Treatment 1-Aspirin administered as a bolus or compound as an infusion. For aspirin treatment, aspirin

is administered as a bolus and a 30 min equilibration period is allowed to assure the platelets are inhibited.

For compound treatment, infusion is started and allowed to run for 30 min to reach steady-state blood levels of compound. Threads are introduced and left in for 30 min, removed and thrombus weighed; Treatment 2-Compound administered as an infusion.

Compound infusion is started and allowed to run for 30 min to reach steady-state blood levels of compound. Threads are introduced and left in for 30 min, removed and thrombus weighed.

During the 30 min equilibration/infusion periods of Treatment 1 and Treatment 2, a piece of tubing containing a copper wire, but no threads, is introduced into the vein to maintain the integrity of the vessel. After the threads have been in the vessel for 30 min, the entire device is removed from the vessel and the threads are cut from the device and weighed. The weight of the threads prior to insertion in the vessel is subtracted to get the net thrombus weight To measure bleeding time, a blood pressure cuff is placed on the upper arm and inflated to 40 mm Hg. Two uniform cuts are made in the volar surface of the forearm, the blood from the cuts is collected onto a gauze pad every 30 sec. The time from when the cuts are made until the bleeding stops is considered the bleeding time. All gauze used to collect blood is placed in Drabkin's solution and the amount of blood lost from the bleeding time site is calculated based on the amount of hemoglobin measured in the Drabkin's solution.

The table below depicts the effects of Aspirin coadministered with a compound of the present invention (compounds 54 and 55 are salts of the compound tested) on thrombus formation, prothrombin time and bleeding time in a non-human primate model of deep vein thrombosis.

Thrombus Pro- Net Bleeding Wt : % A thrombin n= Treatment* Thrombus SD SD SD Time SD from Time Wt (mg) (min) Control (sec) 4 control 34.8 5. 5 -- -- 10. 3 0. 5 3. 5 0. 4 100 15.3 1.5-56 3.8 22.7 2.0 0. 1 µg/kg/min 4 200 5.1 0.7 -85 0.6 46.0 4.0 3.9 0. µg/kg/min 4 ontrol 34.5 9. 3 -- -- 10. 2 0.1 3.3 0.3 4 aspirin 30.9 9. 9-12 5. 3 11.8 1. 2 4. 6 0. 4 100 3.6 1.7 -89 5.2 22.4 1.5 4.7 0. µg/kg/min 4 Control 27. 8 7. 5--10. 5 0.6 3.0 0. 4 aspirin 26. 7 7. 0-4 6. 6 11.5 0. 8 4.3 0. 4 0 19. 516. 8-3439. 2 17.3 3. 5 4.1 0. g/kg/min *All animals treated with Compounds 54 and 55